

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization

International Bureau



(10) International Publication Number

WO 2016/164201 A1

(43) International Publication Date
13 October 2016 (13.10.2016)

WIPO | PCT

(51) International Patent Classification:

C07D 403/12 (2006.01) *C07D 405/12* (2006.01)
A01N 43/36 (2006.01) *C07D 413/10* (2006.01)
A01N 43/40 (2006.01) *C07D 413/12* (2006.01)
A01N 43/647 (2006.01) *C07D 417/10* (2006.01)
A01N 43/80 (2006.01) *C07D 417/12* (2006.01)
C07D 401/10 (2006.01) *C07D 471/04* (2006.01)
C07D 403/10 (2006.01) *C07D 207/277* (2006.01)
C07D 405/10 (2006.01)

Edmund; 21 Tremont Court, Newark, Delaware 19711 (US).

(74) Agent: COATS, Reed A.; E.I. du Pont de Nemours and Company, Legal Patent Records Center, Chestnut Run Plaza 721/2340, 974 Centre Road, PO Box 2915 Wilmington, Delaware 19805 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(21) International Application Number:

PCT/US2016/024669

(22) International Filing Date:

29 March 2016 (29.03.2016)

(25) Filing Language:

English

(26) Publication Language:

English


(30) Priority Data:

62/145,598 10 April 2015 (10.04.2015) US

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

[Continued on next page]

(54) Title: SUBSTITUTED CYCLIC AMIDES AS HERBICIDES



(57) Abstract: Disclosed are compounds of Formula I, including all stereoisomers, *N*-oxides, and thereof. (I) wherein R¹, R⁴, R⁵, R⁶, Q¹, Q², Y¹, and Y² are as defined in the disclosure; and T is j¹-A and also as defined in the disclosure. Also disclosed are compositions containing the compounds of Formula I and methods for controlling undesired vegetation comprising contacting the undesired vegetation or its environment with an effective amount of a compound or a composition of the invention.



Published:

— *with international search report (Art. 21(3))*

TITLE
SUBSTITUTED CYCLIC AMIDES AS HERBICIDES

FIELD OF THE INVENTION

This invention relates to certain substituted cyclic amides, their *N*-oxides and salts, and 5 compositions and methods of their use for controlling undesirable vegetation.


BACKGROUND OF THE INVENTION

The control of undesired vegetation is extremely important in achieving high crop efficiency. Achievement of selective control of the growth of weeds especially in such useful crops as rice, soybean, sugar beet, maize, potato, wheat, barley, tomato and plantation 10 crops, among others, is very desirable. Unchecked weed growth in such useful crops can cause significant reduction in productivity and thereby result in increased costs to the consumer. The control of undesired vegetation in noncrop areas is also important. Many products are commercially available for these purposes, but the need continues for new compounds that are more effective, less costly, less toxic, environmentally safer or have 15 different sites of action.

SUMMARY OF THE INVENTION

This invention is directed to compounds of Formula 1 (including all stereoisomers), *N*-oxides and salts thereof, agricultural compositions containing them and their use as herbicides:

20



1

wherein

Q¹ is a phenyl ring or a naphthalenyl ring system, each ring or ring system optionally 25 substituted with 1 to 4 substituents independently selected from R⁷; or a 5- to 6-membered heteroaromatic ring or an 8- to 10-membered heteroaromatic bicyclic ring system, each ring or ring system containing ring members selected from carbon atoms and 1 to 4 heteroatoms independently selected from up to 2 O, up to 2 S and up to 4 N atoms, wherein up to 3 carbon ring members are independently selected from C(=O) and C(=S), and the sulfur atom ring 30 members are independently selected from S(=O)_u(=NR⁸)_v, each ring or ring

system optionally substituted with up to 4 substituents independently selected from R⁷ on carbon atom ring members and selected from R⁹ on nitrogen atom ring members;

Q² is a phenyl ring or a naphthalenyl ring system, each ring or ring system optionally substituted with up to 5 substituents independently selected from R¹⁰; or a 5- to 6-membered heteroaromatic ring or an 8- to 10-membered heteroaromatic bicyclic ring system, each ring or ring system containing ring members selected from carbon atoms and 1 to 4 heteroatoms independently selected from up to 2 O, up to 2 S and up to 4 N atoms, wherein up to 3 carbon ring members are independently selected from C(=O) and C(=S), and the sulfur atom ring members are independently selected from S(=O)_u(=NR⁸)_v, each ring or ring system optionally substituted with up to 5 substituents independently selected from R¹⁰ on carbon atom ring members and selected from R¹¹ on nitrogen atom ring members;

T is J¹-A-, wherein the free bond projecting to the right next to A indicates the connecting point of J¹-A- to Q¹; or

T is R¹⁷ON=CR^{17a}-, (R¹⁸)₂C=NO-, (R¹⁹)₂NN=CR^{17a}-, (R¹⁸)₂C=NNR^{20a}-, R²⁰N=CR^{17a}-, (R¹⁸)₂C=N-, R¹⁷ON=CR^{17a}C(R^{23b})₂- or (R¹⁸)₂C=NOC(R^{24a})₂-, wherein the free bond projecting to the right indicates the connecting point to Q¹;

A is a saturated, partially unsaturated or fully unsaturated chain containing 1 to 3 atoms selected from up to 3 carbon, up to 1 O, up to 1 S and up to 2 N atoms, the chain optionally substituted with up to 2 substituents independently selected from R¹⁵ on carbon atoms and R¹⁶ on nitrogen atoms;

Y¹ and Y² are each independently O, S or NR¹²;

J¹ is a phenyl ring or a naphthalenyl ring system, each ring or ring system optionally substituted with up to 5 substituents independently selected from R^{7'}; or a 4- to 6-membered heterocyclic ring or an 8- to 10-membered heteroaromatic bicyclic ring system, each ring or ring system containing ring members selected from carbon atoms and 1 to 4 heteroatoms independently selected from up to 2 O, up to 2 S and up to 4 N atoms, wherein up to 3 carbon ring members are independently selected from C(=O) and C(=S), and the sulfur atom ring members are independently selected from S(=O)_u(=NR⁸)_v, each ring or ring system optionally substituted with up to 5 substituents independently selected from R^{7'} on carbon atom ring members and selected from R^{9'} on nitrogen atom ring members; or C₄-C₁₀ cycloalkylalkoxy, C₄-C₁₀ cycloalkylalkyl, C₂-C₈ alkenyloxy, C₂-C₈ haloalkenyloxy, C₂-C₈ alkoxyalkoxy, C₂-C₈ alkylthioalkyl, C₂-C₈ alkylsulfinylalkyl, C₂-C₈ alkylsulfonylalkyl, C₁-C₈ alkylsulfonyloxy, C₁-C₈ haloalkylsulfonyloxy, C₁-C₈ alkylthio, C₁-C₈ haloalkylthio, C₃-C₈

cycloalkylthio, C₁–C₈ alkylsulfinyl, C₁–C₈ haloalkylsulfinyl, C₁–C₈ alkylsulfonyl, C₁–C₈ haloalkylsulfonyl, C₂–C₈ alkynyl, C₂–C₈ haloalkynyl, C₂–C₈ alkoxyalkyl, C₂–C₈ haloalkoxyalkyl, C₃–C₈ haloalkoxyalkoxy, C₂–C₈ haloalkoxyhaloalkyl, C₁–C₈ haloalkyl, C₃–C₈ halocycloalkyl, C₂–C₈

5 alkylcarbonyloxy or C₂–C₈ haloalkylcarbonyloxy;

J² is –CR²R³– or –CR²R³–CR^{2a}R^{3a}– wherein –CR²R³– moiety is connected to N;

R¹ is H, hydroxy, amino, cyano, formyl, C₃–C₈ alkylcarbonylalkyl, -CPh=N-O(C₁–C₄ alkyl), -C(C₁–C₄ alkyl)=N-O(C₁–C₄ alkyl), -C(O)NH₂, C₁–C₆ alkyl, C₁–C₆ haloalkyl, C₂–C₆ alkenyl, C₃–C₆ alkynyl, C₂–C₆ cyanoalkyl, C₃–C₆ cycloalkyl, C₄–C₈ cycloalkylalkyl, C₂–C₈ alkoxyalkyl, C₃–C₈ alkoxyalkoxyalkyl, C₂–C₈ haloalkoxyalkyl, C₂–C₈ alkylthioalkyl, C₂–C₈ alkylsulfinylalkyl, C₂–C₈ alkylsulfonylalkyl, C₂–C₈ alkylcarbonyl, C₂–C₈ haloalkylcarbonyl, C₄–C₁₀ cycloalkylcarbonyl, C₂–C₈ alkoxy carbonyl, C₂–C₈ haloalkoxycarbonyl, C₄–C₁₀ cycloalkoxycarbonyl, C₂–C₈ alkylaminocarbonyl, C₃–C₁₀ dialkylaminocarbonyl, C₄–C₁₀ cycloalkylaminocarbonyl, C₁–C₆ alkoxy, C₁–C₆ alkylthio, C₁–C₆ haloalkylthio, C₃–C₈ cycloalkylthio, C₁–C₆ alkylsulfinyl, C₁–C₆ haloalkylsulfinyl, C₃–C₈ cycloalkylsulfinyl, C₁–C₆ alkylsulfonyl, C₁–C₆ haloalkylsulfonyl, C₃–C₈ cycloalkylsulfonyl, C₁–C₆ alkylaminosulfonyl, C₂–C₈ dialkylaminosulfonyl, C₃–C₁₀ trialkylsilyl, phenylcarbonyl or G¹;

10 R² and R³ are each independently H, halogen, hydroxy, C₁–C₄ alkyl, C₁–C₄ haloalkyl or C₁–C₄ alkoxy; or

15 R² and R³ are taken together with the carbon atom to which they are bonded to form a C₃–C₇ cycloalkyl ring;

20 R^{2a} and R^{3a} are each independently H, halogen or C₁–C₄ alkyl; or

25 R^{2a} and R^{3a} are taken together with the carbon atom to which they are bonded to form a C₃–C₇ cycloalkyl ring;

20 R⁴ and R⁵ are each independently H, halogen, hydroxyl, C₁–C₄ alkoxy or C₁–C₄ alkyl;

30 R⁶ is H, hydroxy, amino, C₁–C₆ alkyl, C₁–C₆ haloalkyl, C₂–C₆ alkenyl, C₃–C₆ alkynyl, C₂–C₈ alkoxyalkyl, C₂–C₈ haloalkoxyalkyl, C₂–C₈ alkylthioalkyl, C₂–C₈ alkylsulfinylalkyl, C₂–C₈ alkylsulfonylalkyl, C₂–C₈ alkylcarbonyl, C₂–C₈ haloalkylcarbonyl, C₄–C₁₀ cycloalkylcarbonyl, C₂–C₈ alkoxy carbonyl, C₂–C₈ haloalkoxycarbonyl, C₄–C₁₀ cycloalkoxycarbonyl, C₂–C₈ alkylaminocarbonyl, C₃–C₁₀ dialkylaminocarbonyl, C₄–C₁₀ cycloalkylaminocarbonyl, C₁–C₆ alkoxy, C₁–C₆ alkylthio, C₁–C₆ haloalkylthio, C₃–C₈ cycloalkylthio, C₁–C₆ alkylsulfinyl, C₁–C₆ haloalkylsulfinyl, C₃–C₈ cycloalkylsulfinyl, C₁–C₆ alkylsulfonyl, C₁–C₆ haloalkylsulfonyl, C₃–C₈ cycloalkylsulfonyl, C₁–C₆ alkylaminosulfonyl, C₂–C₈ dialkylaminosulfonyl, C₃–C₁₀ trialkylsilyl or G¹;

each R⁷ is independently halogen, hydroxyl, cyano, nitro, C₁–C₄ alkyl, C₁–C₄ cyanoalkyl, C₁–C₄ cyanoalkoxy, C₁–C₄ haloalkyl, C₂–C₄ alkenyl, C₂–C₄ haloalkenyl C₂–C₄ alkynyl, C₂–C₄ haloalkynyl, C₁–C₄ nitroalkyl, C₂–C₄ nitroalkenyl, C₂–C₄ alkoxyalkyl, C₃–C₈ alkoxyalkoxyalkyl, C₂–C₄ haloalkoxyalkyl, C₃–C₄ cycloalkyl, C₃–C₄ halocycloalkyl, cyclopropylmethyl, 1-methylcyclopropyl, 2-methylcyclopropyl, C₁–C₄ alkoxy, C₁–C₄ haloalkoxy, C₂–C₄ alkenyloxy, C₂–C₄ haloalkenyloxy, C₃–C₄ alkynyloxy, C₃–C₄ haloalkynyloxy, C₃–C₄ cycloalkoxy, C₁–C₄ alkylthio, C₁–C₄ haloalkylthio, C₁–C₄ alkylsulfinyl, C₁–C₄ haloalkylsulfinyl, C₁–C₄ alkylsulfonyl, C₁–C₄ haloalkylsulfonyl, hydroxy, -CHO, C₂–C₄ alkylcarbonyl, C₂–C₄ alkylcarbonyloxy, C₁–C₄ alkylsulfonyloxy, C₁–C₄ haloalkylsulfonyloxy, amino, C₁–C₄ alkylamino, C₂–C₄ dialkylamino, formylamino, C₂–C₄ alkylcarbonylamino, -SF₅, -SCN, C₃–C₄ trialkylsilyl, trimethylsilylmethyl or trimethylsilylmethoxy; or

two adjacent R⁷ are taken together along with the carbon atoms to which they are bonded to form a C₃–C₇ cycloalkyl ring;

each R¹⁰ is independently halogen, hydroxyl, cyano, nitro, C₁–C₈ alkyl, C₁–C₈ haloalkyl, C₁–C₈ nitroalkyl, C₂–C₈ alkenyl, C₂–C₄ alkoxyalkyl, C₃–C₈ alkoxyalkoxyalkyl, C₁–C₄ cyanoalkyl, C₁–C₄ cyanoalkoxy, C₂–C₈ haloalkenyl, C₂–C₈ nitroalkenyl, C₂–C₈ alkynyl, C₂–C₈ haloalkynyl, C₄–C₁₀ cycloalkylalkyl, C₄–C₁₀ halocycloalkylalkyl, C₅–C₁₂ alkylcycloalkylalkyl, C₅–C₁₂ cycloalkylalkenyl, C₅–C₁₂ cycloalkylalkynyl, C₃–C₈ cycloalkyl, C₃–C₈ halocycloalkyl, C₄–C₁₀ alkylcycloalkyl, C₆–C₁₂ cycloalkylcycloalkyl, C₃–C₈ cycloalkenyl, C₃–C₈ halocycloalkenyl, C₂–C₈ alkoxyalkyl, C₂–C₈ haloalkoxyalkyl, C₄–C₁₀ cycloalkoxyalkyl, C₃–C₁₀ alkoxyalkoxyalkyl, C₂–C₈ alkylthioalkyl, C₂–C₈ alkylsulfinylalkyl, C₂–C₈ alkylsulfonylalkyl, C₂–C₈ alkylaminoalkyl, C₂–C₈ haloalkylaminoalkyl, C₄–C₁₀ cycloalkylaminoalkyl, C₃–C₁₀ dialkylaminoalkyl, -CHO, C₂–C₈ alkylcarbonyl, C₂–C₈ haloalkylcarbonyl, C₄–C₁₀ cycloalkylcarbonyl, -C(=O)OH, C₂–C₈ alkoxy carbonyl, C₂–C₈ haloalkoxycarbonyl, C₄–C₁₀ cycloalkoxycarbonyl, C₅–C₁₂ cycloalkylalkoxycarbonyl, -C(=O)NH₂, C₂–C₈ alkylaminocarbonyl, C₄–C₁₀ cycloalkylaminocarbonyl, C₃–C₁₀ dialkylaminocarbonyl, hydroxy, C₁–C₈ alkoxy, C₁–C₈ haloalkoxy, C₂–C₈ alkoxyalkoxy, C₂–C₈ alkenyloxy, C₂–C₈ haloalkenyloxy, C₃–C₈ alkynyloxy, C₃–C₈ haloalkynyloxy, C₃–C₈ cycloalkoxy, C₃–C₈ halocycloalkoxy, C₄–C₁₀ cycloalkylalkoxy, C₃–C₁₀ alkylcarbonylalkoxy, C₂–C₈ alkylcarbonyloxy, C₂–C₈ haloalkylcarbonyloxy, C₄–C₁₀ cycloalkylcarbonyloxy, C₁–C₈ alkylsulfonyloxy, C₁–C₈ haloalkylsulfonyloxy, C₁–C₈ alkylthio, C₁–C₈ haloalkylthio, C₃–C₈ cycloalkylthio, C₁–C₈

alkylsulfinyl, C₁–C₈ haloalkylsulfinyl, C₁–C₈ alkylsulfonyl, C₁–C₈ haloalkylsulfonyl, C₃–C₈ cycloalkylsulfonyl, amino, C₁–C₈ alkylamino, C₁–C₆ haloalkylamino, C₃–C₈ cycloalkylamino, C₂–C₈ dialkylamino, C₂–C₈ halodialkylamino, formylamino, C₂–C₈ alkylcarbonylamino, C₂–C₈ haloalkylcarbonylamino, C₁–C₆ alkylsulfonylamino, C₁–C₆ haloalkylsulfonylamino, -SF₅, -SCN, C₃–C₁₂ trialkylsilyl, C₄–C₁₂ trialkylsilylalkyl, C₄–C₁₂ trialkylsilylalkoxy or G²; or

5 two adjacent R¹⁰ are taken together along with the carbon atoms to which they are bonded to form a C₃–C₇ cycloalkyl ring;

10 each R⁷ is independently halogen, hydroxyl, cyano, nitro, C₁–C₈ alkyl, C₂–C₄ alkoxyalkyl, C₃–C₈ alkoxyalkoxyalkyl, C₁–C₄ cyanoalkyl, C₁–C₄ cyanoalkoxy, C₁–C₈ haloalkyl, C₁–C₈ nitroalkyl, C₂–C₈ alkenyl, C₂–C₈ haloalkenyl, C₂–C₈ nitroalkenyl, C₂–C₈ alkynyl, C₂–C₈ haloalkynyl, C₄–C₁₀ cycloalkylalkyl, C₄–C₁₀ halocycloalkylalkyl, C₅–C₁₂ alkylcycloalkylalkyl, C₅–C₁₂

15 cycloalkylalkenyl, C₅–C₁₂ cycloalkylalkynyl, C₃–C₈ cycloalkyl, C₃–C₈ halocycloalkyl, C₄–C₁₀ alkylcycloalkyl, C₆–C₁₂ cycloalkylcycloalkyl, C₃–C₈ cycloalkenyl, C₃–C₈ halocycloalkenyl, C₂–C₈ alkoxyalkyl, C₂–C₈ haloalkoxyalkyl, C₄–C₁₀ cycloalkoxyalkyl, C₃–C₁₀ alkoxyalkoxyalkyl, C₂–C₈ alkylthioalkyl, C₂–C₈ alkylsulfinylalkyl, C₂–C₈ alkylsulfonylalkyl, C₂–C₈ alkylaminoalkyl, C₂–C₈ haloalkylaminoalkyl, C₄–C₁₀ cycloalkylaminoalkyl, C₃–C₁₀ dialkylaminoalkyl, -CHO, C₂–C₈ alkylcarbonyl, C₂–C₈ haloalkylcarbonyl, C₄–C₁₀ cycloalkylcarbonyl, -C(=O)OH, C₂–C₈ alkoxy carbonyl, C₂–C₈ haloalkoxycarbonyl, C₄–C₁₀ cycloalkoxycarbonyl, C₅–C₁₂ cycloalkylalkoxycarbonyl, -C(=O)NH₂, C₂–C₈ alkylaminocarbonyl, C₄–C₁₀ cycloalkylaminocarbonyl, C₃–C₁₀ dialkylaminocarbonyl, hydroxy, C₁–C₈ alkoxy, C₁–C₈ haloalkoxy, C₂–C₈ alkoxyalkoxy, C₂–C₈ alkenyloxy, C₂–C₈ haloalkenyloxy, C₃–C₈ alkynyloxy, C₃–C₈ haloalkynyloxy, C₃–C₈ cycloalkoxy, C₃–C₈ halocycloalkoxy, C₄–C₁₀ cycloalkylalkoxy, C₃–C₁₀ alkylcarbonylalkoxy, C₂–C₈ alkylcarbonyloxy, C₂–C₈ haloalkylcarbonyloxy, C₄–C₁₀ cycloalkylcarbonyloxy, C₁–C₈ alkylsulfonyloxy, C₁–C₈ haloalkylsulfonyloxy, C₁–C₈ alkylthio, C₁–C₈ haloalkylthio, C₃–C₈ cycloalkylthio, C₁–C₈ alkylsulfinyl, C₁–C₈ haloalkylsulfinyl, C₁–C₈ alkylsulfonyl, C₁–C₈ haloalkylsulfonyl, C₃–C₈ cycloalkylsulfonyl, amino, C₁–C₈ alkylamino, C₁–C₆ haloalkylamino, C₃–C₈ cycloalkylamino, C₂–C₈ dialkylamino, C₂–C₈ halodialkylamino, formylamino, C₂–C₈ alkylcarbonylamino, C₂–C₈ haloalkylcarbonylamino, C₁–C₆ alkylsulfonylamino, C₁–C₆ haloalkylsulfonylamino, -SF₅, -SCN, C₃–C₁₂ trialkylsilyl, C₄–C₁₂ trialkylsilylalkyl, C₄–C₁₂ trialkylsilylalkoxy; or

20

25

30

35

two adjacent R^7 are taken together along with the carbon atoms to which they are bonded to form a C_3 – C_7 cycloalkyl ring;

each R^8 is independently H, cyano, C_2 – C_3 alkylcarbonyl or C_2 – C_3 haloalkylcarbonyl;

each R^9 , $R^{9'}$ and R^{11} is independently cyano, C_1 – C_3 alkyl, C_2 – C_3 alkenyl, C_2 – C_3 alkynyl, C_3 – C_6 cycloalkyl, C_2 – C_3 alkoxyalkyl, C_1 – C_3 alkoxy, C_2 – C_3 alkylcarbonyl, C_2 – C_3 alkoxy carbonyl, C_2 – C_3 alkylaminoalkyl or C_3 – C_4 dialkylaminoalkyl;

each R^{12} is independently H, cyano, C_1 – C_4 alkyl, C_1 – C_4 haloalkyl, C_1 – C_4 alkoxy, C_1 – C_4 haloalkoxy, $-(C=O)CH_3$ or $-(C=O)CF_3$;

10 each G^1 is independently phenyl, phenylmethyl (i.e. benzyl), pyridinylmethyl, phenylcarbonyl (i.e. benzoyl), phenoxy, phenylethynyl, phenylsulfonyl, phenylcarbonylalkyl; or a 5- or 6-membered heteroaromatic ring, each optionally substituted on ring members with up to 5 substituents independently selected from R^{13} ;

15 each G^2 is independently phenyl, phenylmethyl (i.e. benzyl), pyridinylmethyl, phenylcarbonyl (i.e. benzoyl), phenylcarbonylalkyl, phenoxy, phenylethynyl, phenylsulfonyl; or a 5- or 6-membered heteroaromatic ring, each optionally substituted on ring members with up to 5 substituents independently selected from R^{14} ;

20 each R^{13} and R^{14} is independently halogen, cyano, hydroxy, amino, nitro, $-CHO$, $-C(=O)OH$, $-C(=O)NH_2$, $-SO_2NH_2$, C_1 – C_6 alkyl, C_1 – C_6 haloalkyl, C_2 – C_6 alkenyl, C_2 – C_6 alkynyl, C_2 – C_8 alkylcarbonyl, C_2 – C_8 haloalkylcarbonyl, C_2 – C_8 alkoxy carbonyl, C_4 – C_{10} cycloalkoxycarbonyl, C_5 – C_{12} cycloalkylalkoxycarbonyl, C_2 – C_8 alkylaminocarbonyl, C_3 – C_{10} dialkylaminocarbonyl, C_1 – C_6 alkoxy, C_1 – C_6 haloalkoxy, C_2 – C_8 alkylcarbonyloxy, C_1 – C_6 alkylthio, C_1 – C_6 haloalkylthio, C_1 – C_6 alkylsulfinyl, C_1 – C_6 haloalkylsulfinyl, C_1 – C_6 alkylsulfonyl, C_1 – C_6 haloalkylsulfonyl, C_1 – C_6 alkylaminosulfonyl, C_2 – C_8 dialkylaminosulfonyl, C_3 – C_{10} trialkylsilyl, C_1 – C_6 alkylamino, C_2 – C_8 dialkylamino, C_2 – C_8 alkylcarbonylamino, C_1 – C_6 alkylsulfonylamino, phenyl, pyridinyl or thienyl;

25 each R^{15} is independently halogen, cyano, hydroxy, C_1 – C_4 alkyl, C_1 – C_4 haloalkyl, C_1 – C_4 alkoxy, C_1 – C_4 haloalkoxy, C_2 – C_4 alkoxyalkyl, C_2 – C_4 alkylcarbonyl, C_2 – C_4 alkoxy carbonyl or C_3 – C_6 cycloalkyl;

30 each R^{16} is independently H, cyano, C_1 – C_4 alkyl, C_1 – C_4 haloalkyl, C_1 – C_4 alkoxy, C_2 – C_4 alkylcarbonyl, C_2 – C_4 alkoxy carbonyl or C_3 – C_6 cycloalkyl;

35 each R^{17} is independently H, C_1 – C_6 alkyl, C_3 – C_8 cycloalkyl, C_4 – C_8 cycloalkylalkyl, C_1 – C_6 haloalkyl, C_2 – C_6 alkenyl, C_3 – C_6 alkynyl, C_2 – C_8 alkoxyalkyl, C_2 – C_8 haloalkoxyalkyl, C_2 – C_8 alkylthioalkyl, C_2 – C_8 alkylsulfinylalkyl, C_2 – C_8

alkylsulfonylalkyl, C₂–C₈ alkylcarbonyl, C₂–C₈ haloalkylcarbonyl, C₄–C₁₀ cycloalkylcarbonyl, C₂–C₈ alkoxy carbonyl, C₂–C₈ haloalkoxy carbonyl, C₄–C₁₀ cycloalkoxy carbonyl, C₂–C₈ alkylaminocarbonyl, C₃–C₁₀ dialkylaminocarbonyl, C₄–C₁₀ cycloalkylaminocarbonyl, C₁–C₆ alkylsulfinyl, C₁–C₆ haloalkylsulfinyl, C₃–C₈ cycloalkylsulfinyl, C₁–C₆ alkylsulfonyl, C₁–C₆ haloalkylsulfonyl, C₃–C₈ cycloalkylsulfonyl, C₁–C₆ alkylaminosulfonyl, C₂–C₈ dialkylaminosulfonyl, C₃–C₁₀ trialkylsilyl or G¹;

5 each R^{17a} is independently H, C₁–C₆ alkyl, C₃–C₈ cycloalkyl, C₄–C₈ cycloalkylalkyl, C₁–C₆ haloalkyl, C₂–C₆ alkenyl, C₃–C₆ alkynyl, C₂–C₈ alkoxyalkyl, C₂–C₈ 10 haloalkoxyalkyl, C₂–C₈ alkylthioalkyl, C₂–C₈ alkylsulfinylalkyl, C₂–C₈ alkylsulfonylalkyl, C₁–C₆ alkoxy, C₁–C₆ alkylthio, C₁–C₆ haloalkylthio, C₃–C₈ cycloalkylthio, C₃–C₁₀ trialkylsilyl or G¹;

10 each R¹⁸ is independently H, hydroxy, C₁–C₆ alkyl, C₃–C₈ cycloalkyl, C₄–C₈ cycloalkylalkyl, C₁–C₆ haloalkyl, C₂–C₆ alkenyl, C₃–C₆ alkynyl, C₂–C₈ 15 alkoxyalkyl, C₂–C₈ haloalkoxyalkyl, C₂–C₈ alkylthioalkyl, C₂–C₈ alkylsulfinylalkyl, C₂–C₈ alkylsulfonylalkyl, C₄–C₁₀ cycloalkylcarbonyl, C₂–C₈ alkoxy carbonyl, C₂–C₈ haloalkoxy carbonyl, C₄–C₁₀ cycloalkoxy carbonyl, C₂–C₈ alkylaminocarbonyl, C₃–C₁₀ dialkylaminocarbonyl, C₄–C₁₀ cycloalkylaminocarbonyl, C₁–C₆ alkoxy, 20 C₁–C₆ alkylthio, C₁–C₆ haloalkylthio, C₃–C₈ cycloalkylthio, C₁–C₆ alkylsulfinyl, C₁–C₆ haloalkylsulfinyl, C₃–C₈ cycloalkylsulfinyl, C₁–C₆ alkylsulfonyl, C₁–C₆ haloalkylsulfonyl, C₃–C₈ cycloalkylsulfonyl, C₁–C₆ alkylaminosulfonyl, C₂–C₈ dialkylaminosulfonyl, C₃–C₁₀ trialkylsilyl or G¹;

25 each R¹⁹ is independently H, C₁–C₆ alkyl, C₃–C₈ cycloalkyl, C₄–C₈ cycloalkylalkyl, C₁–C₆ haloalkyl, C₂–C₆ alkenyl, C₃–C₆ alkynyl, C₂–C₈ alkoxyalkyl, C₂–C₈ 30 haloalkoxyalkyl, C₂–C₈ alkylthioalkyl, C₂–C₈ alkylsulfinylalkyl, C₂–C₈ alkylsulfonylalkyl, C₂–C₈ alkylcarbonyl, C₂–C₈ haloalkylcarbonyl, C₄–C₁₀ cycloalkylcarbonyl, C₂–C₈ alkoxy carbonyl, C₂–C₈ haloalkoxy carbonyl, C₄–C₁₀ cycloalkoxy carbonyl, C₂–C₈ alkylaminocarbonyl, C₃–C₁₀ dialkylaminocarbonyl, C₄–C₁₀ cycloalkylaminocarbonyl, C₁–C₆ alkoxy, C₁–C₆ 35 alkylsulfinyl, C₁–C₆ haloalkylsulfinyl, C₃–C₈ cycloalkylsulfinyl, C₁–C₆ alkylsulfonyl, C₁–C₆ haloalkylsulfonyl, C₃–C₈ cycloalkylsulfonyl, C₁–C₆ alkylaminosulfonyl, C₂–C₈ dialkylaminosulfonyl, C₃–C₁₀ trialkylsilyl or G¹;

each R²⁰ is independently H, hydroxy, amino, C₁–C₆ alkyl, C₃–C₈ cycloalkyl, C₄–C₈ cycloalkylalkyl, C₁–C₆ haloalkyl, C₂–C₆ alkenyl, C₃–C₆ alkynyl, C₂–C₈ 40 alkoxyalkyl, C₂–C₈ haloalkoxyalkyl, C₂–C₈ alkylthioalkyl, C₂–C₈ alkylsulfinylalkyl, C₂–C₈ alkylsulfonylalkyl, C₂–C₈ alkylcarbonyl, C₂–C₈ haloalkylcarbonyl, C₄–C₁₀ cycloalkylcarbonyl, C₂–C₈ alkoxy carbonyl, C₂–C₈ haloalkoxy carbonyl, C₄–C₁₀ cycloalkoxy carbonyl, C₂–C₈ alkylaminocarbonyl, C₃–C₈

haloalkoxycarbonyl, C₄–C₁₀ cycloalkoxycarbonyl, C₂–C₈ alkylaminocarbonyl, C₃–C₁₀ dialkylaminocarbonyl, C₄–C₁₀ cycloalkylaminocarbonyl, C₁–C₆ alkoxy, C₁–C₆ alkylsulfinyl, C₁–C₆ haloalkylsulfinyl, C₃–C₈ cycloalkylsulfinyl, C₁–C₆ alkylsulfonyl, C₁–C₆ haloalkylsulfonyl, C₃–C₈ cycloalkylsulfonyl, C₁–C₆ alkylaminosulfonyl, C₂–C₈ dialkylaminosulfonyl, C₃–C₁₀ trialkylsilyl or G¹;

5 each R^{20a} is independently H, C₁–C₆ alkyl, C₃–C₈ cycloalkyl, C₄–C₈ cycloalkylalkyl, C₁–C₆ haloalkyl, C₂–C₆ alkenyl, C₃–C₆ alkynyl, C₂–C₈ alkoxyalkyl, C₂–C₈ haloalkoxyalkyl, C₂–C₈ alkylthioalkyl, C₂–C₈ alkylsulfinylalkyl, C₂–C₈ alkylsulfonylalkyl, C₁–C₆ alkoxyC₃–C₁₀ trialkylsilyl or G¹;

10 each R^{23b} is independently H, halogen, cyano, hydroxy, C₁–C₄ alkyl, C₃–C₈ cycloalkyl, C₄–C₈ cycloalkylalkyl, C₁–C₄ haloalkyl, C₁–C₄ alkoxy, C₁–C₄ haloalkoxy, C₂–C₄ alkoxyalkyl, C₂–C₄ alkylcarbonyl, C₂–C₄ alkoxy carbonyl or C₃–C₆ cycloalkyl;

15 each R^{24a} is independently H, C₁–C₄ alkyl, C₃–C₈ cycloalkyl, C₄–C₈ cycloalkylalkyl, C₁–C₄ haloalkyl, C₁–C₄ alkoxy, C₁–C₄ haloalkoxy, C₂–C₄ alkoxyalkyl, C₂–C₄ alkylcarbonyl, C₂–C₄ alkoxy carbonyl or C₃–C₆ cycloalkyl;

each u and v are independently 0, 1 or 2 in each instance of S(=O)_u(=NR⁸)_v, provided that the sum of u and v is 0, 1 or 2;

provided that when

20 a) J¹ is an unsubstituted phenyl ring, A is other than -CH₂-, -O-, -C≡C-, -C(=O)- or -SO₂-; or

b) J¹ is an unsubstituted pyridinyl ring, A is other than -CH₂-;

c) J¹ is C₄–C₁₀ cycloalkylalkyl, A is other than alkyl; or

d) J¹-A- is at the para position of Q¹, A is other than O and J¹ is other than 2-furanylmethyl.

25

More particularly, this invention pertains to a compound of Formula 1 (including all stereoisomers), an N-oxide or a salt thereof. This invention also relates to a herbicidal composition comprising a compound of the invention (i.e. in a herbicidally effective amount) and at least one component selected from the group consisting of surfactants, solid diluents and liquid diluents. This invention further relates to a method for controlling the growth of undesired vegetation comprising contacting the vegetation or its environment with a herbicidally effective amount of a compound of the invention (e.g., as a composition described herein).

This invention also includes a herbicidal mixture comprising (a) a compound selected from Formula 1, N-oxides and salts thereof, and (b) at least one additional active ingredient selected from (b1) through (b16); and salts of compounds of (b1) through (b16), as described below.

DETAILS OF THE INVENTION

As used herein, the terms “comprises,” “comprising,” “includes,” “including,” “has,” “having,” “contains”, “containing,” “characterized by” or any other variation thereof, are intended to cover a non-exclusive inclusion, subject to any limitation explicitly indicated.

5 For example, a composition, mixture, process, method, article, or apparatus that comprises a list of elements is not necessarily limited to only those elements but may include other elements not expressly listed or inherent to such composition, mixture, process, method, article, or apparatus.

10 The transitional phrase “consisting of” excludes any element, step, or ingredient not specified. If in the claim, such would close the claim to the inclusion of materials other than those recited except for impurities ordinarily associated therewith. When the phrase “consisting of” appears in a clause of the body of a claim, rather than immediately following the preamble, it limits only the element set forth in that clause; other elements are not excluded from the claim as a whole.

15 The transitional phrase “consisting essentially of” is used to define a composition, method or apparatus that includes materials, steps, features, components, or elements, in addition to those literally disclosed, provided that these additional materials, steps, features, components, or elements do not materially affect the basic and novel characteristic(s) of the claimed invention. The term “consisting essentially of” occupies a middle ground between 20 “comprising” and “consisting of”.

Where applicants have defined an invention or a portion thereof with an open-ended term such as “comprising,” it should be readily understood that (unless otherwise stated) the description should be interpreted to also describe such an invention using the terms “consisting essentially of” or “consisting of.”

25 Further, unless expressly stated to the contrary, “or” refers to an inclusive or and not to an exclusive or. For example, a condition A or B is satisfied by any one of the following: A is true (or present) and B is false (or not present), A is false (or not present) and B is true (or present), and both A and B are true (or present).

30 Also, the indefinite articles “a” and “an” preceding an element or component of the invention are intended to be nonrestrictive regarding the number of instances (i.e. occurrences) of the element or component. Therefore “a” or “an” should be read to include one or at least one, and the singular word form of the element or component also includes the plural unless the number is obviously meant to be singular.

35 As referred to herein, the term “seedling”, used either alone or in a combination of words means a young plant developing from the embryo of a seed.

As referred to herein, the term “broadleaf” used either alone or in words such as “broadleaf weed” means dicot or dicotyledon, a term used to describe a group of angiosperms characterized by embryos having two cotyledons.

In the above recitations, the term “alkyl”, used either alone or in compound words such as “alkylthio” or “haloalkyl” includes straight-chain or branched alkyl, such as, methyl, ethyl, *n*-propyl, *i*-propyl, or the different butyl, pentyl or hexyl isomers. “Alkenyl” includes straight-chain or branched alkenes such as ethenyl, 1-propenyl, 2-propenyl, and the different 5 butenyl, pentenyl and hexenyl isomers. “Alkenyl” also includes polyenes such as 1,2-propadienyl and 2,4-hexadienyl.

“Alkoxy” includes, for example, methoxy, ethoxy, *n*-propyloxy, isopropyloxy and the different butoxy, pentoxy and hexyloxy isomers. “Alkoxyalkyl” denotes alkoxy substitution on alkyl. Examples of “alkoxyalkyl” include CH_3OCH_2- , $\text{CH}_3\text{OCH}_2\text{CH}_2-$, $\text{CH}_3\text{CH}_2\text{OCH}_2-$, 10 $\text{CH}_3\text{CH}_2\text{CH}_2\text{OCH}_2-$ and $\text{CH}_3\text{CH}_2\text{OCH}_2\text{CH}_2-$. “Alkoxyalkoxyalkyl” denotes alkoxy substitution on the alkoxy moiety of alkoxyalkyl moiety. Examples of “alkoxyalkoxyalkyl” include $\text{CH}_3\text{OCH}_2\text{OCH}_2-$, $\text{CH}_3\text{CH}_2\text{O}(\text{CH}_3)\text{CHOCH}_2-$ and $(\text{CH}_3\text{O})_2\text{CHOCH}_2-$. “Alkoxyalkoxy” denotes alkoxy substitution on alkoxy. “Alkenyloxy” includes straight-chain or branched alkenyloxy moieties. Examples of “alkenyloxy” include $\text{H}_2\text{C}=\text{CH}_2\text{O}-$, $(\text{CH}_3)_2\text{C}=\text{CH}=\text{CH}_2\text{O}-$, $(\text{CH}_3)\text{CH}=\text{CH}=\text{CH}_2\text{O}-$, $(\text{CH}_3)\text{CH}=\text{C}(\text{CH}_3)\text{CH}_2\text{O}-$ and 15 $\text{CH}_2=\text{CH}=\text{CH}_2\text{CH}_2\text{O}-$. “Alkynyloxy” includes straight-chain or branched alkynyloxy moieties. Examples of “alkynyloxy” include $\text{HC}\equiv\text{CCH}_2\text{O}-$, $\text{CH}_3\text{C}\equiv\text{CCH}_2\text{O}-$ and $\text{CH}_3\text{C}\equiv\text{CCH}_2\text{CH}_2\text{O}-$. “Alkylthio” includes branched or straight-chain alkylthio moieties such as methylthio, ethylthio, and the different propylthio, butylthio, pentylthio and 20 hexylthio isomers. “Alkylsulfinyl” includes both enantiomers of an alkylsulfinyl group. Examples of “alkylsulfinyl” include $\text{CH}_3\text{S}(\text{O})-$, $\text{CH}_3\text{CH}_2\text{S}(\text{O})-$, $\text{CH}_3\text{CH}_2\text{CH}_2\text{S}(\text{O})-$, $(\text{CH}_3)_2\text{CHS}(\text{O})-$ and the different butylsulfinyl, pentylsulfinyl and hexylsulfinyl isomers. Examples of “alkylsulfonyl” include $\text{CH}_3\text{S}(\text{O})_2-$, $\text{CH}_3\text{CH}_2\text{S}(\text{O})_2-$, $\text{CH}_3\text{CH}_2\text{CH}_2\text{S}(\text{O})_2-$, 25 $(\text{CH}_3)_2\text{CHS}(\text{O})_2-$, and the different butylsulfonyl, pentylsulfonyl and hexylsulfonyl isomers. Examples of “alkylsulfonylamino” include $\text{CH}_3\text{S}(\text{O})_2\text{NH}-$, $\text{CH}_3\text{CH}_2\text{S}(\text{O})_2\text{NH}-$, $\text{CH}_3\text{CH}_2\text{CH}_2\text{S}(\text{O})_2\text{NH}-$, $(\text{CH}_3)_2\text{CHS}(\text{O})_2\text{NH}-$, and the different butylsulfonylamino, pentylsulfonylamino and hexylsulfonylamino isomers. Examples of “alkylsulfonyloxy” include $\text{CH}_3\text{S}(\text{O})_2\text{O}-$, $\text{CH}_3\text{CH}_2\text{S}(\text{O})_2\text{O}-$, $\text{CH}_3\text{CH}_2\text{CH}_2\text{S}(\text{O})_2\text{O}-$, $(\text{CH}_3)_2\text{CHS}(\text{O})_2\text{O}-$, and the different butylsulfonyloxy, pentylsulfonyloxy and hexylsulfonyloxy isomers. 30 “Alkylthioalkyl” denotes alkylthio substitution on alkyl. Examples of “alkylthioalkyl” include CH_3SCH_2- , $\text{CH}_3\text{SCH}_2\text{CH}_2-$, $\text{CH}_3\text{CH}_2\text{SCH}_2-$, $\text{CH}_3\text{CH}_2\text{CH}_2\text{CH}_2\text{SCH}_2-$ and $\text{CH}_3\text{CH}_2\text{SCH}_2\text{CH}_2-$. “Cyanoalkyl” denotes an alkyl group substituted with one cyano group. Examples of “cyanoalkyl” include NCCH_2- , $\text{NCCH}_2\text{CH}_2-$ and $\text{CH}_3\text{CH}(\text{CN})\text{CH}_2-$. “Cyanoalkoxy” denotes an alkoxy group substituted with one cyano group. Examples of 35 “cyanoalkoxy” include $\text{NCCH}_2\text{O}-$, $\text{NCCH}_2\text{CH}_2\text{O}-$ and $\text{CH}_3\text{CH}(\text{CN})\text{CH}_2\text{O}-$. “Alkylsulfinylalkyl” denotes alkylsulfinyl substitution on alkyl. Examples of “alkylsulfinylalkyl” include $\text{CH}_3\text{S}(\text{O})\text{CH}_2-$, $\text{CH}_3\text{S}(\text{O})\text{CH}_2\text{CH}_2-$, $\text{CH}_3\text{CH}_2\text{S}(\text{O})\text{CH}_2-$ and $\text{CH}_3\text{CH}_2\text{S}(\text{O})\text{CH}_2\text{CH}_2-$. “Alkylsulfonylalkyl” denotes alkylsulfonyl substitution on alkyl.

Examples of “alkylsulfonylalkyl” include $\text{CH}_3\text{S}(\text{=O})_2\text{CH}_2\text{-}$, $\text{CH}_3\text{S}(\text{=O})_2\text{CH}_2\text{CH}_2\text{-}$, $\text{CH}_3\text{CH}_2\text{S}(\text{=O})_2\text{CH}_2\text{-}$ and $\text{CH}_3\text{CH}_2\text{S}(\text{=O})_2\text{CH}_2\text{CH}_2\text{-}$. “Alkylamino”, “dialkylamino”, and the like, are defined analogously to the above examples. Examples of “alkylaminoalkyl” include $\text{CH}_3\text{NHCH}_2\text{-}$, $(\text{CH}_3)_2\text{CHNHCH}_2\text{-}$ and $\text{CH}_3\text{NHCH}(\text{CH}_3)\text{-}$. Examples of “alkylaminocarbonyl” include $\text{CH}_3\text{NHC(O)-}$, $(\text{CH}_3)_2\text{CHNHC(O)-}$ and $\text{CH}_3\text{CH}_2\text{NHC(O)-}$. Examples of “dialkylaminoalkyl” include $(\text{CH}_3)_2\text{NCH}_2\text{-}$, $(\text{CH}_3)_2\text{NC(CH}_3\text{)H-}$ and $(\text{CH}_3)(\text{CH}_3)\text{NCH}_2\text{-}$. Examples of “alkylaminocarbonyl” include $\text{CH}_3\text{NC(O)-}$ and $\text{CH}_3\text{CH}_2\text{NC(O)-}$. Examples of “dialkylaminocarbonyl” include $(\text{CH}_3)_2\text{NC(O)-}$. Examples of “dialkylaminosulfonyl” include $(\text{CH}_3)_2\text{NS(O)O}_2\text{-}$.

“Cycloalkyl” includes, for example, cyclopropyl, cyclobutyl, cyclopentyl and cyclohexyl. The term “alkylcycloalkyl” denotes alkyl substitution on a cycloalkyl moiety and includes, for example, ethylcyclopropyl, *i*-propylcyclobutyl, 3-methylcyclopentyl and 4-methylcyclohexyl. The term “cycloalkylalkyl” denotes cycloalkyl substitution on an alkyl moiety. Examples of “cycloalkylalkyl” include cyclopropylmethyl, cyclopentylethyl, and other cycloalkyl moieties bonded to straight-chain or branched alkyl groups. The term “cycloalkoxy” denotes cycloalkyl linked through an oxygen atom such as cyclopentyloxy and cyclohexyloxy. “Cycloalkoxyalkyl” denotes cycloalkoxy substitution on an alkyl moiety. Examples of “cycloalkoxyalkyl” include cyclopropoxymethyl, cyclopentoxyethyl, and other cycloalkoxy moieties bonded to straight-chain or branched alkyl groups. “Cycloalkylalkoxy” denotes cycloalkylalkyl linked through an oxygen atom attached to the alkyl chain. Examples of “cycloalkylalkoxy” include cyclopropylmethoxy, cyclopentylethoxy, and other cycloalkyl moieties bonded to straight-chain or branched alkoxy groups. “Cycloalkenyl” includes groups such as cyclopentenyl and cyclohexenyl as well as groups with more than one double bond such as 1,3- and 1,4-cyclohexadienyl.

The term “halogen”, either alone or in compound words such as “haloalkyl”, or when used in descriptions such as “alkyl substituted with halogen” includes fluorine, chlorine, bromine or iodine. Further, when used in compound words such as “haloalkyl”, or when used in descriptions such as “alkyl substituted with halogen” said alkyl may be partially or fully substituted with halogen atoms which may be the same or different. Examples of “haloalkyl” or “alkyl substituted with halogen” include $\text{F}_3\text{C-}$, $\text{ClCH}_2\text{-}$, $\text{CF}_3\text{CH}_2\text{-}$ and $\text{CF}_3\text{CCl}_2\text{-}$. The terms “halocycloalkyl”, “haloalkoxy”, “haloalkylthio”, “haloalkenyl”, “haloalkynyl”, and the like, are defined analogously to the term “haloalkyl”. Examples of “haloalkoxy” include $\text{CF}_3\text{O-}$, $\text{CCl}_3\text{CH}_2\text{O-}$, $\text{HCF}_2\text{CH}_2\text{CH}_2\text{O-}$ and $\text{CF}_3\text{CH}_2\text{O-}$. Examples of “haloalkylthio” include $\text{CCl}_3\text{S-}$, $\text{CF}_3\text{S-}$, $\text{CCl}_3\text{CH}_2\text{S-}$ and $\text{ClCH}_2\text{CH}_2\text{CH}_2\text{S-}$. Examples of “haloalkylsulfinyl” include $\text{CF}_3\text{S(O)-}$, $\text{CCl}_3\text{S(O)-}$, $\text{CF}_3\text{CH}_2\text{S(O)-}$ and $\text{CF}_3\text{CF}_2\text{S(O)-}$. Examples of “haloalkylsulfonyl” include $\text{CF}_3\text{S(O)O}_2\text{-}$, $\text{CCl}_3\text{S(O)O}_2\text{-}$, $\text{CF}_3\text{CH}_2\text{S(O)O}_2\text{-}$ and $\text{CF}_3\text{CF}_2\text{S(O)O}_2\text{-}$. Examples of “haloalkenyl” include $(\text{Cl})_2\text{C=CH=CH}_2\text{-}$ and $\text{CF}_3\text{CH}_2\text{CH=CH=CH}_2\text{-}$. Examples of “haloalkynyl” include $\text{HC}\equiv\text{CCHCl-}$, $\text{CF}_3\text{C}\equiv\text{C-}$, $\text{CCl}_3\text{C}\equiv\text{C-}$ and

FCH₂C≡CCH₂-.

Examples of “haloalkoxyalkoxy” include CF₃OCH₂O-, ClCH₂CH₂OCH₂CH₂O-, Cl₃CCH₂OCH₂O- as well as branched alkyl derivatives.

“Alkylcarbonyl” denotes a straight-chain or branched alkyl moieties bonded to a C(=O) moiety. Examples of “alkylcarbonyl” include CH₃C(=O)-, CH₃CH₂CH₂C(=O)- and (CH₃)₂CHC(=O)-.

Examples of “alkylcarbonylalkoxy” include CH₃C(=O)CH₂O-, CH₃CH₂CH₂C(=O)CH₂O - and (CH₃)₂CHC(=O)CH₂O-. Examples of “alkoxycarbonyl” include CH₃OC(=O)-, CH₃CH₂OC(=O)-, CH₃CH₂CH₂OC(=O)-, (CH₃)₂CHOC(=O)- and the different butoxy- or pentoxy carbonyl isomers. “Alkylcarbonyloxy” denotes an alkylcarbonyl moiety linked through an oxygen atom attached to the carbonyl. Examples of “alkylcarbonyloxy” include CH₃C(=O)O-, CH₃CH₂CH₂C(=O)O- and (CH₃)₂CHC(=O)O-.

The total number of carbon atoms in a substituent group is indicated by the “C_i-C_j” prefix where i and j are numbers from 1 to 12. For example, C₁-C₄ alkylsulfonyl designates methylsulfonyl through butylsulfonyl; C₂ alkoxyalkyl designates CH₃OCH₂-; C₃ alkoxyalkyl designates, for example, CH₃CH(OCH₃)-, CH₃OCH₂CH₂- or CH₃CH₂OCH₂-; and C₄ alkoxyalkyl designates the various isomers of an alkyl group substituted with an alkoxy group containing a total of four carbon atoms, examples including CH₃CH₂CH₂OCH₂- and CH₃CH₂OCH₂CH₂-.

When a compound is substituted with a substituent bearing a subscript that indicates the number of said substituents can exceed 1, said substituents (when they exceed 1) are independently selected from the group of defined substituents, e.g., [(R¹⁰)_n], n is 1, 2, 3, 4 or 5). Further, when the subscript indicates a range, e.g. (R)_{i-j}, then the number of substituents may be selected from the integers between i and j inclusive. When a group contains a substituent which can be hydrogen, for example (R¹ or R⁶), then when this substituent is taken as hydrogen, it is recognized that this is equivalent to said group being unsubstituted. When a variable group is shown to be optionally attached to a position, for example [(R¹⁰)_n] wherein n may be 0, then hydrogen may be at the position even if not recited in the variable group definition. When one or more positions on a group are said to be “not substituted” or “unsubstituted”, then hydrogen atoms are attached to take up any free valency.

The expression “fully saturated” in relation to a ring of atoms means that the bonds between the atoms of the ring are all single. The expression “fully unsaturated” in relation to a ring means that the bonds between the atoms in the ring are single or double bonds according to valence bond theory and furthermore the bonds between the atoms in the ring include as many double bonds as possible without double bonds being cumulative (i.e. no C=C=C, N=C=C, etc.). The term “partially unsaturated” in relation to a ring denotes a ring comprising at least one ring member bonded to an adjacent ring member through a double bond and which conceptually potentially accommodates a number of non-cumulated double bonds through adjacent ring members (i.e. in its fully unsaturated counterpart form) greater

than the number of double bonds present (i.e. in its partially unsaturated form). When a fully unsaturated ring satisfies Hückel's rule then it can also be described as aromatic.

Unless otherwise indicated, a "ring" or "ring system" as a component of Formula 1 (e.g., substituent Q¹) is carbocyclic or heterocyclic. The term "ring system" denotes two or 5 more fused rings. The terms "bicyclic ring system" and "fused bicyclic ring system" denote a ring system consisting of two fused rings, in which either ring can be saturated, partially unsaturated, or fully unsaturated unless otherwise indicated. The term "fused heterobicyclic ring system" denotes a fused bicyclic ring system in which at least one ring atom is not carbon. A "bridged bicyclic ring system" is formed by bonding a segment of one or more 10 atoms to nonadjacent ring members of a ring. The term "ring member" refers to an atom or other moiety (e.g., C(=O), C(=S), S(O) or S(O)₂) forming the backbone of a ring or ring system.

The terms "carbocyclic ring" or "carbocyclic ring system" denote a ring or ring system 15 wherein the atoms forming the ring backbone are selected only from carbon. Unless otherwise indicated, a carbocyclic ring can be a saturated, partially unsaturated, or fully unsaturated ring. When a fully unsaturated carbocyclic ring satisfies Hückel's rule, then said ring is also called an "aromatic ring". "Saturated carbocyclic" refers to a ring having a backbone consisting of carbon atoms linked to one another by single bonds; unless otherwise specified, the remaining carbon valences are occupied by hydrogen atoms.

20 The terms "heterocyclic ring", "heterocycle" or "heterocyclic ring system" denote a ring or ring system in which at least one atom forming the ring backbone is not carbon, e.g., nitrogen, oxygen or sulfur. Typically a heterocyclic ring contains no more than 4 nitrogens, no more than 2 oxygens and no more than 2 sulfurs. Unless otherwise indicated, a heterocyclic ring can be a saturated, partially unsaturated, or fully unsaturated ring. When a 25 fully unsaturated heterocyclic ring satisfies Hückel's rule, then said ring is also called a "heteroaromatic ring". The term "heteroaromatic bicyclic ring system" denotes a heterocyclic ring system in which at least one of the ring system is aromatic. Unless otherwise indicated, heterocyclic rings and ring systems can be attached through any available carbon or nitrogen by replacement of a hydrogen on said carbon or nitrogen.

30 "Aromatic" indicates that each of the ring atoms is essentially in the same plane and has a *p*-orbital perpendicular to the ring plane, and that $(4n + 2) \pi$ electrons, where *n* is a positive integer, are associated with the ring to comply with Hückel's rule. The term "aromatic ring system" denotes a carbocyclic or heterocyclic ring system in which at least one ring of the ring system is aromatic.


35 The term "optionally substituted" in connection with the heterocyclic rings refers to groups which are unsubstituted or have at least one non-hydrogen substituent that does not extinguish the biological activity possessed by the unsubstituted analog. As used herein, the following definitions shall apply unless otherwise indicated. The term "optionally


"substituted" is used interchangeably with the phrase "substituted or unsubstituted" or with the term "(un)substituted." Unless otherwise indicated, an optionally substituted group may have a substituent at each substitutable position of the group, and each substitution is independent of the other.


5 As noted above, Q^1 , J^1 and Q^2 can be (among others) phenyl optionally substituted with one or more substituents selected from a group of substituents as defined in the Summary of the Invention. An example of phenyl optionally substituted with one to five substituents is the ring illustrated as U-1 in Exhibit 1, wherein, for example, R^V is R^7 or $R^{7'}$ as defined in the Summary of the Invention for Q^1 or J^1 and r is an integer (from 0 to 4); or
10 R^V is R^{10} as defined in the Summary of the Invention for Q^2 , and r is an integer (from 0 to 5).

As noted above, Q¹, J¹ and Q² can be (among others) a 5- or 6-membered fully unsaturated heterocyclic ring, optionally substituted with one or more substituents selected from a group of substituents as defined in the Summary of the Invention. Examples of a 5- or 6-membered fully unsaturated heterocyclic ring optionally substituted with from one or more substituents include the rings U-2 through U-61 illustrated in Exhibit 1 wherein R^V is any substituent as defined in the Summary of the Invention for Q¹, J¹ and Q², and r is an integer from 0 to 4, limited by the number of available positions on each U group. As U-29, U-30, U-36, U-37, U-38, U-39, U-40, U-41, U-42 and U-43 have only one available position, for these U groups r is limited to the integers 0 or 1, and r being 0 means that the U group is unsubstituted and a hydrogen is present at the position indicated by (R^V)_r.

Exhibit 1










As noted above, Q¹, J¹ and Q² can be (among others) an 8- to 10-membered heteroaromatic bicyclic ring system optionally substituted with one or more substituents selected from a group of substituents as defined in the Summary of the Invention (i.e. R⁷, R^{7'} and R¹⁰). Examples of 8- to 10-membered heteroaromatic bicyclic ring system optionally substituted with from one or more substituents include the rings U-62 through U-100 illustrated in Exhibit 2 wherein R^V is any substituent as defined in the Summary of the Invention for Q¹, J¹ or Q², and r is typically an integer from 0 to 4 or 5.

Exhibit 2








Some examples of a 4- to 6-membered saturated heterocyclic ring optionally substituted with one or more substituents include but not limited to the rings U-101 through U-104 illustrated in Exhibit 3 wherein R^V is any substituent as defined in the Summary of the Invention for Q^1 or Q^2 , and r is typically an integer from 0 to 4 or 5.

5

Exhibit 3




10 Although R^V groups are shown in the structures U-1 through U-104, it is noted that they do not need to be present since they are optional substituents. Note that when R^V is H when attached to an atom, this is the same as if said atom is unsubstituted. The nitrogen atoms that require substitution to fill their valence are substituted with H or R^V . Note that when the attachment point between $(R^V)_r$ and the U group is illustrated as floating, $(R^V)_r$ can be attached to any available carbon atom or nitrogen atom of the U group. Note that when the attachment point on the U group is illustrated as floating, the U group can be attached to the remainder of Formula 1 through any available carbon or nitrogen of the U group by replacement of a hydrogen atom. Preferably for greatest herbicidal activity, the U group is attached to the remainder of Formula 1 through an available carbon or nitrogen on a fully unsaturated ring of the U group. Note that some U groups can only be substituted with less than 4 R^V groups (e.g., U-2 through U-5, U-7 through U-48, and U-52 through U-61).
15
20

A wide variety of synthetic methods are known in the art to enable preparation of aromatic and nonaromatic heterocyclic rings and ring systems; for extensive reviews see the eight volume set of *Comprehensive Heterocyclic Chemistry*, A. R. Katritzky and C. W. Rees editors-in-chief, Pergamon Press, Oxford, 1 25 and the twelve volume set of *Comprehensive Heterocyclic Chemistry II*, A. R. Katritzky, C. W. Rees and E. F. V. Scriven editors-in-chief, Pergamon Press, Oxford, 1996.

Compounds of this invention can exist as one or more stereoisomers. The various stereoisomers include enantiomers, diastereomers, atropisomers and geometric isomers. Stereoisomers are isomers of identical constitution but differing in the arrangement of their atoms in space and include enantiomers, diastereomers, cis-trans isomers (also known as 5 geometric isomers) and atropisomers. Atropisomers result from restricted rotation about single bonds where the rotational barrier is high enough to permit isolation of the isomeric species. One skilled in the art will appreciate that one stereoisomer may be more active and/or may exhibit beneficial effects when enriched relative to the other stereoisomer(s) or when separated from the other stereoisomer(s). Additionally, the skilled artisan knows how 10 to separate, enrich, and/or to selectively prepare said stereoisomers. The compounds of the invention may be present as a mixture of stereoisomers, individual stereoisomers or as an optically active form. Particularly when R⁴ and R⁵ are each H, the C(O)N(Q²)(R⁶) and Q¹ 15 substituents are typically mostly in the thermodynamically preferred trans configuration on the pyrrolidinone ring.

For example the C(O)N(Q²)(R⁶) moiety (bonded to the carbon at the 3-position of the pyrrolidinone ring wherein Y¹ and Y² are both oxygen and J² is -CR²R³ and both R² and R³ 20 are H) and Q¹ (bonded to the carbon at the 4-position of the pyrrolidinone ring) are generally found in the *trans* configuration. These two carbon atoms (i.e. at the 3- and 4-positions each posses the central ring of Formula 1) both possess a chiral center. The two most prevalent 25 pairs of enantiomers are depicted as Formula 1' and Formula 1" where the chiral centers are identified (i.e. as 3R,4S or as 3S,4R). The skilled artisan will understand that in some Embodiments of the invention, the R or S designation is determined relative to other substituents around the same carbon and therefore a compound of the invention could also be given the 3S,4S designation. For a comprehensive discussion of all aspects of 25 stereoisomerism, see Ernest L. Eliel and Samuel H. Wilen, *Stereochemistry of Organic Compounds*, John Wiley & Sons, 1994.



Molecular depictions drawn herein follow standard conventions for depicting 30 stereochemistry. To indicate stereoconfiguration, bonds rising from the plane of the drawing and towards the viewer are denoted by solid wedges wherein the broad end of the wedge is

attached to the atom rising from the plane of the drawing towards the viewer. Bonds going below the plane of the drawing and away from the viewer are denoted by dashed wedges wherein the narrow end of the wedge is attached to the atom further away from the viewer. Constant width lines indicate bonds with a direction opposite or neutral relative to bonds shown with solid or dashed wedges; constant width lines also depict bonds in molecules or parts of molecules in which no particular stereoconfiguration is intended to be specified.

5 This invention comprises racemic mixtures, for example, equal amounts of the enantiomers of Formulae 1' and 1''. In addition, this invention includes compounds that are enriched compared to the racemic mixture in an enantiomer of Formula 1. Also included are
10 the essentially pure enantiomers of compounds of Formula 1, for example, Formula 1' and Formula 1''.
15

When enantiomerically enriched (i.e. enantio-enriched), one enantiomer is present in greater amounts than the other, and the extent of enrichment can be defined by an expression of enantiomeric excess ("ee"), which is defined as $(2x-1) \cdot 100\%$, where x is the mole
15 fraction of the dominant enantiomer in the mixture (e.g., an ee of 20 % corresponds to a 60:40 ratio of enantiomers). The compounds of the invention can be prepared entantiomerically enriched (i.e. enantio-enriched) by utilizing a corresponding enantiomerically enriched intermediate during the course of synthesis. In these instances the
20 enantiomeric excess is not measured in the final product but is presumed to be "enantiomerically enriched" based on equivalent known chemical transformations in the literature.
25

Preferably the compositions of this invention have at least a 50 % enantiomeric excess; more preferably at least a 75 % enantiomeric excess; still more preferably at least a 90 % enantiomeric excess; and the most preferably at least a 94 % enantiomeric excess of the
25 more active isomer. Of particular note are enantiomerically pure embodiments of the more active isomer.

Compounds of Formula 1 can comprise additional chiral centers. For example, substituents and other molecular constituents such as R² and R³ may themselves contain chiral centers. This invention comprises racemic mixtures as well as enriched and
30 essentially pure stereoconfigurations at these additional chiral centers.

Compounds of this invention can exist as one or more conformational isomers due to restricted rotation about the amide bond (e.g., C(O)N(Q²)(R⁶)) in Formula 1. This invention comprises mixtures of conformational isomers. In addition, this invention includes compounds that are enriched in one conformer relative to others.

35 Compounds of Formula 1 typically exist in more than one form, and Formula 1 thus include all crystalline and non-crystalline forms of the compounds they represent. Non-crystalline forms include embodiments which are solids such as waxes and gums as well as embodiments which are liquids such as solutions and melts. Crystalline forms include

embodiments which represent essentially a single crystal type and embodiments which represent a mixture of polymorphs (i.e. different crystalline types). The term “polymorph” refers to a particular crystalline form of a chemical compound that can crystallize in different crystalline forms, these forms having different arrangements and/or conformations of the molecules in the crystal lattice. Although polymorphs can have the same chemical composition, they can also differ in composition due the presence or absence of co-crystallized water or other molecules, which can be weakly or strongly bound in the lattice. Polymorphs can differ in such chemical, physical and biological properties as crystal shape, density, hardness, color, chemical stability, melting point, hygroscopicity, suspensibility, dissolution rate and biological availability. One skilled in the art will appreciate that a polymorph of a compound of Formula 1 can exhibit beneficial effects (e.g., suitability for preparation of useful formulations, improved biological performance) relative to another polymorph or a mixture of polymorphs of the same compound of Formula 1. Preparation and isolation of a particular polymorph of a compound of Formula 1 can be achieved by methods known to those skilled in the art including, for example, crystallization using selected solvents and temperatures. For a comprehensive discussion of polymorphism see R. Hilfiker, Ed., *Polymorphism in the Pharmaceutical Industry*, Wiley-VCH, Weinheim, 2006.

One skilled in the art will appreciate that not all nitrogen-containing heterocycles can form *N*-oxides since the nitrogen requires an available lone pair for oxidation to the oxide; one skilled in the art will recognize those nitrogen-containing heterocycles which can form *N*-oxides. One skilled in the art will also recognize that tertiary amines can form *N*-oxides. Synthetic methods for the preparation of *N*-oxides of heterocycles and tertiary amines are very well known by one skilled in the art including the oxidation of heterocycles and tertiary amines with peroxy acids such as peracetic and *m*-chloroperbenzoic acid (MCPBA), hydrogen peroxide, alkyl hydroperoxides such as *t*-butyl hydroperoxide, sodium perborate, and dioxiranes such as dimethyldioxirane. These methods for the preparation of *N*-oxides have been extensively described and reviewed in the literature, see for example: T. L. Gilchrist in *Comprehensive Organic Synthesis*, vol. 7, pp 748–750, S. V. Ley, Ed., Pergamon Press; M. Tisler and B. Stanovnik in *Comprehensive Heterocyclic Chemistry*, vol. 3, pp 18–20, A. J. Boulton and A. McKillop, Eds., Pergamon Press; M. R. Grimmett and B. R. T. Keene in *Advances in Heterocyclic Chemistry*, vol. 43, pp 149–161, A. R. Katritzky, Ed., Academic Press; M. Tisler and B. Stanovnik in *Advances in Heterocyclic Chemistry*, vol. 9, pp 285–291, A. R. Katritzky and A. J. Boulton, Eds., Academic Press; and G. W. H. Cheeseman and E. S. G. Werstiuk in *Advances in Heterocyclic Chemistry*, vol. 22, pp 390–392, A. R. Katritzky and A. J. Boulton, Eds., Academic Press.

One skilled in the art recognizes that because in the environment and under physiological conditions salts of chemical compounds are in equilibrium with their corresponding nonsalt forms, salts share the biological utility of the nonsalt forms. Thus a

wide variety of salts of a compound of Formula 1 are useful for control of undesired vegetation (i.e. are agriculturally suitable). The salts of a compound of Formula 1 include acid-addition salts with inorganic or organic acids such as hydrobromic, hydrochloric, nitric, phosphoric, sulfuric, acetic, butyric, fumaric, lactic, maleic, malonic, oxalic, propionic, 5 salicylic, tartaric, 4-toluenesulfonic or valeric acids. When a compound of Formula 1 contains an acidic moiety such as a carboxylic acid or phenol, salts also include those formed with organic or inorganic bases such as pyridine, triethylamine or ammonia, or amides, hydrides, hydroxides or carbonates of sodium, potassium, lithium, calcium, magnesium or barium. Accordingly, the present invention comprises compounds selected from Formula 1, 10 *N*-oxides and agriculturally suitable salts thereof.

Embodiments of the present invention as described in the Summary of the Invention include (where Formula 1 as used in the following Embodiments includes *N*-oxides and salts thereof):

Embodiment 1. A compound of Formula 1 wherein when Q¹ is a 5- to 6-membered 15 heteroaromatic ring or an 8- to 10-membered heteroaromatic bicyclic ring system, each ring or ring system optionally substituted with up to 4 substituents independently selected from R⁷ on carbon atom ring members and selected from R⁹ on nitrogen atom ring members.

Embodiment 2. A compound of Embodiment 1 wherein Q¹ is unsubstituted with R⁷ 20 or R⁹.

Embodiment 3. A compound of Formula 1 wherein Q¹ is a phenyl ring or a naphthalenyl ring system, each ring or ring system optionally substituted with 1 25 to 4 substituents independently selected from R⁷.

Embodiment 4. A compound of Embodiment 3 wherein Q¹ is a phenyl ring 30 optionally substituted with 1 to 2 substituents independently selected from R⁷.

Embodiment 5. A compound of Embodiment 4 wherein Q¹ is a phenyl ring substituted with 1 substituent selected from R⁷.

Embodiment 6. A compound of Embodiment 4 wherein Q¹ is a phenyl ring 35 unsubstituted with R⁷.

Embodiment 7. A compound of Formula 1 or any one of Embodiment 1 through Embodiment 6 wherein when Q² is a 5- to 6-membered heteroaromatic ring or an 8- to 10-membered heteroaromatic bicyclic ring system, each ring or ring system optionally substituted with up to 5 substituents independently selected from R¹⁰ on carbon atom ring members and selected from R¹¹ on nitrogen atom 40 ring members.

Embodiment 8. A compound of Formula 1 or any one of Embodiment 1 through Embodiment 6 wherein Q² is a phenyl ring optionally substituted with 1 to 5 substituents independently selected from R¹⁰.

Embodiment 9. A compound of Embodiment 8 wherein Q² is a phenyl ring
optionally substituted with 1 to 3 substituents independently selected from R¹⁰.

Embodiment 10. A compound of Embodiment 9 wherein Q² is a phenyl ring
optionally substituted with 1 to 2 substituents independently selected from R¹⁰.

5 Embodiment 11. A compound of Formula 1 or any one of Embodiment 1 through
Embodiment 10 wherein Q² is a phenyl ring having at least one substituent
selected from R¹⁰ at an ortho position (and optionally other substituents).

10 Embodiment 12. A compound of Formula 1 or any one of Embodiment 1 through
Embodiment 9 wherein Q² is a phenyl ring substituted with at least two
substituents selected from R¹⁰, then at least one substituent is at an ortho
position and at least one substituent is at a para position of the phenyl ring.

15 Embodiment 13. A compound of Formula 1 or any one of Embodiment 1 through
Embodiment 9 wherein Q² is a phenyl ring substituted with three substituents
selected from R¹⁰ and the three substituents are at an ortho, meta and para
positions of the phenyl ring.

Embodiment 14. A compound of Formula 1 or any one of Embodiment 1 through
Embodiment 13 wherein T is J¹-A-.

20 Embodiment 15. A compound of Embodiment 14 wherein A is a saturated, partially
unsaturated or fully unsaturated chain containing 1- to 3- atoms selected from up
to 3 carbon, up to 1 O, up to 1 S and up to 2 N atoms, the chain optionally
substituted with up to 2 substituents independently selected from R¹⁵ on carbon
atoms and R¹⁶ on nitrogen atoms.

25 Embodiment 16. A compound of Embodiment 15 wherein A is -CH₂-, -CH₂O-,
-CH₂NH-, -CH=CH-, -C≡C-, -NH-, -O-, -S-, -SO- or -SO₂-.

Embodiment 17. A compound of Embodiment 16 wherein A is -CH₂-, -CH₂O-,
-CH₂NH-, -CH=CH-, -C≡C-, -NH- or -O-.

30 Embodiment 18. A compound of Embodiment 17 wherein A is -CH₂O- or -O-.

Embodiment 19. A compound of Formula 1 or any one of Embodiment 1 through
Embodiment 18 wherein J¹ is a phenyl ring or a naphthalenyl ring system, each
ring or ring system optionally substituted with up to 5 substituents independently
selected from R⁷; or a 4- to 6-membered heterocyclic ring or an 8- to 10-
membered heteroaromatic bicyclic ring system, each ring or ring system
containing ring members selected from carbon atoms and 1 to 4 heteroatoms
independently selected from up to 2 O, up to 2 S and up to 4 N atoms, wherein
up to 3 carbon ring members are independently selected from C(=O) and C(=S),
and the sulfur atom ring members are independently selected from
S(=O)_l(=NR⁸)_v, each ring or ring system optionally substituted with up to 5
substituents independently selected from R⁷ on carbon atom ring members and

selected from R⁹ on nitrogen atom ring members; or C₄-C₁₀ cycloalkylalkoxy, C₄-C₁₀ cycloalkylalkyl, C₂-C₈ alkenyloxy, C₂-C₈ haloalkenyloxy, C₂-C₈ alkoxyalkoxy, C₂-C₈ alkylthioalkyl, C₂-C₈ alkylsulfinylalkyl, C₂-C₈ alkylsulfonylalkyl, C₁-C₈ alkylsulfonyloxy, C₁-C₈ haloalkylsulfonyloxy, C₁-C₈ alkylthio, C₁-C₈ haloalkylthio, C₃-C₈ cycloalkylthio, C₁-C₈ alkylsulfinyl, C₁-C₈ haloalkylsulfinyl, C₁-C₈ alkylsulfonyl, C₁-C₈ haloalkylsulfonyl, C₂-C₈ alkynyl, C₂-C₈ haloalkynyl, C₂-C₈ alkoxyalkyl, C₂-C₈ haloalkoxyalkyl, C₃-C₈ haloalkoxyalkoxy, C₁-C₈ haloalkyl, C₃-C₈ halocycloalkyl, C₂-C₈ alkylcarbonyloxy or C₂-C₈ haloalkylcarbonyloxy.

5 Embodiment 20. A compound of Embodiment 19 wherein J¹ is a phenyl ring or a naphthalenyl ring system, each ring or ring system optionally substituted with up to 4 substituents independently selected from R⁷.

10 Embodiment 21. A compound of Embodiment 20 wherein J¹ is a phenyl ring optionally substituted with up to 3 substituents independently selected from R⁷.

15 Embodiment 22. A compound of Embodiment 21 wherein J¹ is a phenyl ring optionally substituted with 1 substituents independently selected from R⁷.

Embodiment 23. A compound of Embodiment 22 wherein J¹ is a phenyl ring unsubstituted with R⁷.

20 Embodiment 24. A compound of Embodiment 19 wherein J¹ is a 4- to 6-membered heterocyclic ring or an 8- to 10-membered heteroaromatic bicyclic ring system, each ring or ring system containing ring members selected from carbon atoms and 1 to 4 heteroatoms independently selected from up to 2 O, up to 2 S and up to 4 N atoms, wherein up to 3 carbon ring members are independently selected from C(=O) and C(=S), and the sulfur atom ring members are independently selected from S(=O)_u(=NR⁸)_v, each ring or ring system optionally substituted with up to 5 substituents independently selected from R⁷ on carbon atom ring members and selected from R⁹ on nitrogen atom ring members.

25 Embodiment 25. A compound of Embodiment 24 wherein J¹ is a 4- to 6-membered heterocyclic ring containing ring members selected from carbon atoms and 1 to 3 heteroatoms independently selected from up to 2 O, up to 2 S and up to 3 N atoms, wherein up to 2 carbon ring members are independently selected from C(=O) and C(=S), and the sulfur atom ring members are independently selected from S(=O)_u(=NR⁸)_v, each ring or ring system optionally substituted with up to 3 substituents independently selected from R⁷ on carbon atom ring members and selected from R⁹ on nitrogen atom ring members.

30 Embodiment 26. A compound of Embodiment 25 wherein J¹ is a 5- to 6-membered heteroaromatic ring optionally substituted with 1 substituent selected from R⁷ on carbon atom ring members.

35

Embodiment 27. A compound of Embodiment 26 wherein J^1 is an unsubstituted pyridine ring.

Embodiment 28. A compound of Embodiment 19 wherein J^1 is C_4 – C_{10} cycloalkylalkoxy, C_4 – C_{10} cycloalkylalkyl, C_2 – C_8 alkenyloxy, C_2 – C_8 haloalkenyloxy, C_2 – C_8 alkoxyalkoxy, C_2 – C_8 alkylthioalkyl, C_2 – C_8 alkylsulfinylalkyl, C_2 – C_8 alkylsulfonylalkyl, C_1 – C_8 alkylsulfonyloxy, C_1 – C_8 haloalkylsulfonyloxy, C_1 – C_8 alkylthio, C_1 – C_8 haloalkylthio, C_3 – C_8 cycloalkylthio, C_1 – C_8 alkylsulfinyl, C_1 – C_8 haloalkylsulfinyl, C_1 – C_8 alkylsulfonyl, C_1 – C_8 haloalkylsulfonyl, C_2 – C_8 alkynyl, C_2 – C_8 haloalkynyl, C_2 – C_8 alkoxyalkyl, C_2 – C_8 haloalkoxyalkyl, C_3 – C_8 haloalkoxyalkoxy, C_2 – C_8 haloalkoxyhaloalkyl, C_1 – C_8 haloalkyl, C_3 – C_8 halocycloalkyl, C_2 – C_8 alkylcarbonyloxy or C_2 – C_8 haloalkylcarbonyloxy.

Embodiment 29. A compound of Formula 1 or any one of Embodiment 1 through Embodiment 13 wherein T is $R^{17}ON=CR^{17a}$ –, $(R^{18})_2C=NO$ –, $(R^{19})_2NN=CR^{17a}$ –, $(R^{18})_2C=NNR^{20a}$ –, $R^{20}N=CR^{17a}$ –, $(R^{18})_2C=N$ –, $R^{23}ON=CR^{17a}C(R^{23b})_2$ – or $(R^{18})_2C=NOC(R^{24a})_2$ –, wherein the free bond projecting to the right indicates the connecting point to Q^1 .

Embodiment 30. A compound of Embodiment 29 wherein each R^{17} is independently H, C_1 – C_6 alkyl, C_3 – C_8 cycloalkyl, C_4 – C_8 cycloalkylalkyl, or C_1 – C_6 haloalkyl.

Embodiment 31. A compound of Embodiment 29 wherein each R^{17a} is independently H, C_1 – C_6 alkyl, C_3 – C_8 cycloalkyl, C_4 – C_8 cycloalkylalkyl, or C_1 – C_6 haloalkyl.

Embodiment 32. A compound of Embodiment 29 wherein each R^{18} is independently H, hydroxy, C_1 – C_6 alkyl, C_3 – C_8 cycloalkyl, C_4 – C_8 cycloalkylalkyl or C_1 – C_6 haloalkyl.

Embodiment 33. A compound of Embodiment 29 wherein each R^{19} is independently H, C_1 – C_6 alkyl, C_3 – C_8 cycloalkyl, C_4 – C_8 cycloalkylalkyl or C_1 – C_6 haloalkyl.

Embodiment 34. A compound of Embodiment 29 wherein each R^{20} is independently H, hydroxy, amino, C_1 – C_6 alkyl, C_3 – C_8 cycloalkyl, C_4 – C_8 cycloalkylalkyl or C_1 – C_6 haloalkyl.

Embodiment 35. A compound of Embodiment 29 wherein each R^{20a} is independently H, C_1 – C_6 alkyl, C_3 – C_8 cycloalkyl, C_4 – C_8 cycloalkylalkyl or C_1 – C_6 haloalkyl.

Embodiment 36. A compound of Embodiment 29 wherein each R^{23b} is independently H, halogen, cyano, hydroxy, C_1 – C_4 alkyl, C_3 – C_8 cycloalkyl, C_4 – C_8 cycloalkylalkyl or C_1 – C_4 haloalkyl.

Embodiment 37. A compound of Embodiment 29 wherein each R^{24a} is independently H, C₁-C₄ alkyl, C₃-C₈ cycloalkyl, C₄-C₈ cycloalkylalkyl or C₁-C₄ haloalkyl.

Embodiment 38. A compound of Formula 1 or any one of Embodiment 1 through Embodiment 37 wherein J² is -CR²R³-.

Embodiment 39. A compound of Formula 1 or any one of Embodiment 1 through Embodiment 37 wherein J² is -CR²R³-CR^{2a}R^{3a}-.

Embodiment 40. A compound of Formula 1 or any one of Embodiment 1 through Embodiment 39 wherein R¹ is H, hydroxy, amino, C₁-C₆ alkyl, C₁-C₆ haloalkyl, C₂-C₆ alkenyl, C₃-C₆ alkynyl, C₂-C₆ cyanoalkyl, C₃-C₆ cycloalkyl or C₄-C₈ cycloalkylalkyl.

Embodiment 41. A compound of Embodiment 40 wherein R¹ is H, C₁-C₆ alkyl or C₁-C₆ haloalkyl.

Embodiment 42. A compound of Embodiment 41 wherein R¹ is H, Me, Et or CHF₂.

Embodiment 43. A compound of Embodiment 42 wherein R¹ is H, Me or Et.

Embodiment 44. A compound of Embodiment 43 wherein R¹ is H.

Embodiment 45. A compound of Embodiment 43 wherein R¹ is Me.

Embodiment 46. A compound of Formula 1 or any one of Embodiment 1 through Embodiment 45 wherein R² is H or CH₃.

Embodiment 47. A compound of Embodiment 46 wherein R² is H.

Embodiment 48. A compound of Formula 1 or any one of Embodiment 1 through Embodiment 47 wherein R³ is H or CH₃.

Embodiment 49. A compound of Embodiment 48 wherein R³ is H.

Embodiment 50. A compound of Formula 1 or any one of Embodiment 1 through Embodiment 49 wherein R^{2a} is H or CH₃.

Embodiment 51. A compound of Embodiment 50 wherein R^{2a} is H.

Embodiment 52. A compound of Formula 1 or any one of Embodiment 1 through Embodiment 51 wherein R^{3a} is H or CH₃.

Embodiment 53. A compound of Embodiment 52 wherein R^{3a} is H.

Embodiment 54. A compound of Formula 1 or any one of Embodiment 1 through Embodiment 53 wherein R⁴ is H or CH₃.

Embodiment 55. A compound of Embodiment 54 wherein R⁴ is H.

Embodiment 56. A compound of Formula 1 or any one of Embodiment 1 through Embodiment 55 wherein R⁵ is H or CH₃.

Embodiment 57. A compound of Embodiment 56 wherein R⁵ is H.

Embodiment 58. A compound of Formula 1 or any one of Embodiment 1 through Embodiment 57 wherein R⁶ is H or CH₃.

Embodiment 59. A compound of Embodiment 58 wherein R⁶ is H.

Embodiment 60. A compound of Formula 1 or any one of Embodiment 1 through

5 Embodiment 59 wherein each R⁷ is independently halogen, cyano, nitro, C₁-C₄ alkyl, C₁-C₄ cyanoalkyl, C₁-C₄ cyanoalkoxy, C₁-C₄ haloalkyl, C₂-C₄ alkenyl, C₂-C₄ haloalkenyl C₂-C₄ alkynyl, C₂-C₄ haloalkynyl, C₁-C₄ nitroalkyl, C₂-C₄ nitroalkenyl, C₂-C₄ alkoxyalkyl, C₂-C₄ haloalkoxyalkyl, C₃-C₄ cycloalkyl, C₃-C₄ halocycloalkyl, cyclopropylmethyl, methylcyclopropyl, C₁-C₄ alkoxy, C₁-C₄ haloalkoxy, C₂-C₄ alkenyloxy, C₂-C₄ haloalkenyloxy, C₃-C₄ alkynyloxy, C₃-C₄ haloalkynyloxy, C₃-C₄ cycloalkoxy, C₁-C₄ alkylthio, C₁-C₄ haloalkylthio, C₁-C₄ alkylsulfinyl, C₁-C₄ haloalkylsulfinyl, C₁-C₄ alkylsulfonyl, C₁-C₄ haloalkylsulfonyl, hydroxy, formyl, C₂-C₄ alkylcarbonyl, C₂-C₄ alkylcarbonyloxy, C₁-C₄ alkylsulfonyloxy, C₁-C₄ haloalkylsulfonyloxy, amino, C₁-C₄ alkylamino, C₂-C₄ dialkylamino, formylamino, C₂-C₄ alkylcarbonylamino, -SF₅, -SCN, C₃-C₄ trialkylsilyl, trimethylsilylmethyl or trimethylsilylmethoxy.

10 Embodiment 61. A compound of Embodiment 60 wherein each R⁷ is independently halogen, cyano, C₁-C₂ alkyl, C₁-C₃ haloalkyl or C₁-C₃ alkylsulfonyl.

15 Embodiment 62. A compound of Embodiment 61 wherein each R⁷ is independently halogen or C₁-C₂ haloalkyl.

20 Embodiment 63. A compound of Embodiment 62 wherein each R⁷ is independently halogen or CF₃.

25 Embodiment 64. A compound of Embodiment 63 wherein each R⁷ is independently F or CF₃.

Embodiment 65. A compound of Formula 1 or any one of Embodiment 1 through
25 Embodiment 64 wherein each R¹⁰ is independently halogen, cyano, nitro, C₁-C₂ alkyl, C₁-C₃ haloalkyl or C₁-C₃ alkylsulfonyl.

30 Embodiment 66. A compound of Embodiment 65 wherein each R¹⁰ is independently halogen or C₁-C₂ haloalkyl.

Embodiment 67. A compound of Embodiment 66 wherein each R¹⁰ is independently halogen or CF₃.

35 Embodiment 68. A compound of Embodiment 67 wherein each R¹⁰ is independently F or CF₃.

Embodiment 69. A compound of Embodiment 68 wherein each R¹⁰ is independently F.

35 Embodiment 70. A compound of Formula 1 or any one of Embodiment 1 through Embodiment 69 wherein each R⁷ is independently halogen, cyano, nitro, C₁-C₈ alkyl or C₁-C₈ haloalkyl.

Embodiment 71. A compound of Embodiment 70 wherein each R⁷ is independently halogen.

Embodiment 72. A compound of Formula 1 or any one of Embodiment 1 through Embodiment 71 wherein Y¹ is O.

5 Embodiment 73. A compound of Formula 1 or any one of Embodiment 1 through Embodiment 72 wherein Y² is O.

Embodiment 74. A compound of Formula 1 or any one of Embodiment 1 through Embodiment 73 wherein Y¹ and Y² are both O.

10 Embodiment 75. A compound of Formula 1 or any one of Embodiment 1 through Embodiment 74 wherein each R⁹, R^{9'} and R¹¹ is independently C₁-C₃ alkyl or C₃-C₆ cycloalkyl.

Embodiment 76. A compound of Formula 1 wherein T is attached at the 2- or 3-position of Q¹.

15 Embodiment 77. A compound of Formula 1 whererin T is attached at the 3-position of Q¹.

Embodiment 78. A compound of Formula 1 wherein T is R¹⁷ON=CR^{17a}-, (R¹⁸)₂C=NO- or (R¹⁹)₂NN=CR^{17a}-, wherein the free bond projecting to the right indicates the connecting point to Q¹.

20 Embodiment 79. A compound of Embodiment 77 wherein T is R¹⁷ON=CR^{17a}- or (R¹⁹)₂NN=CR^{17a}-, wherein the free bond projecting to the right indicates the connecting point to Q¹.

25 Embodiment 80. A compound of Formula 1 wherein J¹ is a phenyl ring or a naphthalenyl ring system, each ring or ring system optionally substituted with up to 5 substituents independently selected from R⁷; or a 4- to 6-membered heterocyclic ring or an 8- to 10-membered heteroaromatic bicyclic ring system, each ring or ring system containing ring members selected from carbon atoms and 1 to 4 heteroatoms independently selected from up to 2 O, up to 2 S and up to 4 N atoms, wherein up to 3 carbon ring members are independently selected from C(=O) and C(=S), and the sulfur atom ring members are independently selected from S(=O)_u(=NR⁸)_v, each ring or ring system optionally substituted with up to 5 substituents independently selected from R⁷ on carbon atom ring members and selected from R⁹ on nitrogen atom ring members.

30

35 Embodiment 81. A compound of Formula 1 wherein J¹ is C₄-C₁₀ cycloalkylalkoxy, C₄-C₁₀ cycloalkylalkyl, C₂-C₈ alkenyloxy, C₂-C₈ haloalkenyloxy, C₂-C₈ alkoxyalkoxy, C₂-C₈ alkylthioalkyl, C₂-C₈ alkylsulfinylalkyl, C₂-C₈ alkylsulfonylalkyl, C₁-C₈ alkylsulfonyloxy, C₁-C₈ haloalkylsulfonyloxy, C₁-C₈ alkylthio, C₁-C₈ haloalkylthio, C₃-C₈ cycloalkylthio, C₁-C₈ alkylsulfinyl, C₁-C₈ haloalkylsulfinyl, C₁-C₈ alkylsulfonyl, C₁-C₈ haloalkylsulfonyl, C₂-C₈

alkynyl, C₂–C₈ haloalkynyl, C₂–C₈ alkoxyalkyl, C₂–C₈ haloalkoxyalkyl, C₃–C₈ haloalkoxyalkoxy, C₂–C₈ haloalkoxyhaloalkyl, C₁–C₈ haloalkyl, C₃–C₈ halocycloalkyl, C₂–C₈ alkylcarbonyloxy or C₂–C₈ haloalkylcarbonyloxy.

Embodiment 82. A compound of Embodiment 80 wherein J¹ is C₄–C₁₀

5 cycloalkylalkoxy, C₂–C₈ alkenyloxy, C₂–C₈ haloalkenyloxy, C₂–C₈ alkoxyalkoxy, C₂–C₈ alkylsulfonylalkyl, C₁–C₈ alkylsulfonyloxy, C₁–C₈ haloalkylsulfonyloxy, C₁–C₈ alkylthio, C₁–C₈ haloalkylthio, C₃–C₈ cycloalkylthio, C₁–C₈ alkylsulfinyl, C₁–C₈ haloalkylsulfinyl, C₁–C₈ alkylsulfonyl, C₁–C₈ haloalkylsulfonyl, C₃–C₈ haloalkoxyalkoxy, C₂–C₈ alkylcarbonyloxy or C₂–C₈ haloalkylcarbonyloxy.

10 Embodiment 83. A compound of Embodiment 81 wherein J¹ is C₄–C₁₀

cycloalkylalkyl, C₂–C₈ alkylthioalkyl, C₂–C₈ alkylsulfinylalkyl, C₂–C₈ alkylsulfonylalkyl, C₂–C₈ alkynyl, C₂–C₈ haloalkynyl, C₂–C₈ alkoxyalkyl, C₂–C₈ haloalkoxyalkyl, C₁–C₈ haloalkyl or C₃–C₈ halocycloalkyl.

15 Embodiment 84. A compound of Embodiment 83 wherein J¹ is C₂–C₈

alkylthioalkyl, C₂–C₈ alkylsulfinylalkyl, C₂–C₈ alkylsulfonylalkyl, C₂–C₈ alkoxyalkyl or C₂–C₈ haloalkoxyalkyl.

20 Embodiment 85. A compound of Formula 1 or Embodiment 15 wherein A is a

saturated, partially unsaturated or fully unsaturated chain containing 2- to

3- atoms selected from up to 3 carbon, up to 1 O, up to 1 S and up to 1 N atom,

the chain optionally substituted with up to 2 substituents independently selected

from R¹⁵ on carbon atoms and R¹⁶ on nitrogen atoms.

25 Embodiment 86. A compound of Embodiment 85 wherin A is a saturated, partially

unsaturated or fully unsaturated chain containing 2- to 3- atoms selected from up

to 3 carbon, up to 1 O, and up to 1 N atom, the chain optionally substituted with

up to 2 substituents independently selected from R¹⁵ on carbon atoms and R¹⁶

on nitrogen atoms.

30 Embodiment 87. A compound of Embodiment 86 wherin A is a chain containing

2- to 3- atoms selected from up to 2 carbon, up to 1 O, and up to 1 N atom, the

chain optionally substituted with up to 2 substituents independently selected

from R¹⁵ on carbon atoms and R¹⁶ on nitrogen atoms.

35 Embodiment 88. A compound of Formula 1 wherein A is -CH₂-, -CH₂O-, -OCH₂-,

-CH₂NH-, -CH₂CH₂-, -CH=CH-, -C≡C-, -NH-, -O-, -S-, -SO- or -SO₂-.

Embodiment 89. A compound of Formula 1 wherein A is -CH₂-, -CH₂O-, -OCH₂-

or -O-.SO- or -SO₂-.

40 Embodiment 90. A compound of Formula 1 wherein A is -CH₂O-, -OCH₂-,

-CH₂CH₂-, -CH=CH- or -C≡C-.

Embodiment 91. A compound of Formula **1** or any one of Embodiments 16 through 19 or 88 through 90 wherein the free bond projecting to the right indicates the connecting point of A to Q¹ and the free bond projecting to the left indicates the connecting point of A to J¹.

5 Embodiment 92. A compound of Formula **1** wherein when J² is -CR²R³- and J¹ is a phenyl ring optionally substituted with up to 5 substituents independently selected from R⁷, then R⁷ is other than halogen, hydroxyl, cyano, nitro, C₁-C₆ alkyl, C₁-C₆ haloalkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, CHO, C₂-C₈ alkylcarbonyl, C₂-C₈ haloalkylcarbonyl, -C(=O)OH, C₂-C₈ alkoxy carbonyl, C₄-C₁₀ cycloalkoxy carbonyl, C₅-C₁₂ cycloalkylalkoxy carbonyl, -C(=O)NH₂, C₂-C₈ alkylaminocarbonyl, C₃-C₁₀ dialkylaminocarbonyl, hydroxy, C₁-C₆ alkoxy, C₁-C₆ haloalkoxy, C₂-C₈ alkylcarbonyloxy, C₁-C₆ alkylthio, C₁-C₆ haloalkylthio, C₁-C₆ alkylsulfinyl, C₁-C₆ haloalkylsulfinyl, C₁-C₆ alkylamino, C₂-C₈ dialkylamino, C₂-C₈ alkylcarbonylamino, C₁-C₆ alkylsulfonylamino or C₃-C₁₀ trialkylsilyl.

10 Embodiment 93. A compound of Formula **1** wherein when J² is -CR²R³-CR^{2a}R^{3a}- and J¹ is a pyridyl ring (i.e. a 6-membered heterocyclic ring optionally substituted with up to 5 substituents independently selected from R⁷ on carbon atom ring members) then R⁷ is other than halogen, hydroxyl, cyano, nitro, C₁-C₆ alkyl, C₁-C₆ haloalkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, CHO, C₂-C₈ alkylcarbonyl, C₂-C₈ haloalkylcarbonyl, -C(=O)OH, C₂-C₈ alkoxy carbonyl, C₄-C₁₀ cycloalkoxy carbonyl, C₅-C₁₂ cycloalkylalkoxy carbonyl, -C(=O)NH₂, C₂-C₈ alkylaminocarbonyl, C₃-C₁₀ dialkylaminocarbonyl, hydroxy, C₁-C₆ alkoxy, C₁-C₆ haloalkoxy, C₂-C₈ alkylcarbonyloxy, C₁-C₆ alkylthio, C₁-C₆ haloalkylthio, C₁-C₆ alkylsulfinyl, C₁-C₆ haloalkylsulfinyl, C₁-C₆ alkylamino, C₂-C₈ dialkylamino, C₂-C₈ alkylcarbonylamino, C₁-C₆ alkylsulfonylamino or C₃-C₁₀ trialkylsilyl.

15 Embodiment 94. A compound of Formula **1** wherein Q¹ is a 5- to 6-membered heteroaromatic ring or an 8- to 10-membered heteroaromatic bicyclic ring system, each ring or ring system optionally substituted with up to 4 substituents independently selected from R⁷ on carbon atom ring members and selected from R⁹ on nitrogen atom ring members.

20 Embodiment 95. A compound of Formula **1** wherein Q¹ is a phenyl ring optionally substituted with 1 to 4 substituents independently selected from R⁷; or a 5- to 6-membered heteroaromatic ring containing ring members selected from carbon atoms and 1 to 4 heteroatoms independently selected from up to 2 O, up to 2 S and up to 4 N atoms, optionally substituted with up to 4 substituents

independently selected from R⁷ on carbon atom ring members and selected from R⁹ on nitrogen atom ring members.

5 Embodiment 96. A compound of Formula 1 or Embodiment 95 wherein Q¹ is a phenyl ring optionally substituted with up to 4 substituents independently selected from R⁷.

10 Embodiment 97. A compound of Formula 1 wherein Q² is a phenyl ring optionally substituted with up to 5 substituents independently selected from R¹⁰; or a 5- to 6-membered heteroaromatic ring containing ring members selected from carbon atoms and 1 to 4 heteroatoms independently selected from up to 2 O, up to 2 S and up to 4 N atoms, optionally substituted with up to 5 substituents independently selected from R¹⁰ on carbon atom ring members and selected from R¹¹ on nitrogen atom ring members.

15 Embodiment 98. A compound of Formula 1 or Embodiment 97 wherein Q² is a phenyl ring optionally substituted with up to 4 substituents independently selected from R¹⁰.

20 Embodiment 99. A compound of Formula 1 wherein J¹ is a phenyl ring optionally substituted with up to 5 substituents independently selected from R^{7'}; or a 4- to 6-membered heterocyclic ring containing ring members selected from carbon atoms and 1 to 4 heteroatoms independently selected from up to 2 O, up to 2 S and up to 4 N atoms, optionally substituted with up to 5 substituents independently selected from R^{7'} on carbon atom ring members and selected from R^{9'} on nitrogen atom ring members.

25 Embodiment 100. A compound of Formula 1 or Embodiment 99 wherein J¹ is a phenyl ring optionally substituted with up to 4 substituents independently selected from R^{7'}; or a 6-membered heterocyclic ring containing ring members selected from carbon atoms and 1 to 3 heteroatoms independently selected from up to 3 N atoms, optionally substituted with up to 4 substituents independently selected from R^{7'} on carbon atom ring members and selected from R^{9'} on nitrogen atom ring members.

30 Embodiment 101. A compound of Formula 1 wherein R⁷ is independently halogen, CH₃, CH₂CH₃ or CF₃.

Embodiment 102. A compound of Formula 1 wherein R¹⁰ is independently halogen, CH₃, CH₂CH₃ or CF₃.

35 Embodiment 103. A compound of Formula 1 wherein each R¹⁰ is independently cyano or CH₃.

Embodiment 104. A compound of Formula 1 wherein each R¹⁶ is H.

Embodiment 105. A compound of Formula 1 wherein each R¹⁶ is other than H.

Embodiments of this invention, including Embodiments 1–105 above as well as any other embodiments described herein, can be combined in any manner, and the descriptions of variables in the embodiments pertain not only to the compounds of Formula 1 but also to the starting compounds and intermediate compounds useful for preparing the compounds of 5 Formula 1. In addition, embodiments of this invention, including Embodiments 1–105 above as well as any other embodiments described herein, and any combination thereof, pertain to the compositions and methods of the present invention.

Combinations of Embodiments 1–105 are illustrated by:

Embodiment A. A compound of Formula 1 wherein

10 Q^1 is a phenyl ring substituted with up to 2 substituents selected from R^7 ;
 Q^2 is a phenyl ring substituted with 1 to 3 substituents independently selected from R^{10} ; and
 A is $-\text{CH}_2-$, $-\text{CH}_2\text{O}-$, $-\text{CH}_2\text{NH}-$, $-\text{CH}=\text{CH}-$, $-\text{C}\equiv\text{C}-$, $-\text{NH}-$, $-\text{O}-$, $-\text{S}-$, $-\text{SO}-$ or $-\text{SO}_2-$.

Embodiment B. A compound of Embodiment A wherein

15 J^1 is a phenyl ring optionally substituted with 1 substituents independently selected from $R^{7'}$;
 J^2 is $-\text{CR}^2\text{R}^3-$;
 Y^1 and Y^2 are both O;
 R^1 is H, Me or Et;
20 R^4 is H;
 R^5 is H;
 R^6 is H;
each R^7 is independently halogen or CF_3 ;
each $R^{7'}$ is independently halogen, cyano, nitro, $\text{C}_1\text{-C}_8$ alkyl or $\text{C}_1\text{-C}_8$ haloalkyl;
25 and
each R^{10} is independently halogen or CF_3 .

Embodiment C. A compound of Embodiment A wherein

30 J^1 is a 5- to 6-membered heteroaromatic ring optionally substituted with 1 substituent selected from $R^{7'}$ on carbon atom ring member;
 J^2 is $-\text{CR}^2\text{R}^3-$;
 Y^1 and Y^2 are both O;
 R^1 is H, Me or Et;
 R^4 is H;
 R^5 is H;
35 R^6 is H;
each R^7 is independently halogen or CF_3 ;
each $R^{7'}$ is independently halogen, cyano, nitro, $\text{C}_1\text{-C}_8$ alkyl or $\text{C}_1\text{-C}_8$ haloalkyl;
and

each R^{10} is independently halogen or CF_3 .

Embodiment D. A compound of Embodiment B wherein

Q^1 is a phenyl ring unsubstituted with R^7 ;

Q^2 is a phenyl ring substituted with at least two substituents selected from R^{10} , at least one substituent is at an ortho position and at least one substituent is at a para position of the phenyl ring;

A is $-CH_2-$, $-CH_2O-$, $-CH_2NH-$, $-CH=CH-$, $-C\equiv C-$, $-NH-$ or O ;

J^1 is a phenyl ring unsubstituted with R^7 ;

R^2 is H ; and

R^3 is H .

Embodiment E. A compound of Embodiment D wherein

A is $-CH_2O-$ or $-O-$.

Embodiment F. A compound of Embodiment C wherein

Q^1 is a phenyl ring unsubstituted with R^7 ;

Q^2 is a phenyl ring substituted with at least two substituents selected from R^{10} , at least one substituent is at an ortho position and at least one substituent is at a para position of the phenyl ring;

A is CH_2 , $-CH_2O-$, $-CH_2NH-$, $-CH=CH-$, $-C\equiv C-$, $-NH-$ or O ;

J^1 is a 5- to 6-membered heteroaromatic ring optionally substituted with up to 1 substituent selected from R^7 on carbon atom ring member;

R^2 is H ; and

R^3 is H .

Embodiment G. A compound of Embodiment F wherein

J^1 is an unsubstituted pyridine ring;

Q^2 is a phenyl ring substituted with three substituents selected from R^{10} and the three substituents are at ortho, meta and para positions (of the phenyl ring); and

A is $-CH_2O-$ or $-O-$.

Embodiment H. A compound of Formula 1 wherein

Q^1 is a phenyl ring optionally substituted with 1 to 4 substituents

independently selected from R^7 , or a 5- to 6-membered heteroaromatic ring containing ring members selected from carbon atoms and 1 to 4 heteroatoms independently selected from up to 2 O, up to 2 S and up to 4 N atoms, optionally substituted with up to 4 substituents

independently selected from R^7 on carbon atom ring members and selected from R^9 on nitrogen atom ring members;

Q^2 is a phenyl ring optionally substituted with up to 5 substituents

independently selected from R^{10} ; or a 5- to 6-membered heteroaromatic

ring containing ring members selected from carbon atoms and 1 to 4 heteroatoms independently selected from up to 2 O, up to 2 S and up to 4 N atoms, optionally substituted with up to 5 substituents independently selected from R¹⁰ on carbon atom ring members and selected from R¹¹ on nitrogen atom ring members;

5 J¹ is a phenyl ring optionally substituted with up to 5 substituents independently selected from R⁷; or a 4- to 6-membered heterocyclic ring containing ring members selected from carbon atoms and 1 to 4 heteroatoms independently selected from up to 2 O, up to 2 S and up to 4 N atoms, optionally substituted with up to 5 substituents independently selected from R⁷ on carbon atom ring members and selected from R⁹ on nitrogen atom ring members;

10 R¹ is H, hydroxy, amino, C₁-C₆ alkyl, C₁-C₆ haloalkyl, C₂-C₆ alkenyl, C₃-C₆ alkynyl, C₂-C₆ cyanoalkyl, C₃-C₆ cycloalkyl or C₄-C₈ cycloalkylalkyl; and

15 A is a saturated, partially unsaturated or fully unsaturated chain containing 2- to 3- atoms selected from up to 3 carbon, up to 1 O, up to 1 S and up to 1 N atom, the chain optionally substituted with up to 2 substituents independently selected from R¹⁵ on carbon atoms and R¹⁶ on nitrogen atoms.

20 Embodiment I. A compound of Formula 1 or Embodiment H wherein

Q¹ is a phenyl ring or a naphthalenyl ring system, each ring or ring system optionally substituted with 1 to 4 substituents independently selected from R⁷;

25 Q² is a phenyl ring optionally substituted with 1 to 5 substituents independently selected from R¹⁰; and

J¹ is a phenyl ring or a naphthalenyl ring system, each ring or ring system optionally substituted with up to 4 substituents independently selected from R⁷.

30 Embodiment J. A compound of Embodiment I wherein

A is -CH₂-, -CH₂O-, -CH₂NH-, -CH=CH-, -C≡C-, -NH-, -O-, -S-, -SO- or -SO₂;

each R⁷ is independently halogen, cyano, C₁-C₂ alkyl, C₁-C₃ haloalkyl or C₁-C₃ alkylsulfonyl;

35 each R¹⁰ is independently halogen, cyano, nitro, C₁-C₂ alkyl, C₁-C₃ haloalkyl or C₁-C₃ alkylsulfonyl;

each R⁷ is independently halogen, cyano, nitro, C₁-C₈ alkyl or C₁-C₈ haloalkyl;

Y¹ and Y² are both O.

Embodiment K. A compound of Formula 1 or Embodiment H wherein

Q¹ is a phenyl ring or a naphthalenyl ring system, each ring or ring system optionally substituted with 1 to 4 substituents independently selected from R⁷;

Q² is a phenyl ring optionally substituted with 1 to 5 substituents independently selected from R¹⁰; and

J¹ is a 4- to 6-membered heterocyclic ring containing ring members selected from carbon atoms and 1 to 3 heteroatoms independently selected from up to 2 O, up to 2 S and up to 3 N atoms, wherein up to 2 carbon ring members are independently selected from C(=O) and C(=S), and the sulfur atom ring members are independently selected from S(=O)_u(=NR⁸)_v, each ring or ring system optionally substituted with up to 3 substituents independently selected from R⁷ on carbon atom ring members and selected from R⁹ on nitrogen atom ring members.

Embodiment L. A compound of Embodiment K wherein

A is -CH₂-, -CH₂O-, -CH₂NH-, -CH=CH-, -C≡C-, -NH-, -O-, -S-, -SO- or -SO₂-,

each R⁷ is independently halogen, cyano, C₁-C₂ alkyl, C₁-C₃ haloalkyl or C₁-C₃ alkylsulfonyl;

each R¹⁰ is independently halogen, cyano, nitro, C₁-C₂ alkyl, C₁-C₃ haloalkyl or C₁-C₃ alkylsulfonyl;

each R⁷ is independently halogen, cyano, nitro, C₁-C₈ alkyl or C₁-C₈ haloalkyl; and

Y¹ and Y² are both O.

Embodiment M. A compound of Formula 1 or Embodiment H wherein

Q¹ is a 5- to 6-membered heteroaromatic ring or an 8- to 10-membered heteroaromatic bicyclic ring system, each ring or ring system optionally substituted with up to 4 substituents independently selected from R⁷ on carbon atom ring members and selected from R⁹ on nitrogen atom ring members;

Q² is a phenyl ring optionally substituted with 1 to 5 substituents independently selected from R¹⁰; and

J¹ is a 4- to 6-membered heterocyclic ring containing ring members selected from carbon atoms and 1 to 3 heteroatoms independently selected from up to 2 O, up to 2 S and up to 3 N atoms, wherein up to 2 carbon ring members are independently selected from C(=O) and C(=S), and the sulfur atom ring members are independently selected from

$S(=O)_u(=NR^8)_v$, each ring or ring system optionally substituted with up to 3 substituents independently selected from R^7 on carbon atom ring members and selected from R^9 on nitrogen atom ring members.

Embodiment N. A compound of Embodiment M wherein

5 A is $-CH_2-$, $-CH_2O-$, $-CH_2NH-$, $-CH=CH-$, $-C\equiv C-$, $-NH-$, $-O-$, $-S-$, $-SO-$ or $-SO_2-$;

each R^7 is independently halogen, cyano, C_1 - C_2 alkyl, C_1 - C_3 haloalkyl or C_1 - C_3 alkylsulfonyl;

each R^{10} is independently halogen, cyano, nitro, C_1 - C_2 alkyl, C_1 - C_3 haloalkyl or C_1 - C_3 alkylsulfonyl;

each R^7' is independently halogen, cyano, nitro, C_1 - C_8 alkyl or C_1 - C_8 haloalkyl; and

Y^1 and Y^2 are both O.

Embodiment O. A compound of Formula 1 or Embodiment H wherein

15 Q¹ is a 5- to 6-membered heteroaromatic ring or an 8- to 10-membered heteroaromatic bicyclic ring system, each ring or ring system optionally substituted with up to 4 substituents independently selected from R^7 on carbon atom ring members and selected from R^9 on nitrogen atom ring members;

20 Q² is a phenyl ring optionally substituted with 1 to 5 substituents independently selected from R^{10} ; and

J¹ is a phenyl ring or a naphthalenyl ring system, each ring or ring system optionally substituted with up to 4 substituents independently selected from R^7' .

25 Embodiment P. A compound of Embodiment O wherein

A is $-CH_2-$, $-CH_2O-$, $-CH_2NH-$, $-CH=CH-$, $-C\equiv C-$, $-NH-$, $-O-$, $-S-$, $-SO-$ or $-SO_2-$;

each R^7 is independently halogen, cyano, C_1 - C_2 alkyl, C_1 - C_3 haloalkyl or C_1 - C_3 alkylsulfonyl;

each R^{10} is independently halogen, cyano, nitro, C_1 - C_2 alkyl, C_1 - C_3 haloalkyl or C_1 - C_3 alkylsulfonyl;

each R^7' is independently halogen, cyano, nitro, C_1 - C_8 alkyl or C_1 - C_8 haloalkyl; and

Y^1 and Y^2 are both O.

35 Specific embodiments include compounds of Formula 1 selected from the group consisting of:

N-(2,4-difluorophenyl)-2-oxo-4-[3-(phenoxyethyl)phenyl]-3-pyrrolidinecarboxamide; and

2-oxo-4-[3-(2-pyridinyloxy)phenyl]-N-(2,3,4-trifluorophenyl)-3-pyrrolidinecarboxamide.

This invention also relates to a method for controlling undesired vegetation comprising applying to the locus of the vegetation herbicidally effective amounts of the compounds of the invention (e.g., as a composition described herein). Of note as embodiments relating to methods of use are those involving the compounds of embodiments described above. Compounds of the invention are particularly useful for selective control of weeds in crops such as wheat, barley, maize, soybean, sunflower, cotton, oilseed rape and rice, and specialty crops such as sugarcane, citrus, fruit and nut crops.

10 Also noteworthy as embodiments are herbicidal compositions of the present invention comprising the compounds of embodiments described above.

This invention also includes a herbicidal mixture comprising (a) a compound selected from Formula 1, *N*-oxides, and salts thereof, and (b) at least one additional active ingredient selected from (b1) photosystem II inhibitors, (b2) acetohydroxy acid synthase (AHAS) inhibitors, (b3) acetyl-CoA carboxylase (ACCase) inhibitors, (b4) auxin mimics, (b5) 5-enol-pyruvylshikimate-3-phosphate (EPSP) synthase inhibitors, (b6) photosystem I electron diverters, (b7) protoporphyrinogen oxidase (PPO) inhibitors, (b8) glutamine synthetase (GS) inhibitors, (b9) very long chain fatty acid (VLCFA) elongase inhibitors, (b10) auxin transport inhibitors, (b11) phytoene desaturase (PDS) inhibitors, (b12) 4-hydroxyphenyl-pyruvate dioxygenase (HPPD) inhibitors, (b13) homogentisate solenesyltransferase (HST) inhibitors, (b14) cellulose biosynthesis inhibitors, (b15) other herbicides including mitotic disruptors, organic arsenicals, asulam, bromobutide, cinmethylin, cumyluron, dazomet, difenzoquat, dymron, etobenzanid, flurenol, fosamine, fosamine-ammonium, hydantocidin, metam, methyldymron, oleic acid, oxaziclofene, pelargonic acid and pyributicarb, and (b16) herbicide safeners; and salts of compounds of (b1) through (b16).

“Photosystem II inhibitors” (b1) are chemical compounds that bind to the D-1 protein at the Q_B-binding niche and thus block electron transport from Q_A to Q_B in the chloroplast thylakoid membranes. The electrons blocked from passing through photosystem II are transferred through a series of reactions to form toxic compounds that disrupt cell membranes and cause chloroplast swelling, membrane leakage, and ultimately cellular destruction. The Q_B-binding niche has three different binding sites: binding site A binds the triazines such as atrazine, triazinones such as hexazinone, and uracils such as bromacil, binding site B binds the phenylureas such as diuron, and binding site C binds benzothiadiazoles such as bentazon, nitriles such as bromoxynil and phenyl-pyridazines such as pyridate. Examples of photosystem II inhibitors include ametryn, amicarbazone, atrazine, bentazon, bromacil, bromofenoxim, bromoxynil, chlorbromuron, chlорidazon, chlorotoluron, chloroxuron, cumyluron, cyanazine, daimuron, desmedipham, desmetryn, dimefuron,

dimethametryn, diuron, ethidimuron, fenuron, fluometuron, hexazinone, ioxynil, isoproturon, isouron, lenacil, linuron, metamitron, methabenzthiazuron, metobromuron, metoxuron, metribuzin, monolinuron, neburon, pentanochlor, phenmedipham, prometon, prometryn, propanil, propazine, pyridafol, pyridate, siduron, simazine, simetryn, tebuthiuron, 5 terbacil, terbumeton, terbutylazine, terbutryn and trietazine.

“AHAS inhibitors” (b2) are chemical compounds that inhibit acetohydroxy acid synthase (AHAS), also known as acetolactate synthase (ALS), and thus kill plants by inhibiting the production of the branched-chain aliphatic amino acids such as valine, leucine and isoleucine, which are required for protein synthesis and cell growth. Examples of 10 AHAS inhibitors include amidosulfuron, azimsulfuron, bensulfuron-methyl, bispyribac-sodium, cloransulam-methyl, chlorimuron-ethyl, chlorsulfuron, cinosulfuron, cyclosulfamuron, diclosulam, ethametsulfuron-methyl, ethoxysulfuron, flazasulfuron, florasulam, flucarbazone-sodium, flumetsulam, flupyrulfuron-methyl, flupyrulfuron-sodium, foramsulfuron, halosulfuron-methyl, imazamethabenz-methyl, imazamox, imazapic, 15 imazapyr, imazaquin, imazethapyr, imazosulfuron, iodosulfuron-methyl (including sodium salt), iofensulfuron (2-iodo-N-[(4-methoxy-6-methyl-1,3,5-triazin-2-yl)amino]carbonyl]benzenesulfonamide), mesosulfuron-methyl, metazosulfuron (3-chloro-4-(5,6-dihydro-5-methyl-1,4,2-dioxazin-3-yl)-N-[(4,6-dimethoxy-2-pyrimidinyl)amino]carbonyl]-1-methyl-1*H*-pyrazole-5-sulfonamide), metosulam, 20 metsulfuron-methyl, nicosulfuron, oxasulfuron, penoxsulam, primisulfuron-methyl, propoxycarbazone-sodium, propyrisulfuron (2-chloro-N-[(4,6-dimethoxy-2-pyrimidinyl)amino]carbonyl]-6-propylimidazo[1,2-*b*]pyridazine-3-sulfonamide), prosulfuron, pyrazosulfuron-ethyl, pyribenzoxim, pyriftalid, pyriminobac-methyl, pyrithiobac-sodium, rimsulfuron, sulfometuron-methyl, sulfosulfuron, thiencarbazone, 25 thifensulfuron-methyl, triafamone (N-[2-[(4,6-dimethoxy-1,3,5-triazin-2-yl)carbonyl]-6-fluorophenyl]-1,1-difluoro-*N*-methylmethanesulfonamide), triasulfuron, tribenuron-methyl, trifloxsulfuron (including sodium salt), triflusulfuron-methyl and tritosulfuron.

“ACCase inhibitors” (b3) are chemical compounds that inhibit the acetyl-CoA carboxylase enzyme, which is responsible for catalyzing an early step in lipid and fatty acid synthesis in plants. Lipids are essential components of cell membranes, and without them, new cells cannot be produced. The inhibition of acetyl CoA carboxylase and the subsequent lack of lipid production leads to losses in cell membrane integrity, especially in regions of active growth such as meristems. Eventually shoot and rhizome growth ceases, and shoot meristems and rhizome buds begin to die back. Examples of ACCase inhibitors include 30 alloxydim, butroxydim, clethodim, clodinafop, cycloxydim, cyhalofop, diclofop, fenoxaprop, fluazifop, haloxyfop, pinoxaden, profoxydim, propaquizafop, quizalofop, sethoxydim, tepraloxydim and tralkoxydim, including resolved forms such as fenoxaprop-P, 35

fluazifop-P, haloxyfop-P and quizalofop-P and ester forms such as clodinafop-propargyl, cyhalofop-butyl, diclofop-methyl and fenoxaprop-P-ethyl.

Auxin is a plant hormone that regulates growth in many plant tissues. “Auxin mimics” (b4) are chemical compounds mimicking the plant growth hormone auxin, thus causing 5 uncontrolled and disorganized growth leading to plant death in susceptible species. Examples of auxin mimics include aminocyclopyrachlor (6-amino-5-chloro-2-cyclopropyl-4-pyrimidinecarboxylic acid) and its methyl and ethyl esters and its sodium and potassium salts, aminopyralid, benazolin-ethyl, chloramben, clacyfos, clomeprop, clopyralid, dicamba, 2,4-D, 2,4-DB, dichlorprop, fluroxypyr, halauxifen (4-amino-3-chloro-6-(4-chloro-2-fluoro-10 3-methoxyphenyl)-2-pyridinecarboxylic acid), halauxifen-methyl (methyl 4-amino-3-chloro-6-(4-chloro-2-fluoro-3-methoxyphenyl)-2-pyridinecarboxylate), MCPA, MCPB, mecoprop, picloram, quinclorac, quinmerac, 2,3,6-TBA, triclopyr, and methyl 4-amino-3-chloro-6-(4-chloro-2-fluoro-3-methoxyphenyl)-5-fluoro-2-pyridinecarboxylate.

“EPSP synthase inhibitors” (b5) are chemical compounds that inhibit the enzyme, 15 5-enol-pyruvylshikimate-3-phosphate synthase, which is involved in the synthesis of aromatic amino acids such as tyrosine, tryptophan and phenylalanine. EPSP inhibitor herbicides are readily absorbed through plant foliage and translocated in the phloem to the growing points. Glyphosate is a relatively nonselective postemergence herbicide that belongs to this group. Glyphosate includes esters and salts such as ammonium, 20 isopropylammonium, potassium, sodium (including sesquisodium) and trimesium (alternatively named sulfosate).

“Photosystem I electron diverters” (b6) are chemical compounds that accept electrons from Photosystem I, and after several cycles, generate hydroxyl radicals. These radicals are extremely reactive and readily destroy unsaturated lipids, including membrane fatty acids 25 and chlorophyll. This destroys cell membrane integrity, so that cells and organelles “leak”, leading to rapid leaf wilting and desiccation, and eventually to plant death. Examples of this second type of photosynthesis inhibitor include diquat and paraquat.

“PPO inhibitors” (b7) are chemical compounds that inhibit the enzyme protoporphyrinogen oxidase, quickly resulting in formation of highly reactive compounds in 30 plants that rupture cell membranes, causing cell fluids to leak out. Examples of PPO inhibitors include acifluorfen-sodium, azafenidin, benzfendizone, bifenox, butafenacil, carfentrazone, carfentrazone-ethyl, chlomethoxyfen, cinidon-ethyl, fluazolate, flufenpyr-ethyl, flumiclorac-pentyl, flumioxazin, fluoroglycofen-ethyl, fluthiacet-methyl, fomesafen, halosafen, lactofen, oxadiargyl, oxadiazon, oxyfluorfen, pentoxazone, profluazol, 35 pyraclonil, pyraflufen-ethyl, saflufenacil, sulfentrazone, thidiazimin, trifludimoxazin (dihydro-1,5-dimethyl-6-thioxo-3-[2,2,7-trifluoro-3,4-dihydro-3-oxo-4-(2-propyn-1-yl)-2H-1,4-benzoxazin-6-yl]-1,3,5-triazine-2,4(1H,3H)-dione) and tiafenacil (methyl *N*-[2-[[2-

chloro-5-[3,6-dihydro-3-methyl-2,6-dioxo-4-(trifluoromethyl)-1(2*H*)-pyrimidinyl]-4-fluorophenyl]thio]-1-oxopropyl]- β -alaninate).

“GS inhibitors” (b8) are chemical compounds that inhibit the activity of the glutamine synthetase enzyme, which plants use to convert ammonia into glutamine. Consequently, 5 ammonia accumulates and glutamine levels decrease. Plant damage probably occurs due to the combined effects of ammonia toxicity and deficiency of amino acids required for other metabolic processes. The GS inhibitors include glufosinate and its esters and salts such as glufosinate-ammonium and other phosphinothricin derivatives, glufosinate-P ((2*S*)-2-amino-4-(hydroxymethylphosphinyl)butanoic acid) and bilanaphos.

“VLCFA elongase inhibitors” (b9) are herbicides having a wide variety of chemical structures, which inhibit the elongase. Elongase is one of the enzymes located in or near chloroplasts which are involved in biosynthesis of VLCFAs. In plants, very-long-chain fatty acids are the main constituents of hydrophobic polymers that prevent desiccation at the leaf surface and provide stability to pollen grains. Such herbicides include acetochlor, alachlor, anilofos, butachlor, cafenstrole, dimethachlor, dimethenamid, diphenamid, fenoxasulfone (3-[[2,5-dichloro-4-ethoxyphenyl)methyl]sulfonyl]-4,5-dihydro-5,5-dimethylisoxazole), fentrazamide, flufenacet, indanofan, mefenacet, metazachlor, metolachlor, naproanilide, napropamide, napropamide-M ((2*R*)-*N,N*-diethyl-2-(1-naphthalenyl)propanamide), pethoxamid, piperophos, pretilachlor, propachlor, propisochlor, pyroxasulfone, and 20 thenylchlor, including resolved forms such as S-metolachlor and chloroacetamides and oxyacetamides.

“Auxin transport inhibitors” (b10) are chemical substances that inhibit auxin transport in plants, such as by binding with an auxin-carrier protein. Examples of auxin transport inhibitors include diflufenzopyr, naptalam (also known as *N*-(1-naphthyl)phthalamic acid 25 and 2-[(1-naphthalenylamino)carbonyl]benzoic acid).


“PDS inhibitors” (b11) are chemical compounds that inhibit carotenoid biosynthesis pathway at the phytoene desaturase step. Examples of PDS inhibitors include beflubutamid, diflufenican, fluridone, flurochloridone, flurtamone norflurzon and picolinafen.

“HPPD inhibitors” (b12) are chemical substances that inhibit the biosynthesis of 30 synthesis of 4-hydroxyphenyl-pyruvate dioxygenase. Examples of HPPD inhibitors include benzobicyclon, benzofenap, bicycloprone (4-hydroxy-3-[[2-[(2-methoxyethoxy)methyl]-6-(trifluoromethyl)-3-pyridinyl]carbonyl]bicyclo[3.2.1]oct-3-en-2-one), fenquinotrione (2-[[8-chloro-3,4-dihydro-4-(4-methoxyphenyl)-3-oxo-2-quinoxalinyl]carbonyl]-1,3-cyclohexanedione), isoxachlortole, isoxaflutole, mesotrione, pyrasulfotole, pyrazolynate, 35 pyrazoxyfen, sulcotrione, tefuryltrione, tembotrione, tolpyralate (1-[[1-ethyl-4-[3-(2-methoxyethoxy)-2-methyl-4-(methylsulfonyl)benzoyl]-1*H*-pyrazol-5-yl]oxy]ethyl methyl carbonate), topramezone, 5-chloro-3-[(2-hydroxy-6-oxo-1-cyclohexen-1-yl)carbonyl]-1-(4-methoxyphenyl)-2(1*H*)-quinoxalinone, 4-(2,6-diethyl-4-methylphenyl)-5-hydroxy-2,6-

dimethyl-3(2*H*)-pyridazinone, 4-(4-fluorophenyl)-6-[(2-hydroxy-6-oxo-1-cyclohexen-1-yl)carbonyl]-2-methyl-1,2,4-triazine-3,5(2*H*,4*H*)-dione, 5-[(2-hydroxy-6-oxo-1-cyclohexen-1-yl)carbonyl]-2-(3-methoxyphenyl)-3-(3-methoxypropyl)-4(3*H*)-pyrimidinone, 2-methyl-*N*-(4-methyl-1,2,5-oxadiazol-3-yl)-3-(methylsulfinyl)-4-(trifluoromethyl)benzamide and 2-methyl-3-(methylsulfonyl)-*N*-(1-methyl-1*H*-tetrazol-5-yl)-4-(trifluoromethyl)benzamide.

“HST inhibitors” (b13) disrupt a plant’s ability to convert homogentisate to 2-methyl-6-solanyl-1,4-benzoquinone, thereby disrupting carotenoid biosynthesis. Examples of HST inhibitors include haloxydine, pyriclor, cyclopyrimorate (6-chloro-3-(2-cyclopropyl-6-methylphenoxy)-4-pyridazinyl 4-morpholinecarboxylate), 3-(2-chloro-3,6-difluorophenyl)-4-hydroxy-1-methyl-1,5-naphthyridin-2(1*H*)-one, 7-(3,5-dichloro-4-pyridinyl)-5-(2,2-difluoroethyl)-8-hydroxypyrido[2,3-*b*]pyrazin-6(5*H*)-one and 4-(2,6-diethyl-4-methylphenyl)-5-hydroxy-2,6-dimethyl-3(2*H*)-pyridazinone.

HST inhibitors also include compounds of Formulae **A** and **B**.



15 wherein R^{d1} is H, Cl or CF₃; R^{d2} is H, Cl or Br; R^{d3} is H or Cl; R^{d4} is H, Cl or CF₃; R^{d5} is CH₃, CH₂CH₃ or CH₂CHF₂; and R^{d6} is OH, or -OC(=O)-*i*-Pr; and R^{e1} is H, F, Cl, CH₃ or CH₂CH₃; R^{e2} is H or CF₃; R^{e3} is H, CH₃ or CH₂CH₃; R^{e4} is H, F or Br; R^{e5} is Cl, CH₃, CF₃, OCF₃ or CH₂CH₃; R^{e6} is H, CH₃, CH₂CHF₂ or C≡CH; R^{e7} is OH, -OC(=O)Et, -OC(=O)-*i*-Pr or -OC(=O)-*t*-Bu; and A^{e8} is N or CH.

20 “Cellulose biosynthesis inhibitors” (b14) inhibit the biosynthesis of cellulose in certain plants. They are most effective when applied preemergence or early postemergence on young or rapidly growing plants. Examples of cellulose biosynthesis inhibitors include chlorthiamid, dichlobenil, flupoxam, indaziflam (*N*²-[(1*R*,2*S*)-2,3-dihydro-2,6-dimethyl-1*H*-inden-1-yl]-6-(1-fluoroethyl)-1,3,5-triazine-2,4-diamine), isoxaben and triaziflam.

25 “Other herbicides” (b15) include herbicides that act through a variety of different modes of action such as mitotic disruptors (e.g., flamprop-M-methyl and flamprop-M-isopropyl), organic arsenicals (e.g., DSMA, and MSMA), 7,8-dihydropteroate synthase inhibitors, chloroplast isoprenoid synthesis inhibitors and cell-wall biosynthesis inhibitors. Other herbicides include those herbicides having unknown modes of action or do 30 not fall into a specific category listed in (b1) through (b14) or act through a combination of

modes of action listed above. Examples of other herbicides include aclonifen, asulam, amitrole, bromobutide, cinmethylin, clomazone, cumyluron, daimuron, difenzoquat, etobenzanid, fluometuron, flurenol, fosamine, fosamine-ammonium, dazomet, dymron, ipfencarbazone (1-(2,4-dichlorophenyl)-N-(2,4-difluorophenyl)-1,5-dihydro-N-(1-methylethyl)-5-oxo-4H-1,2,4-triazole-4-carboxamide), metam, methyldymron, oleic acid, oxaziclomefone, pelargonic acid, pyributicarb and 5-[[2,6-difluorophenyl)methoxy]methyl]-4,5-dihydro-5-methyl-3-(3-methyl-2-thienyl)isoxazole.


“Herbicide safeners” (b16) are substances added to a herbicide formulation to eliminate or reduce phytotoxic effects of the herbicide to certain crops. These compounds protect crops from injury by herbicides but typically do not prevent the herbicide from controlling undesired vegetation. Examples of herbicide safeners include but are not limited to benoxacor, cloquintocet-mexyl, cumyluron, cyometrinil, cyprosulfamide, daimuron, dichlormid, dicycloron, dietholate, dimepiperate, fenchlorazole-ethyl, fenclorim, flurazole, fluxofenim, furilazole, isoxadifen-ethyl, mefenpyr-diethyl, mephenate, methoxyphenone, naphthalic anhydride, oxabetrinil, *N*-(aminocarbonyl)-2-methylbenzenesulfonamide and *N*-(aminocarbonyl)-2-fluorobenzenesulfonamide, 1-bromo-4-[(chloromethyl)sulfonyl]benzene, 2-(dichloromethyl)-2-methyl-1,3-dioxolane (MG 191), 4-(dichloroacetyl)-1-oxa-4-azospiro[4.5]decane (MON 4660), 2,2-dichloro-1-(2,2,5-trimethyl-3-oxazolidinyl)-ethanone and 2-methoxy-*N*-[[4-[(methylamino)carbonyl]amino]phenyl]sulfonyl]-benzamide.

The compounds of Formula 1 can be prepared by general methods known in the art of synthetic organic chemistry. One or more of the following methods and variations as described in Schemes 1–18 can be used to prepare the compounds of Formula 1. The definitions of R¹, R², R³, R⁴, R⁵, R⁶, Q¹, Q², J¹, J², T, Y¹, and Y² in the compounds of Formulae 1–19 below are as defined above in the Summary of the Invention unless otherwise noted.

As shown in Scheme 1 compounds of Formula 1a (i.e. Formula 1 wherein T is –A–J¹, R¹, R⁴ and R⁵ are H, and Y¹ and Y² are O) can be prepared by reaction of acids of Formula 2 with amines of Formula 3 in the presence of a dehydrative coupling reagent such as propylphosphonic anhydride, dicyclohexylcarbodiimide, *N*-(3-dimethylaminopropyl)-*N*'-ethylcarbodiimide, *N,N*'-carbonyldiimidazole, 2-chloro-1,3-dimethylimidazolium chloride or 2-chloro-1-methylpyridinium iodide. Polymer-supported reagents, such as polymer-supported cyclohexylcarbodiimide, are also suitable. These reactions are typically run at temperatures ranging from 0–60 °C in a solvent such as dichloromethane, acetonitrile, *N,N*-dimethylformamide or ethyl acetate in the presence of a base such as triethylamine, *N,N*-diisopropylamine, or 1,8-diazabicyclo[5.4.0]undec-7-ene. See *Organic Process Research & Development* 2009, 13, 900–906 for coupling conditions employing


propylphosphonic anhydride. The method of Scheme 1 utilizing propylphosphonic anhydride is illustrated by Step F of Synthesis Example 2.

Scheme 1



5 As shown in Scheme 2, compounds of Formula 2 can be prepared by hydrolysis of esters of Formula 4 by methods well known to those skilled in the art. Hydrolysis is carried out with aqueous base or aqueous acid, typically in the presence of a co-solvent. Suitable bases for the reaction include, but are not limited to, hydroxides such as sodium and potassium hydroxide and carbonates such as sodium and potassium carbonate. Suitable
10 acids for the reaction include, but are not limited to, inorganic acids such as hydrochloric acid, hydrobromic acid and sulfuric acid, and organic acids such as acetic acid and trifluoroacetic acid. A wide variety of co-solvents are suitable for the reaction including, but not limited to, methanol, ethanol and tetrahydrofuran. The reaction is conducted at temperatures ranging from -20 °C to the boiling point of the solvent, and typically from 0 to
15 100 °C. The method of Scheme 2 is illustrated by Step E of Synthesis Example 2.


Scheme 2



As shown in Scheme 3, a compound of Formula 4a or 4b can be obtained by reduction of a compound of Formula 5a and 5b respectively and subsequent *in situ* cyclization of the
20 resulting intermediate amine. A wide variety of methods for reduction of the aliphatic nitro or nitrile group in compounds of Formula 5a or 5b are known in the literature. Methods well known to those skilled in the art include catalytic hydrogenation in the presence of palladium on carbon or Raney nickel, iron or zinc metal in acidic medium (see, for example, *Berichte*

der Deutschen Chemischen Gesellschaft 1904, 37, 3520–3525), and lithium aluminum hydride. Reduction of aliphatic nitro group can also be achieved with samarium(II) iodide in the presence of a proton source such as methanol (see for example, *Tetrahedron Letters* 1991, 32 (14), 1699–1702). Alternatively sodium borohydride in the presence of a nickel catalyst such as nickel(II) acetate or nickel(II) chloride can be used (see for example, *Tetrahedron Letters* 1985, 26 (52), 6413–6416). The method of Scheme 3 utilizing sodium borohydride in the presence of nickel(II) chloride is illustrated by Step D of Synthesis Example 1.


Scheme 3



10


As shown in Scheme 4, a compound of Formula **5a** or **5b** can be prepared by reacting diesters of Formula **6** with nitroalkanes of Formula **7a** or nitriles of Formula **7b**, typically in the presence of a base. Suitable bases for the reaction include alkali metal lower alkoxides such as sodium methoxide in methanol or sodium ethoxide in ethanol. Compounds of Formula **6** can readily be prepared by methods known to those skilled in the art, e.g., by Knoevenagel condensation of aldehydes and malonates (see for example G. Jones, *Organic Reactions* Volume 15, John Wiley and Sons, 1967).

Scheme 4




Compounds of Formulae **5c** or **5d** (i.e. Formulae **5a** or **5b** wherein R² and R³ are H) can be prepared by reacting compounds of Formulae **8a** or **8b** with malonates of Formula **9** in the presence of a base as shown in Scheme 5. Suitable bases for this reaction include, but are not limited to, alkali metal lower alkoxides such as sodium methoxide in methanol or sodium ethoxide in ethanol, or bases such as lithium bis(trimethylsilyl)amide, sodium bis(trimethylsilyl)amide and lithium diisopropylamide in solvents such as tetrahydrofuran. Typically, the reaction is carried out in the range of from -78 °C to 23 °C. See *Synthesis* **2005**, 2239–2245 for conditions for effecting this transformation. Conditions for effecting this transformation in refluxing water in the absence of a catalyst have been reported in *Synthetic Communications* **2013**, 43, 744–748.

Scheme 5



Compounds of Formula **6** can readily be prepared by Knoevenagel condensation of aldehydes of Formula **14** and malonates **9** as shown in Scheme 6. Also as shown in Scheme 15 6, compounds of Formulae **8a** and **8b** can be prepared by Knoevenagel condensation of 6, compounds of Formulae **8a** and **8b** can be prepared by Knoevenagel condensation of aldehydes of Formula **14** and nitromethane.


Scheme 6



As shown in Scheme 7, aldehydes of Formula **14** can be prepared by reaction of 20 aldehydes of Formula **20** with corresponding electrophiles of Formula **21** in the presence of

base with or without a metal catalyst. In Formula **21**, G denotes a leaving group, i.e. a nucleofuge. Depending upon selection of J^1 , suitable electrophiles for the reaction can include aryl or alkyl halides such as chlorides, bromides and iodides, alkylsulfonates, acid anhydrides such as *tert*-butoxycarbonyl anhydride and acetic anhydride, and haloalkylsilanes such as chlorotrimethylsilane. Suitable bases for the reaction include inorganic bases such as alkali or alkaline earth metal (e.g., lithium, sodium, potassium and cesium) hydroxides, alkoxides, carbonates, and phosphates, and organic bases such as triethylamine, *N,N*-diisopropylethylamine and 1,8-diazabicyclo[5.4.0]undec-7-ene. Suitable catalysts include palladium, nickel, rhodium or copper with or without ligands such as phosphines or 5 N-heterocyclic carbenes. A wide variety of solvents are suitable for the reaction including, for example but not limited to, tetrahydrofuran, dichloromethane, *N,N*-dimethylformamide, *N,N*-dimethylacetamide, *N*-methylpyrrolidinone, acetonitrile, C_2 - C_6 alcohols and acetone as well as mixtures of these solvents. This reaction is conducted at temperatures ranging from 10 -20 to 200 $^{\circ}$ C, and typically between 0 and 50 $^{\circ}$ C. For an example, when A is $-CH_2OH$, see 15 *Organic and Biomolecular Chemistry* **2013**, *11*, 3046-3056. Aldehydes of Formula **20** are commercially available or readily prepared from commercially available material by a skilled one in the art.

Scheme 7




A has a terminal -OH, -SH or -NH.

20 When A comprises 1-3 C atoms, a compound of Formula **14** can be made by one skilled in the art using standard transition metal cross coupling methods. For a representative palladium catalyzed Heck coupling procedure see: *Bioorg. Chem.* **2010**, *38*, 139-143. For an example of a palladium catalyzed aryl halide trialkylbismuth procedure see: *Synlett* **2010**, *19*, 2936-2940. For a palladium catalyzed Suzuki type reactions see: *J. Med. Chem.* **2000**, *43*, 3076 and *J. Med. Chem.* **2012**, *43*, 1831-1843.

25 Compounds of Formulae **5a'** and **5a''** can be prepared stereoselectively by reacting nitroalkenes of Formula **8a** with malonates of Formula **9** in the presence of a chiral catalyst and optionally in the presence of a suitable base as shown in Scheme 7A. Suitable catalysts include, but are not limited to Ni(II) with vicinal diamine ligands such as Ni(II) Bis[(*R,R*)-30 *N,N*'-dibenzylcyclohexane-1,2-diamine]dibromide, Ni(II) Bis[(*S,S*)-*N,N*'-dibenzylcyclohexane-1,2-diamine]dibromide or nickel(II) bromide with chiral 1,1'-bi(tetrahydroisoquinoline) type diamines. Suitable organic bases for this reaction

include, but are not limited to, piperidine, morpholine, triethylamine, 4-methylmorpholine or *N,N*-diisopropylethylamine. This transformation can be accomplished neat or in solvents such as tetrahydrofuran, toluene or dichloromethane. Typically, the reaction is carried out in the range of from -78°C to 80°C using 0 to 1 equivalent of catalyst and optionally 0 to 1 equivalent of a base. Conditions for effecting this transformation have been reported in *J. Am. Chem. Soc.* **2005**, 9958-9959 or *Eur. J. Org. Chem.* **2011**, 5441-5446 for conditions. Nitroalkenes of Formula **8a** can readily be prepared from aldehydes and nitromethane by methods known to those skilled in the art.




10

As shown in Scheme 8, compounds of Formula **1aa** and **1ab** can also be prepared by reductive cyclization of compounds of Formula **10a** and **10b** analogous to the method of Scheme 3. As also shown in Scheme 8, compounds of Formula **1ba** and **1bb** (i.e. Formula 1 wherein R¹ is OH, R⁴ and R⁵ are H, and Y¹ and Y² are O) can be prepared from compounds of Formula **10b** by catalytic transfer hydrogenation with ammonium formate in the presence of palladium on carbon, and subsequent *in situ* cyclization of the intermediate hydroxylamine. See *J. Med. Chem.* **1993**, 36, 1041-1047 for catalytic transfer hydrogenation/cyclization conditions to produce *N*-hydroxypyrrolidinones.


15

Scheme 8




As shown in Scheme 9, compounds of Formula **10a** and **10b** can be prepared by reacting compounds of Formula **11** with a compound of Formula **7a** or a compound of Formula **7b** in a solvent, in the presence of a base analogous to the method described in Scheme 4.

Scheme 9




As shown in Scheme 10, compounds of Formula **10aa** (i.e. Formula **10a** wherein R^{2a} and R^{3a} are H) can be prepared, analogous to the method of Scheme 5, by reacting nitroalkenes of Formula **8** with malonates of Formula **12**.

Scheme 10




As shown in Scheme 11, compounds of Formula **11** can be prepared by reaction of malonic amide of Formula **12** with aldehydes of Formula **14** by methods known to those skilled in the art. As also shown in Scheme 11, malonic amides of Formula **12** can readily be prepared from lower alkyl malonyl chlorides of Formula **13** such as methyl malonyl chloride and amines of Formula **3** by methods known to those skilled in the art.

Scheme 11




As shown in Scheme 12, mixtures of compounds of Formula **1c** (i.e. Formula **1** wherein R^1 and R^5 are H , R^4 is halogen and Y^1 and Y^2 are O) and Formula **1d** (i.e. Formula **1** wherein R^1 and R^4 are H , R^5 is halogen and Y^1 and Y^2 are O) can be prepared by reacting compounds of Formula **1a** with a halogen source in a solvent, in the presence or absence of an initiator. Separation of the regioisomers produced in this reaction can be achieved by standard methods such as chromatography or fractional crystallization. Suitable halogen sources for this reaction include bromine, chlorine, *N*-chlorosuccinimide, *N*-bromosuccinimide and *N*-iodosuccinimide. Suitable initiators for this reaction include 2,2'-azobisisobutyronitrile (AIBN) and benzoyl peroxide. Typically, the reaction is carried out in solvents such as dichloromethane in the range of from 0 °C to the boiling point of the solvent.

Scheme 12



As shown in Scheme 13, compounds of Formula **1e** (i.e. Formula **1** wherein R¹ is NH₂, R⁴ and R⁵ are H and Y¹ and Y² are O) can be prepared by reacting compounds of Formula **1a** with an aminating reagent such as *O*-(diphenylphosphinyl)hydroxylamine and hydroxylamino-*O*-sulphonic acid. For procedures, conditions and reagents see *Bioorg. & Med. Chem. Lett.* **2009**, *19*, 5924–5926 and *J. of Org. Chem.* **2002**, *67*, 6236–6239.


Scheme 13



10


As shown in Scheme 14, compounds of Formula **1f** (i.e. Formula 1 wherein R⁴, R⁵ and R⁶ are H and Y¹ and Y² are O) can be produced by reaction of compounds of Formula **15** with isocyanates (i.e. Formula **16** wherein Y² is O) or isothiocyanates (i.e. Formula **16** wherein Y² is S) in the presence of base. Examples of the base which can be used for the present process include those listed for the method of Scheme 4. The reaction temperature can be selected from the range of from -78 °C to the boiling point of the inert solvent used. Typically, the reaction is carried out at temperatures ranging from -78 °C to 100 °C in solvents such as toluene.

Scheme 14



As shown in Scheme 15, compounds of Formula **15** can be prepared by reaction of compounds of Formula **17** with corresponding electrophiles of Formula **18** in the presence of base. In Formula **18**, G denotes a leaving group, i.e. a nucleofuge. Depending upon selection of R^1 , suitable electrophiles for the reaction can include alkyl halides such as chlorides, bromides and iodides, alkylsulfonates, acid anhydrides such as *tert*-butoxycarbonyl anhydride and acetic anhydride, and haloalkylsilanes such as chlorotrimethylsilane. Suitable bases for the reaction include inorganic bases such as alkali or alkaline earth metal (e.g., lithium, sodium, potassium and cesium) hydroxides, alkoxides, carbonates, and phosphates, and organic bases such as triethylamine, *N,N*-diisopropylethylamine and 1,8-diazabicyclo[5.4.0]undec-7-ene. A wide variety of solvents are suitable for the reaction including, for example but not limited to, tetrahydrofuran, dichloromethane, *N,N*-dimethylformamide, *N,N*-dimethylacetamide, *N*-methylpyrrolidinone, acetonitrile, C_2 – C_6 alcohols and acetone as well as mixtures of these solvents. This reaction is conducted at temperatures ranging from –20 to 200 °C, and typically between 0 and 50 °C.


Scheme 15



As shown in Scheme 16, compounds of Formula **17** can be prepared by decarboxylation of acids of Formula **2** by methods well known to those skilled in the art. Decarboxylation is carried by heating compounds of Formula **2** in a solvent, typically in the presence of an acid. Suitable acids for the reaction include, but are not limited to, *p*-toluenesulfonic acid. A wide variety of co-solvents are suitable for the reaction including, but not limited to, toluene, isopropanol acetate and isobutyl methylketone. The reaction is


conducted at temperatures ranging from -20°C and to the boiling point of the solvent, and typically from 0 to 150°C .

Scheme 16



5 As shown in Scheme 17, compounds of Formula **1g** (i.e. Formula **1** wherein R^1 is H , R^4 and R^5 are H , and Y^1 and Y^2 are S) can be prepared by reacting compounds of Formula **1a** with at least two equivalents of a thionation reagent such as Lawesson's reagent, tetraphosphorus decasulfide or diphosphorus pentasulfide in a solvent such as tetrahydrofuran or toluene. Typically, the reaction is carried out at temperatures ranging 10 from 0 to 115°C . One skilled in the art recognizes that using less than two equivalents of the thionating reagent can provide mixtures comprising Formula **1** products wherein Y^1 is O and Y^2 is S , or Y^1 is S and Y^2 is O , which can be separated by conventional methods such as chromatography and crystallization.


Scheme 17



15

As shown in Scheme 18, compounds of Formula **1h** (i.e. Formula **1** wherein R^1 , R^4 , R^5 are H , Y^2 is O and Y^1 is NH) can be prepared by alkylation of compounds of Formula **1a** triethyloxonium tetrafluoroborate (Meerwein's reagent) followed by treatment of the resulting imino ether of Formula **19** with aqueous ammonia.

Scheme 18



5 It is recognized by one skilled in the art that various functional groups can be converted into others to provide different compounds of Formula 1. For a valuable resource that illustrates the interconversion of functional groups in a simple and straightforward fashion, see Larock, R. C., *Comprehensive Organic Transformations: A Guide to Functional Group Preparations*, 2nd Ed., Wiley-VCH, New York, 1999. For example, intermediates
10 for the preparation of compounds of Formula 1 may contain aromatic nitro groups, which can be reduced to amino groups, and then be converted via reactions well known in the art such as the Sandmeyer reaction, to various halides, providing compounds of Formula 1. The above reactions can also in many cases be performed in alternate order.

It is recognized that some reagents and reaction conditions described above for preparing compounds of Formula 1 may not be compatible with certain functionalities present in the intermediates. In these instances, the incorporation of protection/deprotection sequences or functional group interconversions into the synthesis will aid in obtaining the desired products. The use and choice of the protecting groups will be apparent to one skilled in chemical synthesis (see, for example, Greene, T. W.; Wuts, P. G. M. *Protective Groups in Organic Synthesis*, 2nd ed.; Wiley: New York, 1991). One skilled in the art will recognize that, in some cases, after the introduction of a given reagent as depicted in any individual scheme, it may be necessary to perform additional routine synthetic steps not described in detail to complete the synthesis of compounds of Formula 1. One skilled in the art will also recognize that it may be necessary to perform a combination of the steps illustrated in the above schemes in an order other than that implied by the particular presented to prepare the compounds of Formula 1.

One skilled in the art will also recognize that compounds of Formula 1 and the intermediates described herein can be subjected to various electrophilic, nucleophilic, radical, organometallic, oxidation, and reduction reactions to add substituents or modify existing substituents.

Without further elaboration, it is believed that one skilled in the art using the preceding description can utilize the present invention to its fullest extent. The following non-limiting

Examples are illustrative of the invention. Steps in the following Examples illustrate a procedure for each step in an overall synthetic transformation, and the starting material for each step may not have necessarily been prepared by a particular preparative run whose procedure is described in other Examples or Steps. Percentages are by weight except for chromatographic solvent mixtures or where otherwise indicated. Parts and percentages for chromatographic solvent mixtures are by volume unless otherwise indicated. ^1H NMR spectra are reported in ppm downfield from tetramethylsilane in CDCl_3 at 500 MHz unless otherwise noted; “s” means singlet, “d” means doublet, “t” means triplet, “q” means quartet, “m” means multiplet, “d” means doublet. Mass spectra (MS) are reported as the molecular weight of the highest isotopic abundance parent ion ($\text{M}+1$) formed by addition of H^+ (molecular weight of 1) to the molecule, or ($\text{M}-1$) formed by the loss of H^+ (molecular weight of 1) from the molecule, observed by using liquid chromatography coupled to a mass spectrometer (LCMS) using either atmospheric pressure chemical ionization (AP $^+$) where “amu” stands for unified atomic mass units.

15 **SYNTHESIS EXAMPLE 1**

Preparation N-(2-Fluorophenyl)-2-oxo-4-[3-(2-pyridinyloxy)phenyl]-3-pyrrolidinecarboxamide (Compound 34)

Step A: Preparation of 3-(2-pyridinyloxy)benzaldehyde

20 2-Fluoropyridine (20.0 g, 164 mmol) was dissolved in 150 mL N,N -dimethylformamide and then treated with potassium tert-butoxide (19.9 g, 177 mmol). The reaction exothermed to 57 °C and then was allowed to cool to ambient temperature over 1 hour. 3-Hydroxybenzaldehyde (13.9 mL, 162 mmol) was added and the mixture was heated to 120 °C overnight. The reaction mixture was allowed to cool to ambient temperature and then partitioned between ethyl acetate and 1N aqueous HCl solution. The 25 organic layer was washed with brine, dried over magnesium sulfate and concentrated to yield a brown sludge which was subsequently triturated with diethyl ether. The resulting solid was isolated by filtration and air dried to afford 14.9 g of the title compound.

^1H NMR ($\text{DMSO}-d_6$) δ 10.01 (s, 1H), 8.17 (m, 1H), 7.91 (m, 1H), 7.78 (m, 1H), 7.66 (t, 1H), 7.63 (s, 1H), 7.50 (m, 1H), 7.16–7.20 (m, 1H), 7.13 (d, 1H).

30 Step B: Preparation of 2-[3-[(1E)-2-nitroethyl]phenoxy]pyridine

To a solution of 3-(pyrid-2-ylloxy)benzaldehyde (alternatively known as 3-(2-pyridinyloxy)benzaldehyde, i.e. the product of Step A, 20.1 g, 101 mmol) in 250 mL of 1-chlorobutane was added nitromethane (6.54 mL, 121 mmol), piperidine (0.988 mL, 10.0 mmol) and glacial acetic acid (0.577 mL, 10.0 mmol). The mixture was then heated to reflux for 48 hours with azeotropic removal of water. The reaction was allowed to cool to ambient temperature. The reaction mixture was concentrated onto Celite® diatomaceous

filter aid and then purified by medium pressure liquid chromatography (0% to 15% ethyl acetate in hexanes as eluent) to yield 19.2 g of the title compound as a yellow oil.

^1H NMR δ 8.19 (m, 1H), 7.99 (d, 1H), 7.74 (m, 1H), 7.56 (m, 1H), 7.48 (t, 1H) 7.36 (m, 2H), 7.29 (m, 1H), 7.05 (m, 1H), 6.99 (d, 1H).

5 Step C: Preparation of 1,3-diethyl 2-[2-nitro-1-[3-(2-pyridinyloxy)phenyl]ethyl]propanedioate

2-[3-[(1E)-2-nitroethenyl]phenoxy]pyridine (i.e. the product of Step B, 19.4 g, 105 mmol), diethyl malonate (14.5 mL, 95.2 mmol) and Ni(II) Bis[N,N'-dibenzylcyclohexane-1,2-diamine]dibromide (0.955 g, 1.19 mmol) were refluxed in dichloromethane for 48 hours.

10 The reaction mixture was then cooled to ambient temperature, concentrated onto Celite® diatomaceous filter aid under reduced pressure, and then purified by medium pressure liquid chromatography eluting with 0% to 50% ethyl acetate in hexanes to afford 30.2 g of the title compound as a colorless oil.

15 ^1H NMR (500 MHz, DMSO-*d*₆) δ 8.15 (m, 1H) 7.86 (m, 1H) 7.34 (m, 1H) 7.15 (m, 3H) 7.03 (m, 1H) 6.96 (m, 1H) 4.99 (m, 2H) 4.17 (m, 2H) 4.09 (m, 1H) 4.03 (m, 1H) 3.89 (m, 2H) 1.18 (t, 3H) 0.92 (t, 3H).

Step D: Preparation of Ethyl 2-oxo-4-[3-(2-pyridinyloxy)phenyl]-3-pyrrolidinecarboxylate

20 1,3-Diethyl 2-[2-nitro-1-[3-(2-pyridinyloxy)phenyl]ethyl]propanedioate (i.e. the product of Step C, 30.1 g, 74.9 mmol) was dissolved in 500 mL of ethanol at ambient temperature. $\text{NiCl}_2 \cdot 6\text{H}_2\text{O}$ (17.8 g, 74.9 mmol) was added and the mixture was stirred until completely dissolved. The reaction mass was then cooled to 0 °C in an ice bath and then sodium borohydride (8.50 g, 225 mmol) was added slowly, so that the temperature did not exceed 5 °C. Upon complete addition, the ice bath was removed and the reaction mass was 25 stirred at ambient temperature overnight. The ethanol was then removed under reduced pressure and 500 mL ethyl acetate and 1.25 L of saturated ammonium chloride solution were added, and the reaction was stirred until the next day. The organic layer was separated from the aqueous layer and then concentrated onto silica gel under reduced pressure and then purified by MPLC eluting with 0% to 100% ethyl acetate in hexanes to give 7.5 g of the title compound as a yellow oil.

30 ^1H NMR δ 8.19 (m, 1H), 7.71 (m, 1H), 7.37 (m, 1H), 7.05 (m, 4H), 6.93 (m, 1H), 6.37 (bs, 1H), 4.24 (m, 2H), 4.13 (m, 1H), 3.82 (m, 1H), 3.55 (d, 1H), 3.45 (m, 1H), 1.27 (m, 3H).

Step E: Preparation of N-(2-Fluorophenyl)-2-oxo-4-[3-(2-pyridinyloxy)phenyl]-3-pyrrolidinecarboxamide

35 Ethyl 2-oxo-4-[3-(2-pyridinyloxy)phenyl]-3-pyrrolidinecarboxylate (i.e. the product of Step D, 0.40 g, 1.2 mmol) was added to 2-fluoroaniline (2.0 mL, 6.8 mmol) and heated in a CEM Microwave reactor for 45 minutes at 190 °C. The reaction mixture was cooled to

ambient temperature and then diluted with 200 mL dichloromethane. This solution was concentrated under reduced pressure onto Celite® and then purified by MPLC (0% to 100% ethyl acetate in hexanes as eluent) resulting in 0.23 g of the title compound, a product of the present invention, as a solid.

5 ^1H NMR δ 10.04 (s, 1H), 8.13 (m, 2H), 8.00 (m, 1H), 7.83 (m, 1H), 7.38 (m, 1H), 7.12 (m, 8H), 4.00 (m, 2H), 3.70 (t, 1H), 3.25 (t, 1H).

SYNTHESIS EXAMPLE 2

Preparation of N-(2,3-difluorophenyl)-2-oxo-4-[3-[3-(trifluoromethyl)-1*H*-pyrazol-1-yl]methyl]phenyl]-3-pyrrolidinecarboxamide (Compound 25)

10 Step A: Preparation of 3-[3-(Trifluoromethyl)-1*H*-pyrazole-1-yl]methyl]benzaldehyde

15 3-(Trifluoromethyl)pyrazole (0.82 g, 6.0 mmol), 3-(bromomethyl)benzaldehyde (1.0 g, 5.0 mmol) and potassium carbonate (2.1 g, 15 mmol) were combined in 50 mL *N,N*-dimethylformamide and heated to 80 °C for 18 hours. The reaction mixture was cooled to ambient temperature and then partitioned between ethyl acetate and brine. The organic layer was dried over magnesium sulfate and concentrated under reduced pressure to yield a green oil which was adsorbed onto silica gel and then purified by MPLC eluting with 0% to 100% ethyl acetate in hexanes to afford 0.82 g of the title compound.

20 ^1H NMR δ 10.01 (s, 1H), 7.86 (m, 1H), 7.76 (s, 1H), 7.56 (m, 1H), 7.50 (m, 1H), 7.45 (m, 1H), 6.58 (d, 1H), 5.44 (s, 2H).

Step B: Preparation of 1-[3-[3-[(1*E*)-2-Nitroethenyl]phenyl]methyl]-3-(trifluoromethyl)-1*H*-pyrazole (i.e. 1-[3-[3-[(1*E*)-2-Nitroethenyl]phenyl]methyl]-3-(trifluoromethyl)-1*H*-pyrazole)

25 To a solution of 3-[3-(trifluoromethyl)-1*H*-pyrazole-1-yl]methyl]benzaldehyde (i.e. the product of Step A, 16.5 g, 65 mmol) in 100 mL of 1-chlorobutane was added nitromethane (4.2 mL, 78 mmol), piperidine (0.64 mL, 6.5 mmol) and glacial acetic acid (0.37 mL, 6.5 mmol). The mixture was then heated to reflux for 48 hours with azeotropic removal of water. The reaction was allowed to cool to ambient temperature. The reaction mixture was concentrated onto Celite® diatomaceous filter aid and then purified by MPLC, eluting with 0% to 15% ethyl acetate in hexanes to yield 11.2 g of the title compound as a yellow solid.

30 ^1H NMR (500 MHz, CHLOROFORM-*d*) δ 7.97 (d, 1H), 7.55 (m, 2H), 7.46 (m, 2H), 7.38 (m, 2H), 6.58 (d, 1H), 5.40 (s, 2H).

Step C: Preparation of 1,3-diethyl 2-[2-nitro-1-[3-[[3-(trifluoromethyl)-1H-pyrazol-1-yl]methyl]phenyl]ethyl]propanedioate

1-[3-[(1*E*)-2-Nitroethenyl]phenyl]methyl]-3-(trifluoromethyl)-1H-pyrazole (i.e. 1-[3-[(1*E*)-2-Nitroethenyl]phenyl]methyl]-3-(trifluoromethyl)-1H-pyrazole, i.e. the product of Step B, 11 g, 38 mmol), diethyl malonate (6.9 mL, 45 mmol) and Ni(II) Bis[*N,N'*-dibenzylcyclohexane-1,2-diamine]dibromide (0.46 g, 0.57 mmol) were stirred in dichloromethane for approximately 16 hours. The reaction mixture was then cooled to ambient temperature, concentrated onto Celite® diatomaceous filter aid under reduced pressure, and then purified by MPLC eluting with 0% to 50% ethyl acetate in hexanes to afford 11 g of the title compound as a yellow oil.

¹H NMR δ 7.34 (m, 2H), 7.23 (d, 1H), 7.15 (m, 2H), 6.54 (d, 1H), 5.32 (m, 2H), 4.88 (m, 2H), 4.21 (m, 3H), 3.98 (q, 2H), 3.78 (d, 1H), 1.25 (t, 3H), 1.01 (t, 3H).

Step D: Preparation of Ethyl 2-oxo-4-[3-[[3-(trifluoromethyl)-1H-pyrazole-1-yl]methyl]phenyl]-3-pyrrolidinecarboxylate

15 1,3-Diethyl 2-[2-nitro-1-[3-[[3-(trifluoromethyl)-1H-pyrazol-1-yl]methyl]phenyl]ethyl]propanedioate (i.e. the product of Step C, 30.1 g, 74.9 mmol) was dissolved in 500 mL of ethanol at ambient temperature. NiCl₂·6H₂O (17.8 g, 74.9 mmol) was added and the mixture was stirred until completely dissolved. The reaction mass was then cooled to 0 °C in an ice bath and then sodium borohydride (8.50 g, 225 mmol) was added slowly so that the temperature did not exceed 5 °C. Upon complete addition, the ice bath was removed and the reaction mass was stirred at ambient temperature for 3 hours. 300 mL of ethyl acetate and 300 mL of saturated ammonium chloride solution were added, and the reaction was stirred until the organic layer was clear and the aqueous layer was blue. The organic layer was separated from the aqueous layer, and the aqueous layer was extracted again with ethyl acetate. The combined organic layers were washed with ammonium chloride, dried over magnesium sulfate and then concentrated onto silica gel under reduced pressure and then purified by MPLC eluting with 0% to 100% ethyl acetate in hexanes to afford 3.5 g of the title compound as a yellow oil with some impurities which was used without additional purification. MS (M-1)=380 amu.

20 30 Step E: Preparation of 2-oxo-4-[3-[[3-(trifluoromethyl)-1H-pyrazole-1-yl]methyl]phenyl]-3-pyrrolidinecarboxylic acid

Ethyl 2-oxo-4-[3-[[3-(trifluoromethyl)-1H-pyrazole-1-yl]methyl]phenyl]-3-pyrrolidinecarboxylate (i.e. the product of Step D, 3.78 g, 9.1 mmol) was dissolved in 65 mL of ethanol and then 1.4 mL of 50% sodium hydroxide solution was added over 5 minutes. The reaction was then stirred overnight at ambient temperature. The mixture was diluted with water until the white precipitate was dissolved. The organic layer was extracted twice with 125 mL diethyl ether and then acidified to a pH of 2 with concentrated hydrochloric

acid. The aqueous layer was then extracted with ethyl acetate. The ethyl acetate layer was washed with brine and dried over magnesium sulfate and concentrated under reduced pressure to yield 1.9 g of the title compound as a pink glass.

¹H NMR (DMSO-*d*₆) δ 12.74 (bs, 1H), 8.09 (d, 2H), 7.33 (m, 3H), 7.12 (m, 1H), 6.74 (d, 1H), 5.41 (s, 2H), 3.83 (m, 2H), 3.51 (m, 2H).

Step F: Preparation of N-(2,3-Difluorophenyl)-2-oxo-4-[3-[[3-(trifluoromethyl)-1H-pyrazol-1-yl]methyl]phenyl]-3-pyrrolidinecarboxamide

2-oxo-4-[3-[[3-(trifluoromethyl)-1H-pyrazole-1-yl]methyl]phenyl]-3-pyrrolidinecarboxylic acid (i.e. the product of Step E, 0.33 g, 0.92 mmol), triethyl amine (0.38 mL, 0.28 mmol) and 2,3-difluoroaniline (0.14 g, 1.1 mmol) were dissolved in 25 mL of dichloromethane and stirred at ambient temperature for 15 minutes and then treated with 50% propylphosphonic anhydride (T3P®) in ethyl acetate (1.8 mL, 3.1 mmol) and stirred overnight. The reaction mixture was concentrated under reduced pressure and then purified by MPLC eluting with 0% to 100% ethyl acetate in hexanes to afford 0.092 g of the title compound, a product of the present invention, as a solid.

¹H NMR (DMSO-*d*₆) δ 10.22 (s, 1H), 8.21 (s, 1H), 8.07 (d, 1H), 7.77 (m, 1H), 7.34 (m, 3H), 7.16 (m, 3H), 6.71 (d, 1H), 5.42 (s, 2H), 4.02 (m, 1H), 3.92 (m, 1H), 3.67 (t, 1H), 3.26 (t, 1H).

SYNTHESIS EXAMPLE 3

Preparation of *N*-(2-fluorophenyl)-4-[3-[(methoxyimino)methyl]phenyl]-1-methyl-2-oxo-3-pyrrolidinecarboxamide (Compound 53)

Step A: Preparation of 1,3-diethyl 2-[(3-iodophenyl)methylene]propanedioate

To a solution of 3-iodobenzaldehyde (10 g, 43 mmol) in benzene (100 mL), was added diethyl malonate (8.3 g, 52 mmol) and piperidine (0.73 g, 8.6 mmol) at 5 °C. The reaction mixture was heated to the reflux temperature of the solvent with a Dean-Stark apparatus to remove water for 24 h. The reaction mixture was evaporated to give the crude product which was purified by silica gel column chromatography eluting with a 5% to 20% gradient of ethyl acetate in petroleum ether gave to the title product (17 g).

¹H NMR (400 MHz) δ 7.80 (s, 1H), 7.60 (s, 1H), 7.40 (m, 1H), 7.30 (s, 1H), 7.10 (m, 1H), 4.35 (m, 4H), 1.77 (m, 6 H).

Step B: Preparation of 1,3-diethyl 2-[1-(3-iodophenyl)-2-nitroethyl]propanedioate

To a solution of 1,3-diethyl 2-[(3-iodophenyl)methylene]propanedioate (i.e. the compound prepared in Step A, 17 g, 45 mmol) in ethanol (170 mL), was added nitromethane (28 g, 450 mmol) and 20% sodium methoxide in methanol (0.25 g, 4.55 mmol) at 5 °C and the reaction mixture was stirred at ambient temperature for 16 h. The reaction mixture was evaporated to give the title crude compound (16 g) which was used without further purification.

¹H NMR (400 MHz) δ 7.60 (t, 2H), 7.20 (d, 1H), 7.10 (t, 1H), 4.95 (m, 2H), 4.20 (m, 3H), 4.00 (m, 2H), 3.75 (d, 1H), 1.20 (m, 6 H).

Step C: Preparation of ethyl 4-(3-iodophenyl)-2-oxo-3-pyrrolidinecarboxylate

To a solution of 1,3-diethyl 2-[1-(3-iodophenyl)-2-nitroethyl]propanedioate (i.e. the compound prepared in Step B, 16 g, 36 mmol) in ethanol (150 mL) / water (32 mL) was added iron powder (10 g, 180 mmol), ammonium chloride (1.0 g, 18 mmol) and the reaction mixture was heated at 110 °C for 24 h. The reaction mixture was filtered through Celite® diatomaceous earth filter aid and the filtrate was concentrated. Water was added to the crude residue, and the mixture was extracted (3 ×) with ethyl acetate. The combined organic layers were washed with water, brine and then dried over sodium sulfate. The solvent was evaporated to provide the title compound as a crude intermediate (15 g). A 500 mg sample of the crude intermediate was purified by preparative thin-layer chromatography to provide 250 mg of the title compound.

¹H NMR (400 MHz) δ 7.60 (m, 2H), 7.20 (m, 1H), 7.10 (m, 1H), 6.10 (s, 1H), 4.20 (m, 2H), 4.00 (m, 1H), 3.63 (t, 1H), 3.40 (m, 1H), 3.30 (m, 1H), 1.23 (m, 3H).

Step D: Preparation of 4-(3-iodophenyl)-2-oxo-3-pyrrolidinecarboxylic acid

To a solution of ethyl 4-(3-iodophenyl)-2-oxo-3-pyrrolidinecarboxylate (i.e. the compound prepared in Step C, 9.0 g, 25 mmol) in tetrahydrofuran (50 mL) and water (10 mL) was added lithium hydroxide monohydrate (1.6 g, 38 mmol) at 0 °C and the reaction mixture was stirred at ambient temperature for 4 h. The reaction mixture was then evaporated and the solid was mixed in water. The aqueous mixture was extracted with ethyl acetate and the organic layer was discarded. The aqueous layer was acidified with concentrated hydrochloric acid at 0 °C. The resulting solid was collected by filtration and dried under vacuum to give the title compound (5 g) as an off-white solid.

¹H NMR (400 MHz) δ 12.89 (s, 1H), 8.10 (s, 1H), 7.65 (d, 1H), 7.53 (d, 1H), 7.39 (d, 1H), 7.18 (t, 1H), 3.81 (m, 1H), 3.50 (m, 2H), 3.20 (m, 1H).

Step E: Preparation of 4-(3-iodophenyl)-1-methyl-2-oxo-3-pyrrolidinecarboxylic acid

Potassium *t*-butoxide (37 mL, 1 M solution in tetrahydrofuran) was cooled to 0 °C. To this solution was added 4-(3-iodophenyl)-2-oxo-3-pyrrolidinecarboxylic acid (i.e. the compound prepared in Step D, 5.0 g, 15 mmol) in tetrahydrofuran was slowly added and stirred for 10 min. Methyl bromide (25% in acetonitrile, 14 mL, 38 mmol), was added and the reaction mixture was stirred for 4 h. The reaction mixture was diluted with acetonitrile and acidified with 1 N aqueous hydrochloric acid at 0 °C. The reaction mixture was then extracted (3 ×) with ethyl acetate and the combined organics were washed with brine and dried over sodium sulfate to give a crude residue which was washed with diethyl ether to give the title compound (2.3 g) as an off-white solid.

¹H NMR (400 MHz) δ 12.77 (s, 1H), 7.74 (s, 1H), 7.65 (d, 1H), 7.38 (d, 1H), 7.15 (t, 1H), 3.81 (m, 2H), 3.62 (m, 1H), 3.45 (d, 1H), 2.80 (s, 3H).

Step F: Preparation of *N*-(2-fluorophenyl)-4-(3-iodophenyl)-1-methyl-2-oxo-3-pyrrolidinecarboxamide

5 To a solution of 4-(3-iodophenyl)-1-methyl-2-oxo-3-pyrrolidinecarboxylic acid (i.e. the compound prepared in Step E, 0.5 g, 1.4 mmol) and 2-fluoroaniline (0.15 mL, 1.6 mmol) in *N,N*-dimethylformamide (10 mL) was added triethylamine (0.6 mL, 4.3 mmol) and stirred at ambient temperature for 10 min. Then propylphosphonic anhydride (T3P®) solution (50% in ethyl acetate, 1.7 mL, 2.89 mmol) was added at 0 °C and stirred for 2 h. The 10 reaction mixture was then diluted with water and extracted with ethyl acetate. The combined organic layers were washed with water and brine and then dried over sodium sulfate. The solvent was evaporated to give a crude residue which was washed with diethyl ether/pentane to give the title compound (0.4 g) as an off-white solid.

¹H NMR (400 MHz) δ 10.08 (s, 1H), 8.00 (m, 1H), 7.75 (s, 1H), 7.63 (d, 1H), 7.37 (d, 1H), 15 7.35 (m, 1H), 7.15 (m, 3H), 3.95 (m, 2H), 3.77 (m, 1H), 3.41 (m, 1H), 2.80 (s, 3H).

Step G: Preparation of *N*-(2-fluorophenyl)-4-(3-formylphenyl)-1-methyl-2-oxo-3-pyrrolidinecarboxamide

20 To a solution of *N*-(2-fluorophenyl)-4-(3-iodophenyl)-1-methyl-2-oxo-3-pyrrolidinecarboxamide (i.e. the compound prepared in Step F, 0.5 g, 1.1 mmol) and tetrakis(triphenylphosphine)palladium(0) (0.086 g, 0.075 mmol) in *N,N*-dimethylformamide (5 mL) in steel bomb was stirred under carbon monoxide gas (100 p.s.i.) for 30 min. the pressure was released and tributyl silane (0.83 mL) was added and the reaction mixture was stirred under carbon monoxide gas (100 p.s.i.) at ambient temperature for 48 h. The 25 reaction mixture was then diluted with water and extracted with ethyl acetate. The combined organic layers were washed with water and brine and dried over sodium sulfate. The solvent was evaporated to give the crude residue which was purified via silica gel column chromatography eluting with 20% ethyl acetate in petroleum ether to yield the title compound (0.27 g) as light brown solid.

¹H NMR (400 MHz) δ 10.15 (s, 1H), 10.00 (s, 1H), 8.15 (t, 1H), 7.82 (m, 1H), 7.64 (m, 1H), 30 7.55 (m, 1H), 7.39 (m, 1H), 7.12 (m, 3H), 4.20 (m, 1H), 3.80 (t, 1H), 3.31 (d, 1H), 3.22 (m, 1H), 3.10 (s, 3H).

Step H: Preparation of *N*-(2-fluorophenyl)-4-[3-[(methoxyimino)methyl]phenyl]-1-methyl-2-oxo-3-pyrrolidinecarboxamide

35 To a solution of *N*-(2-fluorophenyl)-4-(3-formylphenyl)-1-methyl-2-oxo-3-pyrrolidinecarboxamide (i.e. the compound prepared in Step G, 0.15 g, 0.41 mmol) and methoxylamine hydrochloride (0.054 g, 0.64 mmol) in tetrahydrofuran (10 mL) was added sodium acetate (0.047 g, 0.57 mmol) and stirred at ambient temperature for 2 h. The

reaction mixture was then diluted with water and extracted with ethyl acetate. The combined organic layers were washed with water and brine and dried over sodium sulfate. The solvent was evaporated to give the crude product which was purified by preparative silica gel thin-layer chromatography in 40% ethyl acetate / petroleum ether to yield (0.07 g) of the title compound, a compound of the present invention, as an off-white solid.

¹H NMR (400 MHz) δ 9.85 (s, 1H), 8.25 (t, 1H), 8.10 (s, 1H), 7.55 (s, 1H), 7.45 (s, 1H), 7.25 (s, 2H), 6.99 (m, 3H), 4.25 (m, 1H), 4.10 (s, 3H), 3.75 (d, 1H), 3.50 (m, 1H), 3.33 (m, 1H), 3.00 (s, 3H).

SYNTHESIS EXAMPLE 4

10 Preparation of (3*S*,4*S*)-4-[3-[(5-fluoro-2-pyridinyl)oxy]phenyl]-1-methyl-2-oxo-*N*-(2,3,4-trifluorophenyl)-3-pyrrolidinecarboxamide (Compound 87)

Step A. Preparation of 3-[(5-fluoro-2-pyridinyl)oxy]benzaldehyde

A solution 3-hydroxybenzaldehyde (20 g, 164 mmol) in *N,N*-dimethylformamide (150 mL) was treated with potassium *tert*-butoxide (23.0 g, 205 mmol) over a period of 1 h.

15 The resulting mixture was stirred at 25 °C for 1 h and then treated with 2,5-difluoropyridine (18.64 g, 162 mmol). The resulting reaction mixture was stirred at 120 °C for 18 h. The reaction mixture was then cooled and partitioned between ethyl acetate and brine. The organic phase was washed with brine, dried over MgSO₄ and concentrated under reduced pressure onto Celite® diatomaceous earth filter aid. Purification by solid chromatography 20 eluting with a gradient of ethyl acetate in hexanes (0 to 35%) provided 10.0 g of the title compound a white solid.

¹H NMR (DMSO-*d*6) δ 10.00 (s, 1H), 8.18 (d, 1H), 7.88 (m, 1H), 7.78 (m, 1H), 7.66 (t, 1H), 7.62 (m, 1H), 7.50 (m, 1H), 7.23 (m, 1H).

Step B: Preparation of 5-fluoro-2-[3-[(1*E*)-2-nitroethenyl]phenoxy]pyridine

25 A solution of 3-[(5-fluoro-2-pyridinyl)oxy]benzaldehyde (i.e. the product obtained in Step A, 10 g, 46.0 mmol) in 1-chlorobutane (250 mL) was treated with nitromethane (3.36 g, 55.2 mmol) followed by piperidine (391 mg, 4.6 mmol) and acetic acid (276 mg, 4.6 mmol). The resulting reaction mass was stirred at reflux, with azeotropic removal of water, for 18 h. The crude reaction mixture was then concentrated under reduced pressure and purified by 30 chromatography (0 to 25% ethyl acetate in hexanes as eluent) resulting in 8.7 g of a yellow oil.

¹H NMR δ 8.02 (d, 1H), 7.98 (d, 1H), 7.55 (d, 1H), 7.49 (m, 2H), 7.38 (d, 1H), 7.31 (m, 1H), 7.26 (m, 1H), 6.98 (m, 1H).

Step C: Preparation of 1,3-dimethyl 2-[(1*S*)-1-[3-[(5-fluoro-2-pyridinyl)oxy]phenyl]-35 2-nitroethyl]propanedioate

A stirred mixture of 5-fluoro-2-[3-[(1*E*)-2-nitroethenyl]phenoxy]pyridine (i.e. the product obtained in Step B, 8.67 g, 33.3 mmol) and dimethyl malonate (5.5 g, 41.7 mmol) in

toluene (150 mL) was treated with Ni(II) bis[(*R,R*)-*N,N*'-dibenzylcyclohexane-1,2-diamine]bromide (prepared as described in *J. Am. Chem. Soc.* **2005**, *127*, 9958-9959; 0.400 g, 0.499 mmol). The reaction mass was stirred at 80 °C for 18 h. The resulting mixture was cooled to 25 °C, filtered and concentrated under reduced pressure to yield

5 13.0 g of an amber oil which was used without further purification in the next step.

¹H NMR δ 8.05 (d, 1H), 7.45 (m, 1H), 7.35 (t, 1H), 7.06 (m, 2H), 6.99 (m, 1H), 6.87 (m, 1H), 4.90 (m, 2H), 4.25 (m, 1H), 3.85 (d, 1H), 3.75 (s, 3H), 3.62 (s, 3H).

Step D: Preparation of methyl (3*R*,4*S*)-4-[3-[(5-fluoro-2-pyridinyl)oxy]phenyl]-2-oxo-3-pyrrolidinecarboxylate

10 A stirred mixture of 1,3-dimethyl 2-[(1*S*)-1-[3-[(5-fluoro-2-pyridinyl)oxy]phenyl]-2-nitroethyl]propanedioate (13.0 g, 33.1 mmol), nickel(II) chloride hexahydrate (7.88 g, 33.1 mmol) and methanol (300 mL) was cooled in an ice bath and treated with sodium borohydride (i.e. the product obtained in Step C, 3.76 g, 99.3 mmol) in 0.5 g portions added over 60 min. The resulting mixture was stirred at 25 °C for 18 h. Saturated

15 ethylenediaminetetraacetic acid, disodium salt solution (800 mL) and ethyl acetate (500 mL) were then added and the mixture was stirred for 18 h and then filtered through a pad of Celite® diatomaceous filter aid to remove insoluble particulates. The layers of the filtrate were separated, and the aqueous layer was extracted with ethyl acetate (2 × 500 mL). The combined organic extracts were washed with saturated ammonium chloride solution

20 (800 mL), and brine (1000 mL). The organic extract was dried over MgSO₄ and concentrated under reduced pressure to afford a viscous grey oil (8.99 g) which was used without further purification.

¹H NMR δ 8.02 (d, 1H), 7.45 (m, 1H), 7.37 (t, 1H), 7.09 (m, 1H), 7.02 (m, 2H), 6.94 (m, 2H), 4.13 (m, 1H), 3.82 (m, 1H), 3.78 (s, 3H), 3.58 (d, 1H), 3.42 (m, 1H).

25 Step E: Preparation of (3*R*,4*S*)-4-[3-[(5-fluoro-2-pyridinyl)oxy]phenyl]-2-oxo-3-pyrrolidinecarboxylic acid

30 A mixture of methyl (3*R*,4*S*)-4-[3-[(5-fluoro-2-pyridinyl)oxy]phenyl]-2-oxo-3-pyrrolidinecarboxylate (i.e. the product obtained in Step D, 8.49 g, 25.7 mmol) and aqueous sodium hydroxide (50 wt%, 6.16 g, 77.2 mmol) in methanol (125mL) was stirred at 25 °C for 18 h. The reaction mixture was then diluted with water (250 mL) and extracted with diethyl ether (2 × 150 mL). The ether extract was discarded and the aqueous phase was acidified with concentrated hydrochloric acid to pH 2. The acidic aqueous was extracted with ethyl acetate (2 × 300 mL). The combined organic extracts were washed with brine, dried (MgSO₄), and concentrated under reduced pressure to afford 5.5 g of a beige glass

35 which was carried to the next step without further purification.

¹H NMR (DMSO-*d*₆) δ 12.7 (s, 1H), 8.16 (d, 1H), 8.07 (s, 1H), 7.83 (m, 1H), 7.37 (m, 1H), 7.17 (m, 1H), 7.12 (m, 2H), 7.01 (m, 1H), 3.88 (m, 1H), 3.62 (m, 1H), 3.51 (d, 1H), 3.21 (t, 1H).

Step F: Preparation of (3*R*,4*S*)-4-[3-[(5-fluoro-2-pyridinyl)oxy]phenyl]-1-methyl-2-oxo-3-pyrrolidinecarboxylic acid

To a solution of potassium *tert*-butoxide (4.75 g, 42.4 mmol) in 42.4 mL of terahydrofuran at 0 °C was charged a solution of (3*R*,4*S*)-4-[3-[(5-fluoro-2-pyridinyl)oxy]phenyl]-2-oxo-3-pyrrolidinecarboxylic acid (i.e. the product obtained in Step E, 5.5 g, 17.4 mmol) in tetrahydrofuran (50 mL). The resulting reaction mass was stirred for 15 min. at 0 °C. Iodomethane (6.24 g, 44 mmol) in 40 mL of tetrahydrofuran was dripped in over 20 min. The resulting mixture was allowed to warm to 25 °C and stirred over night. The reaction mass was concentrated under reduced pressure and partitioned between ethyl ether and water. The organic phase was discarded and the aqueous was acidified to a pH of 1 with concentrated hydrochloric acid. The acidified aqueous layer was extracted with ethyl acetate. The organic extract was dried (MgSO_4) and concentrated under reduced pressure to yield 4.0 g of a yellow glass which was carried on without further purification.

¹⁵ ^1H NMR δ 9.29 (s, 1H), 8.03 (d, 1H), 7.46 (m, 1H), 7.37 (m, 1H), 7.13 (m, 1H), 7.06 (m, 1H), 7.02 (m, 1H), 6.92 (m, 1H), 3.96 (m, 1H), 3.79 (m, 1H), 3.57 (d, 1H), 3.50 (m, 1H), 2.97 (d, 3H).

Step G: Preparation of (3*S*,4*S*)-4-[3-[(5-fluoro-2-pyridinyl)oxy]phenyl]-1-methyl-2-oxo-*N*-(2,3,4-trifluorophenyl)-3-pyrrolidinecarboxamide


To a solution of (3*R*,4*S*)-4-[3-[(5-fluoro-2-pyridinyl)oxy]phenyl]-1-methyl-2-oxo-3-pyrrolidinecarboxylic acid (i.e. the product obtained in Step F, 500 mg, 1.51 mmol) in 5.0 mL of tetrahydrofuran at 25 °C was charged triethylamine (632 μl , 4.54 mmol). The reaction mixture was stirred for 5 min. and then treated with 2,3,4-trifluoroaniline (208 μl , 1.97 mmol). After stirring for another 5 min. the mixture was treated with propylphosphonic anhydride (50% in ethyl acetate, 1.63 g, 2.57 mmol). The resulting mixture was stirred overnight at 25 °C. The crude mixture was concentrated under reduced pressure and purified by silica gel chromatography eluting with 0 to 15% ethyl acetate in dichloromethane resulting in 278 mg of the title compound, a compound of the invention, as a viscous yellow oil.

³⁰ ^1H NMR δ 9.86 (s, 1H), 8.02 (d, 1H), 7.93 (m, 1H), 7.45 (m, 1H), 7.39 (t, 1H), 7.19 (m, 1H), 7.12 (m, 1H), 7.03 (m, 1H), 6.93 (m, 1H), 6.90 (m, 1H), 4.11 (m, 1H), 3.80 (m, 1H), 3.62 (d, 1H), 3.50 (m, 1H), 2.99 (d, 3H).

By the procedures described herein together with methods known in the art, the following compounds of Tables 1 to 6120 can be prepared. The following abbreviations are used in the Tables which follow: *t* means tertiary, *s* means secondary, *n* means normal, *i* means iso, *c* means cyclo, Me means methyl, Et means ethyl, Pr means propyl, Bu means butyl, *t*-Pr means isopropyl, *c*-Pr cyclopropyl, *t*-Bu means tertiary butyl, *c*-Bu means cyclobutyl, Ph means phenyl, OMe means methoxy, OEt means ethoxy, SMe means

methylthio, NHMe means methylamino, CN means cyano, NO₂ means nitro, TMS means trimethylsilyl, SOMe means methylsulfinyl, C₂F₅ means CF₂CF₃ and SO₂Me means methylsulfonyl.

Table 1



5

J² is -CH₂-; A is -CH₂-; Q² is Ph(2-F); and J¹ is

J ¹	J ¹	J ¹
Ph(3-Cl)	Ph(4-OCF ₂ H)	2-Pyridinyl(4-Me)
Ph(3-F)	Ph(4-OMe)	2-Pyridinyl(3-F)
Ph(3-Br)	Ph(4-OCF ₂ CF ₂ H)	2-Pyridinyl(3-CF ₃)
Ph(3-Me)	Ph(2,3-di-F)	2-Pyridinyl(3-Me)
Ph(3-CF ₃)	Ph(2,4-di-F)	3-Pyridinyl
Ph(3-OCF ₃)	Ph(2,5-di-F)	3-Pyridinyl(6-F)
Ph(3-OCF ₂ H)	Ph(2,6-di-F)	3-Pyridinyl(6-CF ₃)
Ph(3-OMe)	Ph(3,4-di-F)	3-Pyridinyl(6-Me)
Ph(3-OCF ₂ CF ₂ H)	Ph(3,5-di-F)	3-Pyridinyl(5-F)
Ph(2-Cl)	Ph(3-Me,4-F)	3-Pyridinyl(5-CF ₃)
Ph(2-F)	Ph(3-F,4-Me)	3-Pyridinyl(5-Me)
Ph(2-Br)	Ph(3-CF ₃ ,4-F)	3-Pyridinyl(4-F)
Ph(2-Me)	Ph(3-F,4-CF ₃)	3-Pyridinyl(4-CF ₃)
Ph(2-CF ₃)	Ph(2,3,4-tri-F)	3-Pyridinyl(4-Me)
Ph(2-OCF ₃)	Ph(3,4,5-tri-F)	3-Pyridinyl(2-F)
Ph(2-OCF ₂ H)	2-Pyridinyl	3-Pyridinyl(2-CF ₃)
Ph(2-OMe)	2-Pyridinyl(6-F)	3-Pyridinyl(2-Me)
Ph(2-OCF ₂ CF ₂ H)	2-Pyridinyl(6-CF ₃)	4-Pyridinyl
Ph(4-Cl)	2-Pyridinyl(6-Me)	4-Pyridinyl(6-F)
Ph(4-F)	2-Pyridinyl(5-F)	4-Pyridinyl(6-CF ₃)
Ph(4-Br)	2-Pyridinyl(5-CF ₃)	4-Pyridinyl(6-Me)
Ph(4-Me)	2-Pyridinyl(5-Me)	4-Pyridinyl(5-F)
Ph(4-CF ₃)	2-Pyridinyl(4-F)	4-Pyridinyl(5-CF ₃)
Ph(4-OCF ₃)	2-Pyridinyl(4-CF ₃)	4-Pyridinyl(5-Me)

J ¹	J ¹	J ¹
4-Pyridinyl(3-F)	1,3,5-Triazin-2-yl	1-naphthyl
4-Pyridinyl(3-CF ₃)	Thiazol-2-yl	2-naphthyl
4-Pyridinyl(3-Me)	Thiazol-2-yl(5-CF ₃)	Benzofuran-2-yl
4-Pyridinyl(2-F)	Thiazol-5-yl	Benzothiophen-2-yl
4-Pyridinyl(2-CF ₃)	Thiazol-5-yl(2-CF ₃)	1,3-Benzoxazol-2-yl
4-Pyridinyl(2-Me)	Oxazol-2-yl	1,3-Benzthiazol-2-yl
2-Thienyl	Oxazol-2-yl(5-CF ₃)	7-quinolyl
2-Thienyl(4-CF ₃)	Oxazol-5-yl	Indazol-1-yl
2-Thienyl(5-CF ₃)	Oxazol-5-yl(2-CF ₃)	Benzimidazol-1-yl
3-Thienyl	Iothiazol-5-yl	Indol-1-yl
3-Thienyl(4-CF ₃)	Iothiazol-5-yl(3-CF ₃)	Pyrrolo[2,3-c]pyridin-1-yl
3-Thienyl(5-CF ₃)	Iothiazol-3-yl	Cyclopropylmethoxy
2-Furanyl	Iothiazol-3-yl(5-CF ₃)	2-cyclopropylethoxy
2-Furanyl(4-CF ₃)	Ioxazol-5-yl	4-cyclohexylbutoxy
2-Furanyl(5-CF ₃)	Ioxazol-5-yl (3-CF ₃)	Cyclopropylmethyl
3-Furanyl	Ioxazol-3-yl	4-cyclohexylbutyl
3-Furanyl(4-CF ₃)	Ioxazol-3-yl(5-CF ₃)	Oct-7-enoxy
3-Furanyl(5-CF ₃)	Tetrazol-1-yl	[(E)-but-2-enoxy]
Pyrazol-1-yl	Tetrazol-1-yl(5-Me)	2,2-difluorovinyloxy
Pyrazol-1-yl (4-CF ₃)	Tetrazol-5-yl(1-Me)	3,3-dichloroallyloxy
Imidazol-1-yl	1,2,4-Triazol-1-yl	2-methoxyethoxy
Imidazol-1-yl(4-CF ₃)	1,3,4-Oxadiazol-2-yl	3-propoxypropoxy
Imidazol-1-yl(2-CF ₃)	1,3,4-Thiadiazol-2-yl	2-methylthioethyl
Imidazol-2-yl(1-Me)	1,2,4-Oxadiazol-3-yl	2-methylsulfinylethyl
Imidazol-4-yl(1-Me)	1,2,4-Thiadiazol-3-yl	2-methylsulfonylethyl
Imidazol-4-yl(2-Me)	Tetrahydropyran-2-yl	2-CF ₃ SO ₂ CH ₂ CH ₂ O
Pyrazol-4-yl(1-Me)	Tetrahydropyran-3-yl	Methylsulfanyl
Triazol-4-yl(1-Me)	Tetrahydrofuran-2-yl	Trifluoromethylthio
Triazol-4-yl(2-Me)	Tetrahydrofuran-3-yl	Cyclopropylthio
Triazol-2-yl(4-Me)	Oxetan-2-yl	Methylsulfinyl
Triazol-1-yl(4-Me)	Oxetan-3-yl	Trifluoromethylsulfinyl
Pyrazin-2-yl	Oxiran-2-yl	Cyclopropylsulfanyl
Pyrazin-2-yl(5-CF ₃)	1,3-Dioxolan-4-yl	Methylsulfonyl
Pyrimidin-2-yl	2,2-difluoro-1,3-Dioxolan-4-yl	Trifluoromethylsulfonyl
Pyrimidin-2-yl(5-CF ₃)	1,3-Dithiolan-4-yl	Cyclopropylsulfonyl
Pyrimidin-5-yl	1,4-Dioxolan-2-yl	Prop-2-ynyl
Pyrimidin-5-yl(2-CF ₃)	1,4-Dithiolan-2-yl	But-2-ynyl

J ¹	J ¹	J ¹
3-fluoroprop-2-ynyl	2-(trifluoromethoxy)ethyl	2-fluorocyclopropyl
3-chloroprop-2-ynyl	4-(1,1,2,2,- tetrafluoroethoxy)butoxy	4,4-difluorocyclohexyl
5-propoxypentyl	2-(1,1,2,2,- tetrafluoroethoxy)ethoxy	Acetoxy
2-ethoxyethyl	4-(trifluoromethoxy)butoxy	2,2-dimethylpropanoyloxy
5-(1,1,2,2,- tetrafluoroethoxy)pentyl	2(trifluoromethoxy)ethoxy	3-methylbutanoyloxy
2-(1,1,2,2,- tetrafluoroethoxy)ethyl	Trifluoromethyl	2,2,2-trifluoroacetyloxy
5-(trifloromethoxy)pentyl	3,3,3-trifluoropropyl	4,4,4-trifluorobutanoyloxy

Table 2-360

Table 2 is constructed in the same manner except that the Row heading “J² is -CH₂-; A is -CH₂-; Q² is Ph(2-F); and J¹ is” is replaced with the Row Heading listed for Table 2 below (i.e. “J² is -CH₂-; A is -CH₂-; Q² is Ph(2,3-di-F); and J¹ is”). Therefore the first entry in Table 2 is a compound of Formula 1 wherein J² is -CH₂-; A is -CH₂-; Q² is Ph(2,3-di-F); and J¹ is Ph(3-Cl) (i.e. 3-chlorophenyl). Tables 3 through 360 are constructed similarly.

Table	Row Heading
2	J ² is -CH ₂ -; A is -CH ₂ -; Q ² is Ph(2,3-di-F); and J ¹ is
3	J ² is -CH ₂ -; A is -CH ₂ -; Q ² is Ph(2,4-di-F); and J ¹ is
4	J ² is -CH ₂ -; A is -CH ₂ -; Q ² is Ph(2,3,4-tri-F); and J ¹ is
5	J ² is -CH ₂ -; A is -CH ₂ -; Q ² is Ph(2-CF ₃); and J ¹ is
6	J ² is -CH ₂ -; A is -CH ₂ -; Q ² is Ph(2-Me); and J ¹ is
7	J ² is -CH ₂ -; A is -CH ₂ -; Q ² is Ph(2-NO ₂); and J ¹ is
8	J ² is -CH ₂ -; A is -CH ₂ -; Q ² is Ph(2-Cl); and J ¹ is
9	J ² is -CH ₂ -; A is -CH ₂ -; Q ² is Ph(2- SO ₂ Me); and J ¹ is
10	J ² is -CH ₂ -; A is -CH ₂ -; Q ² is Ph(2-F,3-Cl); and J ¹ is
11	J ² is -CH ₂ -; A is -CH ₂ CH ₂ -; Q ² is Ph(2-F); and J ¹ is
12	J ² is -CH ₂ -; A is -CH ₂ CH ₂ -; Q ² is Ph(2,3-di-F); and J ¹ is
13	J ² is -CH ₂ -; A is -CH ₂ CH ₂ -; Q ² is Ph(2,4-di-F); and J ¹ is
14	J ² is -CH ₂ -; A is -CH ₂ CH ₂ -; Q ² is Ph(2,3,4-tri-F); and J ¹ is
15	J ² is -CH ₂ -; A is -CH ₂ CH ₂ -; Q ² is Ph(2-CF ₃); and J ¹ is
16	J ² is -CH ₂ -; A is -CH ₂ CH ₂ -; Q ² is Ph(2-Me); and J ¹ is
17	J ² is -CH ₂ -; A is -CH ₂ CH ₂ -; Q ² is Ph(2-NO ₂); and J ¹ is
18	J ² is -CH ₂ -; A is -CH ₂ CH ₂ -; Q ² is Ph(2-Cl); and J ¹ is

19	J^2 is $-\text{CH}_2-$; A is $-\text{CH}_2\text{CH}_2-$; Q^2 is $\text{Ph}(2-\text{SO}_2\text{Me})$; and J^1 is
20	J^2 is $-\text{CH}_2-$; A is $-\text{CH}_2\text{CH}_2-$; Q^2 is $\text{Ph}(2\text{-F},3\text{-Cl})$; and J^1 is
21	J^2 is $-\text{CH}_2-$; A is $-\text{CH}_2\text{CH}_2\text{CH}_2-$; Q^2 is $\text{Ph}(2\text{-F})$; and J^1 is
22	J^2 is $-\text{CH}_2-$; A is $-\text{CH}_2\text{CH}_2\text{CH}_2-$; Q^2 is $\text{Ph}(2,3\text{-di-F})$; and J^1 is
23	J^2 is $-\text{CH}_2-$; A is $-\text{CH}_2\text{CH}_2\text{CH}_2-$; Q^2 is $\text{Ph}(2,4\text{-di-F})$; and J^1 is
24	J^2 is $-\text{CH}_2-$; A is $-\text{CH}_2\text{CH}_2\text{CH}_2-$; Q^2 is $\text{Ph}(2,3,4\text{-tri-F})$; and J^1 is
25	J^2 is $-\text{CH}_2-$; A is $-\text{CH}_2\text{CH}_2\text{CH}_2-$; Q^2 is $\text{Ph}(2\text{-CF}_3)$; and J^1 is
26	J^2 is $-\text{CH}_2-$; A is $-\text{CH}_2\text{CH}_2\text{CH}_2-$; Q^2 is $\text{Ph}(2\text{-Me})$; and J^1 is
27	J^2 is $-\text{CH}_2-$; A is $-\text{CH}_2\text{CH}_2\text{CH}_2-$; Q^2 is $\text{Ph}(2\text{-NO}_2)$; and J^1 is
28	J^2 is $-\text{CH}_2-$; A is $-\text{CH}_2\text{CH}_2\text{CH}_2-$; Q^2 is $\text{Ph}(2\text{-Cl})$; and J^1 is
29	J^2 is $-\text{CH}_2-$; A is $-\text{CH}_2\text{CH}_2\text{CH}_2-$; Q^2 is $\text{Ph}(2\text{-SO}_2\text{Me})$; and J^1 is
30	J^2 is $-\text{CH}_2-$; A is $-\text{CH}_2\text{CH}_2\text{CH}_2-$; Q^2 is $\text{Ph}(2\text{-F},3\text{-Cl})$; and J^1 is
31	J^2 is $-\text{CH}_2-$; A is $-\text{O}-$; Q^2 is $\text{Ph}(2\text{-F})$; and J^1 is
32	J^2 is $-\text{CH}_2-$; A is $-\text{O}-$; Q^2 is $\text{Ph}(2,3\text{-di-F})$; and J^1 is
33	J^2 is $-\text{CH}_2-$; A is $-\text{O}-$; Q^2 is $\text{Ph}(2,4\text{-di-F})$; and J^1 is
34	J^2 is $-\text{CH}_2-$; A is $-\text{O}-$; Q^2 is $\text{Ph}(2,3,4\text{-tri-F})$; and J^1 is
35	J^2 is $-\text{CH}_2-$; A is $-\text{O}-$; Q^2 is $\text{Ph}(2\text{-CF}_3)$; and J^1 is
36	J^2 is $-\text{CH}_2-$; A is $-\text{O}-$; Q^2 is $\text{Ph}(2\text{-Me})$; and J^1 is
37	J^2 is $-\text{CH}_2-$; A is $-\text{O}-$; Q^2 is $\text{Ph}(2\text{-NO}_2)$; and J^1 is
38	J^2 is $-\text{CH}_2-$; A is $-\text{O}-$; Q^2 is $\text{Ph}(2\text{-Cl})$; and J^1 is
39	J^2 is $-\text{CH}_2-$; A is $-\text{O}-$; Q^2 is $\text{Ph}(2\text{-SO}_2\text{Me})$; and J^1 is
40	J^2 is $-\text{CH}_2-$; A is $-\text{O}-$; Q^2 is $\text{Ph}(2\text{-F},3\text{-Cl})$; and J^1 is
41	J^2 is $-\text{CH}_2-$; A is $-\text{OCH}_2-$; Q^2 is $\text{Ph}(2\text{-F})$; and J^1 is
42	J^2 is $-\text{CH}_2-$; A is $-\text{OCH}_2-$; Q^2 is $\text{Ph}(2,3\text{-di-F})$; and J^1 is
43	J^2 is $-\text{CH}_2-$; A is $-\text{OCH}_2-$; Q^2 is $\text{Ph}(2,4\text{-di-F})$; and J^1 is
44	J^2 is $-\text{CH}_2-$; A is $-\text{OCH}_2-$; Q^2 is $\text{Ph}(2,3,4\text{-tri-F})$; and J^1 is
45	J^2 is $-\text{CH}_2-$; A is $-\text{OCH}_2-$; Q^2 is $\text{Ph}(2\text{-CF}_3)$; and J^1 is
46	J^2 is $-\text{CH}_2-$; A is $-\text{OCH}_2-$; Q^2 is $\text{Ph}(2\text{-Me})$; and J^1 is
47	J^2 is $-\text{CH}_2-$; A is $-\text{OCH}_2-$; Q^2 is $\text{Ph}(2\text{-NO}_2)$; and J^1 is
48	J^2 is $-\text{CH}_2-$; A is $-\text{OCH}_2-$; Q^2 is $\text{Ph}(2\text{-Cl})$; and J^1 is
49	J^2 is $-\text{CH}_2-$; A is $-\text{OCH}_2-$; Q^2 is $\text{Ph}(2\text{-SO}_2\text{Me})$; and J^1 is
50	J^2 is $-\text{CH}_2-$; A is $-\text{OCH}_2-$; Q^2 is $\text{Ph}(2\text{-F},3\text{-Cl})$; and J^1 is
51	J^2 is $-\text{CH}_2-$; A is $-\text{OCH}_2\text{CH}_2-$; Q^2 is $\text{Ph}(2\text{-F})$; and J^1 is
52	J^2 is $-\text{CH}_2-$; A is $-\text{OCH}_2\text{CH}_2-$; Q^2 is $\text{Ph}(2,3\text{-di-F})$; and J^1 is
53	J^2 is $-\text{CH}_2-$; A is $-\text{OCH}_2\text{CH}_2-$; Q^2 is $\text{Ph}(2,4\text{-di-F})$; and J^1 is
54	J^2 is $-\text{CH}_2-$; A is $-\text{OCH}_2\text{CH}_2-$; Q^2 is $\text{Ph}(2,3,4\text{-tri-F})$; and J^1 is
55	J^2 is $-\text{CH}_2-$; A is $-\text{OCH}_2\text{CH}_2-$; Q^2 is $\text{Ph}(2\text{-CF}_3)$; and J^1 is

56	J^2 is $-\text{CH}_2-$; A is $-\text{OCH}_2\text{CH}_2-$; Q^2 is $\text{Ph}(2\text{-Me})$; and J^1 is
57	J^2 is $-\text{CH}_2-$; A is $-\text{OCH}_2\text{CH}_2-$; Q^2 is $\text{Ph}(2\text{-NO}_2)$; and J^1 is
58	J^2 is $-\text{CH}_2-$; A is $-\text{OCH}_2\text{CH}_2-$; Q^2 is $\text{Ph}(2\text{-Cl})$; and J^1 is
59	J^2 is $-\text{CH}_2-$; A is $-\text{OCH}_2\text{CH}_2-$; Q^2 is $\text{Ph}(2\text{-SO}_2\text{Me})$; and J^1 is
60	J^2 is $-\text{CH}_2-$; A is $-\text{OCH}_2\text{CH}_2-$; Q^2 is $\text{Ph}(2\text{-F,3-Cl})$; and J^1 is
61	J^2 is $-\text{CH}_2-$; A is $-\text{CH}_2\text{O}-$; Q^2 is $\text{Ph}(2\text{-F})$; and J^1 is
62	J^2 is $-\text{CH}_2-$; A is $-\text{CH}_2\text{O}-$; Q^2 is $\text{Ph}(2,3\text{-di-F})$; and J^1 is
63	J^2 is $-\text{CH}_2-$; A is $-\text{CH}_2\text{O}-$; Q^2 is $\text{Ph}(2,4\text{-di-F})$; and J^1 is
64	J^2 is $-\text{CH}_2-$; A is $-\text{CH}_2\text{O}-$; Q^2 is $\text{Ph}(2,3,4\text{-tri-F})$; and J^1 is
65	J^2 is $-\text{CH}_2-$; A is $-\text{CH}_2\text{O}-$; Q^2 is $\text{Ph}(2\text{-CF}_3)$; and J^1 is
66	J^2 is $-\text{CH}_2-$; A is $-\text{CH}_2\text{O}-$; Q^2 is $\text{Ph}(2\text{-Me})$; and J^1 is
67	J^2 is $-\text{CH}_2-$; A is $-\text{CH}_2\text{O}-$; Q^2 is $\text{Ph}(2\text{-NO}_2)$; and J^1 is
68	J^2 is $-\text{CH}_2-$; A is $-\text{CH}_2\text{O}-$; Q^2 is $\text{Ph}(2\text{-Cl})$; and J^1 is
69	J^2 is $-\text{CH}_2-$; A is $-\text{CH}_2\text{O}-$; Q^2 is $\text{Ph}(2\text{-SO}_2\text{Me})$; and J^1 is
70	J^2 is $-\text{CH}_2-$; A is $-\text{CH}_2\text{O}-$; Q^2 is $\text{Ph}(2\text{-F,3-Cl})$; and J^1 is
71	J^2 is $-\text{CH}_2-$; A is $-\text{CH}_2\text{CH}_2\text{O}-$; Q^2 is $\text{Ph}(2\text{-F})$; and J^1 is
72	J^2 is $-\text{CH}_2-$; A is $-\text{CH}_2\text{CH}_2\text{O}-$; Q^2 is $\text{Ph}(2,3\text{-di-F})$; and J^1 is
73	J^2 is $-\text{CH}_2-$; A is $-\text{CH}_2\text{CH}_2\text{O}-$; Q^2 is $\text{Ph}(2,4\text{-di-F})$; and J^1 is
74	J^2 is $-\text{CH}_2-$; A is $-\text{CH}_2\text{CH}_2\text{O}-$; Q^2 is $\text{Ph}(2,3,4\text{-tri-F})$; and J^1 is
75	J^2 is $-\text{CH}_2-$; A is $-\text{CH}_2\text{CH}_2\text{O}-$; Q^2 is $\text{Ph}(2\text{-CF}_3)$; and J^1 is
76	J^2 is $-\text{CH}_2-$; A is $-\text{CH}_2\text{CH}_2\text{O}-$; Q^2 is $\text{Ph}(2\text{-Me})$; and J^1 is
77	J^2 is $-\text{CH}_2-$; A is $-\text{CH}_2\text{CH}_2\text{O}-$; Q^2 is $\text{Ph}(2\text{-NO}_2)$; and J^1 is
78	J^2 is $-\text{CH}_2-$; A is $-\text{CH}_2\text{CH}_2\text{O}-$; Q^2 is $\text{Ph}(2\text{-Cl})$; and J^1 is
79	J^2 is $-\text{CH}_2-$; A is $-\text{CH}_2\text{CH}_2\text{O}-$; Q^2 is $\text{Ph}(2\text{-SO}_2\text{Me})$; and J^1 is
80	J^2 is $-\text{CH}_2-$; A is $-\text{CH}_2\text{CH}_2\text{O}-$; Q^2 is $\text{Ph}(2\text{-F,3-Cl})$; and J^1 is
81	J^2 is $-\text{CH}_2-$; A is $-\text{S}-$; Q^2 is $\text{Ph}(2\text{-F})$; and J^1 is
82	J^2 is $-\text{CH}_2-$; A is $-\text{S}-$; Q^2 is $\text{Ph}(2,3\text{-di-F})$; and J^1 is
83	J^2 is $-\text{CH}_2-$; A is $-\text{S}-$; Q^2 is $\text{Ph}(2,4\text{-di-F})$; and J^1 is
84	J^2 is $-\text{CH}_2-$; A is $-\text{S}-$; Q^2 is $\text{Ph}(2,3,4\text{-tri-F})$; and J^1 is
85	J^2 is $-\text{CH}_2-$; A is $-\text{S}-$; Q^2 is $\text{Ph}(2\text{-CF}_3)$; and J^1 is
86	J^2 is $-\text{CH}_2-$; A is $-\text{S}-$; Q^2 is $\text{Ph}(2\text{-Me})$; and J^1 is
87	J^2 is $-\text{CH}_2-$; A is $-\text{S}-$; Q^2 is $\text{Ph}(2\text{-NO}_2)$; and J^1 is
88	J^2 is $-\text{CH}_2-$; A is $-\text{S}-$; Q^2 is $\text{Ph}(2\text{-Cl})$; and J^1 is
89	J^2 is $-\text{CH}_2-$; A is $-\text{S}-$; Q^2 is $\text{Ph}(2\text{-SO}_2\text{Me})$; and J^1 is
90	J^2 is $-\text{CH}_2-$; A is $-\text{S}-$; Q^2 is $\text{Ph}(2\text{-F,3-Cl})$; and J^1 is
91	J^2 is $-\text{CH}_2-$; A is $-\text{SCH}_2-$; Q^2 is $\text{Ph}(2\text{-F})$; and J^1 is
92	J^2 is $-\text{CH}_2-$; A is $-\text{SCH}_2-$; Q^2 is $\text{Ph}(2,3\text{-di-F})$; and J^1 is

93	J^2 is $-\text{CH}_2-$; A is $-\text{SCH}_2-$; Q^2 is $\text{Ph}(2,4\text{-di-F})$; and J^1 is
94	J^2 is $-\text{CH}_2-$; A is $-\text{SCH}_2-$; Q^2 is $\text{Ph}(2,3,4\text{-tri-F})$; and J^1 is
95	J^2 is $-\text{CH}_2-$; A is $-\text{SCH}_2-$; Q^2 is $\text{Ph}(2\text{-CF}_3)$; and J^1 is
96	J^2 is $-\text{CH}_2-$; A is $-\text{SCH}_2-$; Q^2 is $\text{Ph}(2\text{-Me})$; and J^1 is
97	J^2 is $-\text{CH}_2-$; A is $-\text{SCH}_2-$; Q^2 is $\text{Ph}(2\text{-NO}_2)$; and J^1 is
98	J^2 is $-\text{CH}_2-$; A is $-\text{SCH}_2-$; Q^2 is $\text{Ph}(2\text{-Cl})$; and J^1 is
99	J^2 is $-\text{CH}_2-$; A is $-\text{SCH}_2-$; Q^2 is $\text{Ph}(2\text{-SO}_2\text{Me})$; and J^1 is
100	J^2 is $-\text{CH}_2-$; A is $-\text{SCH}_2-$; Q^2 is $\text{Ph}(2\text{-F,3-Cl})$; and J^1 is
101	J^2 is $-\text{CH}_2-$; A is $-\text{CH}_2\text{S}-$; Q^2 is $\text{Ph}(2\text{-F})$; and J^1 is
102	J^2 is $-\text{CH}_2-$; A is $-\text{CH}_2\text{S}-$; Q^2 is $\text{Ph}(2,3\text{-di-F})$; and J^1 is
103	J^2 is $-\text{CH}_2-$; A is $-\text{CH}_2\text{S}-$; Q^2 is $\text{Ph}(2,4\text{-di-F})$; and J^1 is
104	J^2 is $-\text{CH}_2-$; A is $-\text{CH}_2\text{S}-$; Q^2 is $\text{Ph}(2,3,4\text{-tri-F})$; and J^1 is
105	J^2 is $-\text{CH}_2-$; A is $-\text{CH}_2\text{S}-$; Q^2 is $\text{Ph}(2\text{-CF}_3)$; and J^1 is
106	J^2 is $-\text{CH}_2-$; A is $-\text{CH}_2\text{S}-$; Q^2 is $\text{Ph}(2\text{-Me})$; and J^1 is
107	J^2 is $-\text{CH}_2-$; A is $-\text{CH}_2\text{S}-$; Q^2 is $\text{Ph}(2\text{-NO}_2)$; and J^1 is
108	J^2 is $-\text{CH}_2-$; A is $-\text{CH}_2\text{S}-$; Q^2 is $\text{Ph}(2\text{-Cl})$; and J^1 is
109	J^2 is $-\text{CH}_2-$; A is $-\text{CH}_2\text{S}-$; Q^2 is $\text{Ph}(2\text{-SO}_2\text{Me})$; and J^1 is
110	J^2 is $-\text{CH}_2-$; A is $-\text{CH}_2\text{S}-$; Q^2 is $\text{Ph}(2\text{-F,3-Cl})$; and J^1 is
111	J^2 is $-\text{CH}_2-$; A is $-\text{NH}-$; Q^2 is $\text{Ph}(2\text{-F})$; and J^1 is
112	J^2 is $-\text{CH}_2-$; A is $-\text{NH}-$; Q^2 is $\text{Ph}(2,3\text{-di-F})$; and J^1 is
113	J^2 is $-\text{CH}_2-$; A is $-\text{NH}-$; Q^2 is $\text{Ph}(2,4\text{-di-F})$; and J^1 is
114	J^2 is $-\text{CH}_2-$; A is $-\text{NH}-$; Q^2 is $\text{Ph}(2,3,4\text{-tri-F})$; and J^1 is
115	J^2 is $-\text{CH}_2-$; A is $-\text{NH}-$; Q^2 is $\text{Ph}(2\text{-CF}_3)$; and J^1 is
116	J^2 is $-\text{CH}_2-$; A is $-\text{NH}-$; Q^2 is $\text{Ph}(2\text{-Me})$; and J^1 is
117	J^2 is $-\text{CH}_2-$; A is $-\text{NH}-$; Q^2 is $\text{Ph}(2\text{-NO}_2)$; and J^1 is
118	J^2 is $-\text{CH}_2-$; A is $-\text{NH}-$; Q^2 is $\text{Ph}(2\text{-Cl})$; and J^1 is
119	J^2 is $-\text{CH}_2-$; A is $-\text{NH}-$; Q^2 is $\text{Ph}(2\text{-SO}_2\text{Me})$; and J^1 is
120	J^2 is $-\text{CH}_2-$; A is $-\text{NH}-$; Q^2 is $\text{Ph}(2\text{-F,3-Cl})$; and J^1 is
121	J^2 is $-\text{CH}_2-$; A is $-\text{CH}_2\text{NH}-$; Q^2 is $\text{Ph}(2\text{-F})$; and J^1 is
122	J^2 is $-\text{CH}_2-$; A is $-\text{CH}_2\text{NH}-$; Q^2 is $\text{Ph}(2,3\text{-di-F})$; and J^1 is
123	J^2 is $-\text{CH}_2-$; A is $-\text{CH}_2\text{NH}-$; Q^2 is $\text{Ph}(2,4\text{-di-F})$; and J^1 is
124	J^2 is $-\text{CH}_2-$; A is $-\text{CH}_2\text{NH}-$; Q^2 is $\text{Ph}(2,3,4\text{-tri-F})$; and J^1 is
125	J^2 is $-\text{CH}_2-$; A is $-\text{CH}_2\text{NH}-$; Q^2 is $\text{Ph}(2\text{-CF}_3)$; and J^1 is
126	J^2 is $-\text{CH}_2-$; A is $-\text{CH}_2\text{NH}-$; Q^2 is $\text{Ph}(2\text{-Me})$; and J^1 is
127	J^2 is $-\text{CH}_2-$; A is $-\text{CH}_2\text{NH}-$; Q^2 is $\text{Ph}(2\text{-NO}_2)$; and J^1 is
128	J^2 is $-\text{CH}_2-$; A is $-\text{CH}_2\text{NH}-$; Q^2 is $\text{Ph}(2\text{-Cl})$; and J^1 is
129	J^2 is $-\text{CH}_2-$; A is $-\text{CH}_2\text{NH}-$; Q^2 is $\text{Ph}(2\text{-SO}_2\text{Me})$; and J^1 is

130	J^2 is -CH ₂ -; A is -CH ₂ NH-; Q ² is Ph(2-F,3-Cl); and J ¹ is
131	J^2 is -CH ₂ -; A is -NHCH ₂ -; Q ² is Ph(2-F); and J ¹ is
132	J^2 is -CH ₂ -; A is -NHCH ₂ -; Q ² is Ph(2,3-di-F); and J ¹ is
133	J^2 is -CH ₂ -; A is -NHCH ₂ -; Q ² is Ph(2,4-di-F); and J ¹ is
134	J^2 is -CH ₂ -; A is -NHCH ₂ -; Q ² is Ph(2,3,4-tri-F); and J ¹ is
135	J^2 is -CH ₂ -; A is -NHCH ₂ -; Q ² is Ph(2-CF ₃); and J ¹ is
136	J^2 is -CH ₂ -; A is -NHCH ₂ -; Q ² is Ph(2-Me); and J ¹ is
137	J^2 is -CH ₂ -; A is -NHCH ₂ -; Q ² is Ph(2-NO ₂); and J ¹ is
138	J^2 is -CH ₂ -; A is -NHCH ₂ -; Q ² is Ph(2-Cl); and J ¹ is
139	J^2 is -CH ₂ -; A is -NHCH ₂ -; Q ² is Ph(2- SO ₂ Me); and J ¹ is
140	J^2 is -CH ₂ -; A is -NHCH ₂ -; Q ² is Ph(2-F,3-Cl); and J ¹ is
141	J^2 is -CH ₂ -; A is -HC=CH-; Q ² is Ph(2-F); and J ¹ is
142	J^2 is -CH ₂ -; A is -HC=CH-; Q ² is Ph(2,3-di-F); and J ¹ is
143	J^2 is -CH ₂ -; A is -HC=CH-; Q ² is Ph(2,4-di-F); and J ¹ is
144	J^2 is -CH ₂ -; A is -HC=CH-; Q ² is Ph(2,3,4-tri-F); and J ¹ is
145	J^2 is -CH ₂ -; A is -HC=CH-; Q ² is Ph(2-CF ₃); and J ¹ is
146	J^2 is -CH ₂ -; A is -HC=CH-; Q ² is Ph(2-Me); and J ¹ is
147	J^2 is -CH ₂ -; A is -HC=CH-; Q ² is Ph(2-NO ₂); and J ¹ is
148	J^2 is -CH ₂ -; A is -HC=CH-; Q ² is Ph(2-Cl); and J ¹ is
149	J^2 is -CH ₂ -; A is -HC=CH-; Q ² is Ph(2- SO ₂ Me); and J ¹ is
150	J^2 is -CH ₂ -; A is -HC=CH-; Q ² is Ph(2-F,3-Cl); and J ¹ is
151	J^2 is -CH ₂ -; A is -HC≡CH-; Q ² is Ph(2-F); and J ¹ is
152	J^2 is -CH ₂ -; A is -HC≡CH-; Q ² is Ph(2,3-di-F); and J ¹ is
153	J^2 is -CH ₂ -; A is -HC≡CH-; Q ² is Ph(2,4-di-F); and J ¹ is
154	J^2 is -CH ₂ -; A is -HC≡CH-; Q ² is Ph(2,3,4-tri-F); and J ¹ is
155	J^2 is -CH ₂ -; A is -HC≡CH-; Q ² is Ph(2-CF ₃); and J ¹ is
156	J^2 is -CH ₂ -; A is -HC≡CH-; Q ² is Ph(2-Me); and J ¹ is
157	J^2 is -CH ₂ -; A is -HC≡CH-; Q ² is Ph(2-NO ₂); and J ¹ is
158	J^2 is -CH ₂ -; A is -HC≡CH-; Q ² is Ph(2-Cl); and J ¹ is
159	J^2 is -CH ₂ -; A is -HC≡CH-; Q ² is Ph(2- SO ₂ Me); and J ¹ is
160	J^2 is -CH ₂ -; A is -HC≡CH-; Q ² is Ph(2-F,3-Cl); and J ¹ is
161	J^2 is -CH ₂ -; A is -HNN=CH-; Q ² is Ph(2-F); and J ¹ is
162	J^2 is -CH ₂ -; A is -HNN=CH-; Q ² is Ph(2,3-di-F); and J ¹ is
163	J^2 is -CH ₂ -; A is -HNN=CH-; Q ² is Ph(2,4-di-F); and J ¹ is
164	J^2 is -CH ₂ -; A is -HNN=CH-; Q ² is Ph(2,3,4-tri-F); and J ¹ is
165	J^2 is -CH ₂ -; A is -HNN=CH-; Q ² is Ph(2-CF ₃); and J ¹ is
166	J^2 is -CH ₂ -; A is -HNN=CH-; Q ² is Ph(2-Me); and J ¹ is


315	J ² is -CH ₂ CH ₂ -; A is -NHCH ₂ -; Q ² is Ph(2-CF ₃); and J ¹ is
316	J ² is -CH ₂ CH ₂ -; A is -NHCH ₂ -; Q ² is Ph(2-Me); and J ¹ is
317	J ² is -CH ₂ CH ₂ -; A is -NHCH ₂ -; Q ² is Ph(2-NO ₂); and J ¹ is
318	J ² is -CH ₂ CH ₂ -; A is -NHCH ₂ -; Q ² is Ph(2-Cl); and J ¹ is
319	J ² is -CH ₂ CH ₂ -; A is -NHCH ₂ -; Q ² is Ph(2- SO ₂ Me); and J ¹ is
320	J ² is -CH ₂ CH ₂ -; A is -NHCH ₂ -; Q ² is Ph(2-F,3-Cl); and J ¹ is
321	J ² is -CH ₂ CH ₂ -; A is -HC=CH-; Q ² is Ph(2-F); and J ¹ is
322	J ² is -CH ₂ CH ₂ -; A is -HC=CH-; Q ² is Ph(2,3-di-F); and J ¹ is
323	J ² is -CH ₂ CH ₂ -; A is -HC=CH-; Q ² is Ph(2,4-di-F); and J ¹ is
324	J ² is -CH ₂ CH ₂ -; A is -HC=CH-; Q ² is Ph(2,3,4-tri-F); and J ¹ is
325	J ² is -CH ₂ CH ₂ -; A is -HC=CH-; Q ² is Ph(2-CF ₃); and J ¹ is
326	J ² is -CH ₂ CH ₂ -; A is -HC=CH-; Q ² is Ph(2-Me); and J ¹ is
327	J ² is -CH ₂ CH ₂ -; A is -HC=CH-; Q ² is Ph(2-NO ₂); and J ¹ is
328	J ² is -CH ₂ CH ₂ -; A is -HC=CH-; Q ² is Ph(2-Cl); and J ¹ is
329	J ² is -CH ₂ CH ₂ -; A is -HC=CH-; Q ² is Ph(2- SO ₂ Me); and J ¹ is
330	J ² is -CH ₂ CH ₂ -; A is -HC=CH-; Q ² is Ph(2-F,3-Cl); and J ¹ is
331	J ² is -CH ₂ CH ₂ -; A is -HC≡CH-; Q ² is Ph(2-F); and J ¹ is
332	J ² is -CH ₂ CH ₂ -; A is -HC≡CH-; Q ² is Ph(2,3-di-F); and J ¹ is
333	J ² is -CH ₂ CH ₂ -; A is -HC≡CH-; Q ² is Ph(2,4-di-F); and J ¹ is
334	J ² is -CH ₂ CH ₂ -; A is -HC≡CH-; Q ² is Ph(2,3,4-tri-F); and J ¹ is
335	J ² is -CH ₂ CH ₂ -; A is -HC≡CH-; Q ² is Ph(2-CF ₃); and J ¹ is
336	J ² is -CH ₂ CH ₂ -; A is -HC≡CH-; Q ² is Ph(2-Me); and J ¹ is
337	J ² is -CH ₂ CH ₂ -; A is -HC≡CH-; Q ² is Ph(2-NO ₂); and J ¹ is
338	J ² is -CH ₂ CH ₂ -; A is -HC≡CH-; Q ² is Ph(2-Cl); and J ¹ is
339	J ² is -CH ₂ CH ₂ -; A is -HC≡CH-; Q ² is Ph(2- SO ₂ Me); and J ¹ is
340	J ² is -CH ₂ CH ₂ -; A is -HC≡CH-; Q ² is Ph(2-F,3-Cl); and J ¹ is
341	J ² is -CH ₂ CH ₂ -; A is -HNN=CH-; Q ² is Ph(2-F); and J ¹ is
342	J ² is -CH ₂ CH ₂ -; A is -HNN=CH-; Q ² is Ph(2,3-di-F); and J ¹ is
343	J ² is -CH ₂ CH ₂ -; A is -HNN=CH-; Q ² is Ph(2,4-di-F); and J ¹ is
344	J ² is -CH ₂ CH ₂ -; A is -HNN=CH-; Q ² is Ph(2,3,4-tri-F); and J ¹ is
345	J ² is -CH ₂ CH ₂ -; A is -HNN=CH-; Q ² is Ph(2-CF ₃); and J ¹ is
346	J ² is -CH ₂ CH ₂ -; A is -HNN=CH-; Q ² is Ph(2-Me); and J ¹ is
347	J ² is -CH ₂ CH ₂ -; A is -HNN=CH-; Q ² is Ph(2-NO ₂); and J ¹ is
348	J ² is -CH ₂ CH ₂ -; A is -HNN=CH-; Q ² is Ph(2-Cl); and J ¹ is
349	J ² is -CH ₂ CH ₂ -; A is -HNN=CH-; Q ² is Ph(2- SO ₂ Me); and J ¹ is
350	J ² is -CH ₂ CH ₂ -; A is -HNN=CH-; Q ² is Ph(2-F,3-Cl); and J ¹ is
351	J ² is -CH ₂ CH ₂ -; A is -CHN=NH-; Q ² is Ph(2-F); and J ¹ is

352	J^2 is $-\text{CH}_2\text{CH}_2-$; A is $-\text{CHN}=\text{NH}-$; Q^2 is $\text{Ph}(2,3\text{-di-F})$; and J^1 is
353	J^2 is $-\text{CH}_2\text{CH}_2-$; A is $-\text{CHN}=\text{NH}-$; Q^2 is $\text{Ph}(2,4\text{-di-F})$; and J^1 is
354	J^2 is $-\text{CH}_2\text{CH}_2-$; A is $-\text{CHN}=\text{NH}-$; Q^2 is $\text{Ph}(2,3,4\text{-tri-F})$; and J^1 is
355	J^2 is $-\text{CH}_2\text{CH}_2-$; A is $-\text{CHN}=\text{NH}-$; Q^2 is $\text{Ph}(2\text{-CF}_3)$; and J^1 is
356	J^2 is $-\text{CH}_2\text{CH}_2-$; A is $-\text{CHN}=\text{NH}-$; Q^2 is $\text{Ph}(2\text{-Me})$; and J^1 is
357	J^2 is $-\text{CH}_2\text{CH}_2-$; A is $-\text{CHN}=\text{NH}-$; Q^2 is $\text{Ph}(2\text{-NO}_2)$; and J^1 is
358	J^2 is $-\text{CH}_2\text{CH}_2-$; A is $-\text{CHN}=\text{NH}-$; Q^2 is $\text{Ph}(2\text{-Cl})$; and J^1 is
359	J^2 is $-\text{CH}_2\text{CH}_2-$; A is $-\text{CHN}=\text{NH}-$; Q^2 is $\text{Ph}(2\text{-SO}_2\text{Me})$; and J^1 is
360	J^2 is $-\text{CH}_2\text{CH}_2-$; A is $-\text{CHN}=\text{NH}-$; Q^2 is $\text{Ph}(2\text{-F},3\text{-Cl})$; and J^1 is

Table 361

Table 361 is constructed the same way as Table 1 above, except the structure is replaced with the following:


5

Tables 362 through 720

This disclosure also includes Tables 362 through 720, each Table is constructed in the same fashion as Tables 2 through 360 above, except that the structure is replaced with the structure in Table 361 above.

Table 1081

Table 1081 is constructed the same way as Table 1 above, except the structure is replaced with the following:




Tables 1082 through 1440

This disclosure also includes Tables 1082 through 1440, each Table is constructed in the same fashion as Tables 2 through 360 above, except that the structure is replaced with the structure in Table 1081 above.

5

Table 1441


Table 1441 is constructed the same way as Table 1 above, except the structure is replaced with the following:

Tables 1442 through 1800

10 This disclosure also includes Tables 1442 through 1800, each Table is constructed in the same fashion as Tables 2 through 360 above, except that the structure is replaced with the structure in Table 1441 above.

Table 1801


15 Table 1801 is constructed the same way as Table 1 above, except the structure is replaced with the following:

Tables 1802 through 2160

20 This disclosure also includes Tables 1802 through 2160, each Table is constructed in the same fashion as Tables 2 through 360 above, except that the structure is replaced with the structure in Table 1801 above.

Table 2161

Table 2161 is constructed the same way as Table 1 above, except the structure is replaced with the following:



5


Tables 2162 through 2520

This disclosure also includes Tables 2162 through 2520, each Table is constructed in the same fashion as Tables 2 through 360 above, except that the structure is replaced with the structure in Table 2161 above.

10

Table 2521

Table 2521 is constructed the same way as Table 1 above, except the structure is replaced with the following:


Tables 2522 through 2880

15

This disclosure also includes Tables 2522 through 2880, each Table is constructed in the same fashion as Tables 2 through 360 above, except that the structure is replaced with the structure in Table 2521 above.

Table 2881

Table 2881 is constructed the same way as Table 1 above, except the structure is replaced with the following:




5

Tables 2882 through 3240

This disclosure also includes Tables 2882 through 3240, each Table is constructed in the same fashion as Tables 2 through 360 above, except that the structure is replaced with the structure in Table 7561 above.

Table 3241


10 Table 3241 is constructed the same way as Table 1 above, except the structure is replaced with the following:

Tables 3242 through 3600

15 This disclosure also includes Tables 3242 through 3600, each Table is constructed in the same fashion as Tables 2 through 360 above, except that the structure is replaced with the structure in Table 3241 above.

Table 3601

Table 3601 is constructed the same way as Table 1 above, except the structure is replaced with the following:




5

Tables 3602 through 3960

This disclosure also includes Tables 3602 through 3960, each Table is constructed in the same fashion as Tables 2 through 360 above, except that the structure is replaced with the structure in Table 3601 above.

Table 3961


10 Table 3961 is constructed the same way as Table 1 above, except the structure is replaced with the following:

Tables 3962 through 4320

15 This disclosure also includes Tables 3962 through 4320, each Table is constructed in the same fashion as Tables 2 through 360 above, except that the structure is replaced with the structure in Table 3961 above.

Table 4321

Table 4321 is constructed the same way as Table 1 above, except the structure is replaced with the following:




5

Tables 4322 through 4680

This disclosure also includes Tables 4322 through 4680, each Table is constructed in the same fashion as Tables 2 through 360 above, except that the structure is replaced with the structure in Table 4321 above.

Table 4681


10 Table 4681 is constructed the same way as Table 1 above, except the structure is replaced with the following:

Tables 4682 through 5040

15 This disclosure also includes Tables 4682 through 5040, each Table is constructed in the same fashion as Tables 2 through 360 above, except that the structure is replaced with the structure in Table 4681 above.

Table 5041

Table 5041 is constructed the same way as Table 1 above, except the structure is replaced with the following:




Tables 5042 through 5400

This disclosure also includes Tables 5042 through 5400, each Table is constructed in the same fashion as Tables 2 through 360 above, except that the structure is replaced with the structure in Table 5041 above.

Table 5401

10 Table 5401 is constructed the same way as Table 1 above, except the structure is replaced with the following:




Tables 5402 through 5760

This disclosure also includes Tables 5402 through 5760, each Table is constructed in the same fashion as Tables 2 through 360 above, except that the structure is replaced with the structure in Table 5401 above.

Table 5761

Table 5761 is constructed the same way as Table 1 above, except the structure is replaced with the following:



5

Tables 5762 through 6120

This disclosure also includes Tables 5762 through 6120, each Table is constructed in the same fashion as Tables 2 through 360 above, except that the structure is replaced with the structure in Table 5761 above.

Formulation/Utility

10 A compound of this invention will generally be used as a herbicidal active ingredient in a composition, i.e. formulation, with at least one additional component selected from the group consisting of surfactants, solid diluents and liquid diluents, which serves as a carrier. The formulation or composition ingredients are selected to be consistent with the physical properties of the active ingredient, mode of application and environmental factors such as
15 soil type, moisture and temperature.

Useful formulations include both liquid and solid compositions. Liquid compositions include solutions (including emulsifiable concentrates), suspensions, emulsions (including microemulsions, oil-in -water emulsions, flowable concentrates and/or suspoemulsions) and the like, which optionally can be thickened into gels. The general types of aqueous liquid
20 compositions are soluble concentrate, suspension concentrate, capsule suspension, concentrated emulsion, microemulsion, oil-in-water emulsion, flowable concentrate and suspo-emulsion. The general types of nonaqueous liquid compositions are emulsifiable concentrate, microemulsifiable concentrate, dispersible concentrate and oil dispersion.

The general types of solid compositions are dusts, powders, granules, pellets, prills, pastilles, tablets, filled films (including seed coatings) and the like, which can be water-dispersible (“wettable”) or water-soluble. Films and coatings formed from film-forming solutions or flowable suspensions are particularly useful for seed treatment. Active ingredient can be (micro)encapsulated and further formed into a suspension or solid formulation; alternatively the entire formulation of active ingredient can be encapsulated (or
30 “overcoated”). Encapsulation can control or delay release of the active ingredient. An emulsifiable granule combines the advantages of both an emulsifiable concentrate

formulation and a dry granular formulation. High-strength compositions are primarily used as intermediates for further formulation.

Sprayable formulations are typically extended in a suitable medium before spraying. Such liquid and solid formulations are formulated to be readily diluted in the spray medium, 5 usually water, but occasionally another suitable medium like an aromatic or paraffinic hydrocarbon or vegetable oil. Spray volumes can range from about from about one to several thousand liters per hectare, but more typically are in the range from about ten to several hundred liters per hectare. Sprayable formulations can be tank mixed with water or another suitable medium for foliar treatment by aerial or ground application, or for 10 application to the growing medium of the plant. Liquid and dry formulations can be metered directly into drip irrigation systems or metered into the furrow during planting.

The formulations will typically contain effective amounts of active ingredient, diluent and surfactant within the following approximate ranges which add up to 100 percent by weight.

	Weight Percent		
	<u>Active Ingredient</u>	<u>Diluent</u>	<u>Surfactant</u>
Water-Dispersible and Water-soluble Granules, Tablets and Powders	0.001–90	0–99.999	0–15
Oil Dispersions, Suspensions, Emulsions, Solutions (including Emulsifiable Concentrates)	1–50	40–99	0–50
Dusts	1–25	70–99	0–5
Granules and Pellets	0.001–99	5–99.999	0–15
High Strength Compositions	90–99	0–10	0–2

15 Solid diluents include, for example, clays such as bentonite, montmorillonite, attapulgite and kaolin, gypsum, cellulose, titanium dioxide, zinc oxide, starch, dextrin, sugars (e.g., lactose, sucrose), silica, talc, mica, diatomaceous earth, urea, calcium carbonate, sodium carbonate and bicarbonate, and sodium sulfate. Typical solid diluents are described in Watkins et al., *Handbook of Insecticide Dust Diluents and Carriers*, 2nd Ed., Dorland Books, Caldwell, New Jersey.

20 Liquid diluents include, for example, water, *N,N*-dimethylalkanamides (e.g., *N,N*-dimethylformamide), limonene, dimethyl sulfoxide, *N*-alkylpyrrolidones (e.g., *N*-methylpyrrolidinone), alkyl phosphates (e.g., triethyl phosphate), ethylene glycol, triethylene glycol, propylene glycol, dipropylene glycol, polypropylene glycol, propylene carbonate, butylene carbonate, paraffins (e.g., white mineral oils, normal paraffins, isoparaffins), alkylbenzenes, alkylnaphthalenes, glycerine, glycerol triacetate, sorbitol,

aromatic hydrocarbons, dearomatized aliphatics, alkylbenzenes, alkylnaphthalenes, ketones such as cyclohexanone, 2-heptanone, isophorone and 4-hydroxy-4-methyl-2-pentanone, acetates such as isoamyl acetate, hexyl acetate, heptyl acetate, octyl acetate, nonyl acetate, tridecyl acetate and isobornyl acetate, other esters such as alkylated lactate esters, dibasic esters, alkyl and aryl benzoates and γ -butyrolactone, and alcohols, which can be linear, branched, saturated or unsaturated, such as methanol, ethanol, *n*-propanol, isopropyl alcohol, *n*-butanol, isobutyl alcohol, *n*-hexanol, 2-ethylhexanol, *n*-octanol, decanol, isodecyl alcohol, isoctadecanol, cetyl alcohol, lauryl alcohol, tridecyl alcohol, oleyl alcohol, cyclohexanol, tetrahydrofurfuryl alcohol, diacetone alcohol, cresol and benzyl alcohol. Liquid diluents also 5 include glycerol esters of saturated and unsaturated fatty acids (typically C₆–C₂₂), such as plant seed and fruit oils (e.g., oils of olive, castor, linseed, sesame, corn (maize), peanut, sunflower, grapeseed, safflower, cottonseed, soybean, rapeseed, coconut and palm kernel), animal-sourced fats (e.g., beef tallow, pork tallow, lard, cod liver oil, fish oil), and mixtures thereof. Liquid diluents also include alkylated fatty acids (e.g., 10 methylated, ethylated, butylated) wherein the fatty acids may be obtained by hydrolysis of glycerol esters from plant and animal sources, and can be purified by distillation. Typical 15 liquid diluents are described in Marsden, *Solvents Guide*, 2nd Ed., Interscience, New York, 1950.

The solid and liquid compositions of the present invention often include one or more 20 surfactants. When added to a liquid, surfactants (also known as “surface-active agents”) generally modify, most often reduce, the surface tension of the liquid. Depending on the nature of the hydrophilic and lipophilic groups in a surfactant molecule, surfactants can be useful as wetting agents, dispersants, emulsifiers or defoaming agents.

Surfactants can be classified as nonionic, anionic or cationic. Nonionic surfactants 25 useful for the present compositions include, but are not limited to: alcohol alkoxylates such as alcohol alkoxylates based on natural and synthetic alcohols (which may be branched or linear) and prepared from the alcohols and ethylene oxide, propylene oxide, butylene oxide or mixtures thereof; amine ethoxylates, alkanolamides and ethoxylated alkanolamides; alkoxylated triglycerides such as ethoxylated soybean, castor and rapeseed oils; alkylphenol 30 alkoxylates such as octylphenol ethoxylates, nonylphenol ethoxylates, dinonyl phenol ethoxylates and dodecyl phenol ethoxylates (prepared from the phenols and ethylene oxide, propylene oxide, butylene oxide or mixtures thereof); block polymers prepared from ethylene oxide or propylene oxide and reverse block polymers where the terminal blocks are prepared from propylene oxide; ethoxylated fatty acids; ethoxylated fatty esters and oils; 35 ethoxylated methyl esters; ethoxylated tristyrylphenol (including those prepared from ethylene oxide, propylene oxide, butylene oxide or mixtures thereof); fatty acid esters, glycerol esters, lanolin-based derivatives, polyethoxylate esters such as polyethoxylated sorbitan fatty acid esters, polyethoxylated sorbitol fatty acid esters and polyethoxylated

glycerol fatty acid esters; other sorbitan derivatives such as sorbitan esters; polymeric surfactants such as random copolymers, block copolymers, alkyd peg (polyethylene glycol) resins, graft or comb polymers and star polymers; polyethylene glycols (pegs); polyethylene glycol fatty acid esters; silicone-based surfactants; and sugar-derivatives such as sucrose esters, alkyl polyglycosides and alkyl polysaccharides.

Useful anionic surfactants include, but are not limited to: alkylaryl sulfonic acids and their salts; carboxylated alcohol or alkylphenol ethoxylates; diphenyl sulfonate derivatives; lignin and lignin derivatives such as lignosulfonates; maleic or succinic acids or their anhydrides; olefin sulfonates; phosphate esters such as phosphate esters of alcohol 10 alkoxylates, phosphate esters of alkylphenol alkoxylates and phosphate esters of styryl phenol ethoxylates; protein-based surfactants; sarcosine derivatives; styryl phenol ether sulfate; sulfates and sulfonates of oils and fatty acids; sulfates and sulfonates of ethoxylated alkylphenols; sulfates of alcohols; sulfates of ethoxylated alcohols; sulfonates of amines and amides such as *N,N*-alkyltaurates; sulfonates of benzene, cumene, toluene, xylene, and 15 dodecyl and tridecylbenzenes; sulfonates of condensed naphthalenes; sulfonates of naphthalene and alkyl naphthalene; sulfonates of fractionated petroleum; sulfosuccinamates; and sulfosuccinates and their derivatives such as dialkyl sulfosuccinate salts.

Useful cationic surfactants include, but are not limited to: amides and ethoxylated amides; amines such as *N*-alkyl propanediamines, tripropylenetriamines and 20 dipropylenetetramines, and ethoxylated amines, ethoxylated diamines and propoxylated amines (prepared from the amines and ethylene oxide, propylene oxide, butylene oxide or mixtures thereof); amine salts such as amine acetates and diamine salts; quaternary ammonium salts such as quaternary salts, ethoxylated quaternary salts and diquaternary salts; and amine oxides such as alkyldimethylamine oxides and bis-(2-hydroxyethyl)-alkylamine 25 oxides.

Also useful for the present compositions are mixtures of nonionic and anionic surfactants or mixtures of nonionic and cationic surfactants. Nonionic, anionic and cationic surfactants and their recommended uses are disclosed in a variety of published references including *McCutcheon's Emulsifiers and Detergents*, annual American and International 30 Editions published by McCutcheon's Division, The Manufacturing Confectioner Publishing Co.; Sisely and Wood, *Encyclopedia of Surface Active Agents*, Chemical Publ. Co., Inc., New York, 1964; and A. S. Davidson and B. Milwidsky, *Synthetic Detergents*, Seventh Edition, John Wiley and Sons, New York, 1987.

Compositions of this invention may also contain formulation auxiliaries and additives, 35 known to those skilled in the art as formulation aids (some of which may be considered to also function as solid diluents, liquid diluents or surfactants). Such formulation auxiliaries and additives may control: pH (buffers), foaming during processing (antifoams such polyorganosiloxanes), sedimentation of active ingredients (suspending agents), viscosity

(thixotropic thickeners), in-container microbial growth (antimicrobials), product freezing (antifreezes), color (dyes/pigment dispersions), wash-off (film formers or stickers), evaporation (evaporation retardants), and other formulation attributes. Film formers include, for example, polyvinyl acetates, polyvinyl acetate copolymers, polyvinylpyrrolidone-vinyl acetate copolymer, polyvinyl alcohols, polyvinyl alcohol copolymers and waxes. Examples of formulation auxiliaries and additives include those listed in *McCutcheon's Volume 2: Functional Materials*, annual International and North American editions published by McCutcheon's Division, The Manufacturing Confectioner Publishing Co.; and PCT Publication WO 03/024222.

The compound of Formula 1 and any other active ingredients are typically incorporated into the present compositions by dissolving the active ingredient in a solvent or by grinding in a liquid or dry diluent. Solutions, including emulsifiable concentrates, can be prepared by simply mixing the ingredients. If the solvent of a liquid composition intended for use as an emulsifiable concentrate is water-immiscible, an emulsifier is typically added to emulsify the active-containing solvent upon dilution with water. Active ingredient slurries, with particle diameters of up to 2,000 μm can be wet milled using media mills to obtain particles with average diameters below 3 μm . Aqueous slurries can be made into finished suspension concentrates (see, for example, U.S. 3,060,084) or further processed by spray drying to form water-dispersible granules. Dry formulations usually require dry milling processes, which produce average particle diameters in the 2 to 10 μm range. Dusts and powders can be prepared by blending and usually grinding (such as with a hammer mill or fluid-energy mill). Granules and pellets can be prepared by spraying the active material upon preformed granular carriers or by agglomeration techniques. See Browning, "Agglomeration", *Chemical Engineering*, December 4, 1967, pp 147-48, *Perry's Chemical Engineer's Handbook*, 4th Ed., McGraw-Hill, New York, 1963, pages 8-57 and following, and WO 91/13546. Pellets can be prepared as described in U.S. 4,172,714. Water-dispersible and water-soluble granules can be prepared as taught in U.S. 4,144,050, U.S. 3,920,442 and DE 3,246,493. Tablets can be prepared as taught in U.S. 5,180,587, U.S. 5,232,701 and U.S. 5,208,030. Films can be prepared as taught in GB 2,095,558 and U.S. 3,299,566.

For further information regarding the art of formulation, see T. S. Woods, "The Formulator's Toolbox – Product Forms for Modern Agriculture" in *Pesticide Chemistry and Bioscience, The Food-Environment Challenge*, T. Brooks and T. R. Roberts, Eds., Proceedings of the 9th International Congress on Pesticide Chemistry, The Royal Society of Chemistry, Cambridge, 1999, pp. 120-133. See also U.S. 3,235,361, Col. 6, line 16 through Col. 7, line 19 and Examples 10-41; U.S. 3,309,192, Col. 5, line 43 through Col. 7, line 62 and Examples 8, 12, 15, 39, 41, 52, 53, 58, 132, 138-140, 162-164, 166, 167 and 169-182; U.S. 2,891,855, Col. 3, line 66 through Col. 5, line 17 and Examples 1-4; Klingman, *Weed*

Control as a Science, John Wiley and Sons, Inc., New York, 1961, pp 81–96; Hance et al., *Weed Control Handbook*, 8th Ed., Blackwell Scientific Publications, Oxford, 1989; and *Developments in formulation technology*, PJB Publications, Richmond, UK, 2000.

In the following Examples, all percentages are by weight and all formulations are prepared in conventional ways. Compound numbers refer to compounds in Index Table A. Without further elaboration, it is believed that one skilled in the art using the preceding description can utilize the present invention to its fullest extent. The following Examples are, therefore, to be construed as merely illustrative, and not limiting of the disclosure in any way whatsoever. Percentages are by weight except where otherwise indicated.

10

Example A

High Strength Concentrate

Compound 20	98.5%
silica aerogel	0.5%
synthetic amorphous fine silica	1.0%

Example B

Wettable Powder

Compound 20	65.0%
dodecylphenol polyethylene glycol ether	2.0%
sodium ligninsulfonate	4.0%
sodium silicoaluminate	6.0%
montmorillonite (calcined)	23.0%

Example C

Granule

Compound 20	10.0%
attapulgite granules (low volatile matter, 0.71/0.30 mm; U.S.S. No. 25–50 sieves)	90.0%

Example D

Extruded Pellet

Compound 20	25.0%
anhydrous sodium sulfate	10.0%
crude calcium ligninsulfonate	5.0%
sodium alkylnaphthalenesulfonate	1.0%
calcium/magnesium bentonite	59.0%

Example E

Emulsifiable Concentrate

Compound 20	10.0%
polyoxyethylene sorbitol hexoleate	20.0%
C ₆ –C ₁₀ fatty acid methyl ester	70.0%

Example FMicroemulsion

Compound 20	5.0%
polyvinylpyrrolidone-vinyl acetate copolymer	30.0%
alkylpolyglycoside	30.0%
glyceryl monooleate	15.0%
water	20.0%

Example GSuspension Concentrate

Compound 20	35%
butyl polyoxyethylene/polypropylene block copolymer	4.0%
stearic acid/polyethylene glycol copolymer	1.0%
styrene acrylic polymer	1.0%
xanthan gum	0.1%
propylene glycol	5.0%
silicone based defoamer	0.1%
1,2-benzisothiazolin-3-one	0.1%
water	53.7%

Example HEmulsion in Water

Compound 20	10.0%
butyl polyoxyethylene/polypropylene block copolymer	4.0%
stearic acid/polyethylene glycol copolymer	1.0%
styrene acrylic polymer	1.0%
xanthan gum	0.1%
propylene glycol	5.0%
silicone based defoamer	0.1%
1,2-benzisothiazolin-3-one	0.1%
aromatic petroleum based hydrocarbon	20.0
water	58.7%

Example IOil Dispersion

Compound 20	25%
polyoxyethylene sorbitol hexaoleate	15%
organically modified bentonite clay	2.5%
fatty acid methyl ester	57.5%

The present disclosure also includes Examples A through I above except the "Compound 20" is replaced with "Compound 1", "Compound 2", "Compound 3", "Compound 4", "Compound 5", "Compound 6", "Compound 7", "Compound 8", "Compound 9", "Compound 10", "Compound 11", "Compound 12", "Compound 13", 5 "Compound 14", "Compound 15", "Compound 16", "Compound 17", "Compound 18", "Compound 19", "Compound 21", "Compound 22", "Compound 23", "Compound 24", "Compound 25", "Compound 26", "Compound 27", "Compound 28", "Compound 29", "Compound 30", "Compound 31", "Compound 32", "Compound 33", "Compound 34", "Compound 35", Compound 36, Compound 37, Compound 38, Compound 39, Compound 10 40, Compound 41, Compound 42, Compound 43, Compound 44, Compound 45, Compound 45, Compound 46, Compound 47, Compound 48, Compound 49, Compound 50, Compound 51, Compound 52, Compound 53, Compound 54, Compound 55, Compound 56, Compound 57, Compound 58, Compound 59, Compound 60, Compound 61, Compound 62, Compound 63, Compound 64, Compound 65, Compound 66, Compound 67, Compound 68, Compound 15 69, Compound 70, Compound 71, Compound 72, Compound 73, Compound 74, Compound 75, Compound 76, Compound 77, Compound 78, Compound 79, Compound 80, Compound 81, Compound 82, Compound 83, Compound 84, Compound 85, Compound 86, Compound 87, Compound 88, Compound 89 Compound 90, Compound 91, Compound 92, Compound 93 or Compound 94.

20 Test results indicate that the compounds of the present invention are highly active preemergent and/or postemergent herbicides and/or plant growth regulants. The compounds of the invention generally show highest activity for postemergence weed control (i.e. applied after weed seedlings emerge from the soil) and preemergence weed control (i.e. applied before weed seedlings emerge from the soil). Many of them have utility for broad-spectrum 25 pre- and/or postemergence weed control in areas where complete control of all vegetation is desired such as around fuel storage tanks, industrial storage areas, parking lots, drive-in theaters, air fields, river banks, irrigation and other waterways, around billboards and highway and railroad structures. Many of the compounds of this invention, by virtue of selective metabolism in crops versus weeds, or by selective activity at the locus of 30 physiological inhibition in crops and weeds, or by selective placement on or within the environment of a mixture of crops and weeds, are useful for the selective control of grass and broadleaf weeds within a crop/weed mixture. One skilled in the art will recognize that the preferred combination of these selectivity factors within a compound or group of compounds can readily be determined by performing routine biological and/or biochemical 35 assays. Compounds of this invention may show tolerance to important agronomic crops including, but is not limited to, alfalfa, barley, cotton, wheat, rape, sugar beets, corn (maize), sorghum, soybeans, rice, oats, peanuts, vegetables, tomato, potato, perennial plantation crops

including coffee, cocoa, oil palm, rubber, sugarcane, citrus, grapes, fruit trees, nut trees, banana, plantain, pineapple, hops, tea and forests such as eucalyptus and conifers (e.g., loblolly pine), and turf species (e.g., Kentucky bluegrass, St. Augustine grass, Kentucky fescue and Bermuda grass). Compounds of this invention can be used in crops genetically transformed or bred to incorporate resistance to herbicides, express proteins toxic to invertebrate pests (such as *Bacillus thuringiensis* toxin), and/or express other useful traits. Those skilled in the art will appreciate that not all compounds are equally effective against all weeds. Alternatively, the subject compounds are useful to modify plant growth.

Compounds of this invention may show surprising selective activity controlling weed species growing in rice including, but not limited to, common waterplantain (*Alisma plantago-aquatica* L.), umbrella sedge (*Cyperus difformis* L.), rice flatsedge (*Cyperus iria* L.), junglerice (*Echinochloa coloym* (L.) LINK), barnyardgrass (*Echinochloa crus-galli* (L.) P.BEAUV.), early watergrass (2 Leaf Stage; *Echinochloa oryzoides* (ARD.) FRITSCH), late watergrass (2 Leaf Stage; *Echinochloa phyllopon* (STAPF) KOSS./VASC.), Chinese waterchestnut (*Eleocharis dulcis* (BURM.f.) TRIN. ex HENSCHEL), ducksalad (*Heteranthera limosa* (SW.) WILLD./VAHL), bearded sprangletop (*Leptochloa fascicularis* (LAM.) GRAY), monochoria (*Monochoria vaginalis* (BURM.f.) C.PRESL ex KUNTH), common arrowhead (*Sagittaria latifolia* WILLD.), California arrowhead (*Sagittaria montevidensis* CHAM. & SCHLECHT.), stiff arrowhead (*Sagittaria rigida* PURSH), Japanese bulrush (*Scirpus juncoides* ROXB.) and ricefield bulrush (*Scirpus mucronatus* L.).

Compounds of this invention also show particular activities (biological activity) controlling weed species growing in cereal crops including, but not limited to, blackgrass (*Alopecurus myosuroides* Huds.), windgrass (*Apera spica-venti* (L.) BEAUV.), wild oats (*Avena fatua* L.), Italian ryegrass (*Lolium multiflorum* LAM.), littleseed canarygrass (*Phalaris minor* RETZ.), green foxtail (*Setaria viridis* (L.) P.BEAUV.).

As the compounds of the invention have (both preemergent and postemergent herbicidal) activity, to control undesired vegetation by killing or injuring the vegetation or reducing its growth, the compounds can be usefully applied by a variety of methods involving contacting a herbicidally effective amount of a compound of the invention, or a composition comprising said compound and at least one of a surfactant, a solid diluent or a liquid diluent, to the foliage or other part of the undesired vegetation or to the environment of the undesired vegetation such as the soil or water in which the undesired vegetation is growing or which surrounds the seed or other propagule of the undesired vegetation.

A herbicidally effective amount of the compounds of this invention is determined by a number of factors. These factors include: formulation selected, method of application, amount and type of vegetation present, growing conditions, etc. In general, a herbicidally effective amount of compounds of this invention is about 0.001 to 20 kg/ha with a preferred

range of about 0.004 to 1 kg/ha. One skilled in the art can easily determine the herbicidally effective amount necessary for the desired level of weed control.

In one common embodiment, a compound of the invention is applied, typically in a formulated composition, to a locus comprising desired vegetation (e.g., crops) and undesired vegetation (i.e. weeds), both of which may be seeds, seedlings and/or larger plants, in contact with a growth medium (e.g., soil). In this locus, a composition comprising a compound of the invention can be directly applied to a plant or a part thereof, particularly of the undesired vegetation, and/or to the growth medium in contact with the plant.

Plant varieties and cultivars of the desired vegetation in the locus treated with a compound of the invention can be obtained by conventional propagation and breeding methods or by genetic engineering methods. Genetically modified plants (transgenic plants) are those in which a heterologous gene (transgene) has been stably integrated into the plant's genome. A transgene that is defined by its particular location in the plant genome is called a transformation or transgenic event.

Genetically modified plant cultivars in the locus which can be treated according to the invention include those that are resistant against one or more biotic stresses (pests such as nematodes, insects, mites, fungi, etc.) or abiotic stresses (drought, cold temperature, soil salinity, etc.), or that contain other desirable characteristics. Plants can be genetically modified to exhibit traits of, for example, herbicide tolerance, insect-resistance, modified oil profiles or drought tolerance. Useful genetically modified plants containing single gene transformation events or combinations of transformation events are listed in Exhibit C. Additional information for the genetic modifications listed in Exhibit C can be obtained from publicly available databases maintained, for example, by the U.S. Department of Agriculture.

The following abbreviations, T1 through T37, are used in Exhibit C for traits. A “-“ means the entry is not available; “tol.” means “tolerance” and “res.” means resistance.

Trait	Description	Trait	Description	Trait	Description
T1	Glyphosate tol.	T15	Cold tol.	T27	High tryptophan
T2	High lauric acid oil	T16	Imidazolinone herb. tol.	T28	Erect leaves semidwarf
T3	Glufosinate tol.	T17	Modified alpha-amylase	T29	Semidwarf
T4	Phytate breakdown	T18	Pollination control	T30	Low iron tol.
T5	Oxynil tol.	T19	2,4-D tol.	T31	Modified oil/fatty acid
T6	Disease res.	T20	Increased lysine	T32	HPPD tol.
T7	Insect res.	T21	Drought tol.	T33	High oil
T9	Modified flower color	T22	Delayed ripening/senescence	T34	Aryloxyalkanoate tol.
T11	ALS Herbicide tol.	T23	Modified product quality	T35	Mesotrione tol.
T12	Dicamba tol.	T24	High cellulose	T36	Reduced nicotine
T13	Anti-allergy	T25	Modified starch/carbohydrate	T37	Modified product
T14	Salt tol.	T26	Insect & disease resist.		

Exhibit C

Crop	Event Name	Event Code	Trait(s)	Gene(s)
Alfalfa	J101	MON-00101-8	T1	cp4 epsps (aroA:CP4)
Alfalfa	J163	MON-00163-7	T1	cp4 epsps (aroA:CP4)
Canola*	23-18-17 (Event 18)	CGN-89465-2	T2	te
Canola*	23-198 (Event 23)	CGN-89465-2	T2	te
Canola*	61061	DP-061061-7	T1	gat4621
Canola*	73496	DP-073496-4	T1	gat4621
Canola*	GT200 (RT200)	MON-89249-2	T1	cp4 epsps (aroA:CP4); goxv247
Canola*	GT73 (RT73)	MON-00073-7	T1	cp4 epsps (aroA:CP4); goxv247
Canola*	HCN10 (Topas 19/2)	-	T3	bar
Canola*	HCN28 (T45)	ACS-BN008-2	T3	pat (syn)
Canola*	HCN92 (Topas 19/2)	ACS-BN007-1	T3	bar
Canola*	MON88302	MON-88302-9	T1	cp4 epsps (aroA:CP4)
Canola*	MPS961	-	T4	phyA
Canola*	MPS962	-	T4	phyA
Canola*	MPS963	-	T4	phyA
Canola*	MPS964	-	T4	phyA
Canola*	MPS965	-	T4	phyA
Canola*	MS1 (B91-4)	ACS-BN004-7	T3	bar
Canola*	MS8	ACS-BN005-8	T3	bar
Canola*	OXY-235	ACS-BN011-5	T5	bxn
Canola*	PHY14	-	T3	bar
Canola*	PHY23	-	T3	bar
Canola*	PHY35	-	T3	bar
Canola*	PHY36	-	T3	bar
Canola*	RF1 (B93-101)	ACS-BN001-4	T3	bar
Canola*	RF2 (B94-2)	ACS-BN002-5	T3	bar
Canola*	RF3	ACS-BN003-6	T3	bar
Bean	EMBRAPA 5.1	EMB-PV051-1	T6	ac1 (sense and antisense)
Brinjal #	EE-1	-	T7	cry1Ac
Cotton	19-51a	DD-01951A-7	T11	S4-HrA
Cotton	281-24-236	DAS-24236-5	T3,T7	pat (syn); cry1F
Cotton	3006-210-23	DAS-21023-5	T3,T7	pat (syn); cry1Ac
Cotton	31707	-	T5,T7	bxn; cry1Ac
Cotton	31803	-	T5,T7	bxn; cry1Ac
Cotton	31807	-	T5,T7	bxn; cry1Ac

Cotton	31808	-	T5,T7	bxn; cry1Ac
Cotton	42317	-	T5,T7	bxn; cry1Ac
Cotton	BNLA-601	-	T7	cry1Ac
Cotton	BXN10211	BXN10211-9	T5	bxn; cry1Ac
Cotton	BXN10215	BXN10215-4	T5	bxn; cry1Ac
Cotton	BXN10222	BXN10222-2	T5	bxn; cry1Ac
Cotton	BXN10224	BXN10224-4	T5	bxn; cry1Ac
Cotton	COT102	SYN-IR102-7	T7	vip3A(a)
Cotton	COT67B	SYN-IR67B-1	T7	cry1Ab
Cotton	COT202	-	T7	vip3A
Cotton	Event 1	-	T7	cry1Ac
Cotton	GMF Cry1A	GTL-GMF311-7	T7	cry1Ab-Ac
Cotton	GHB119	BCS-GH005-8	T7	cry2Ae
Cotton	GHB614	BCS-GH002-5	T1	2mepsps
Cotton	GK12	-	T7	cry1Ab-Ac
Cotton	LLCotton25	ACS-GH001-3	T3	bar
Cotton	MLS 9124	-	T7	cry1C
Cotton	MON1076	MON-89924-2	T7	cry1Ac
Cotton	MON1445	MON-01445-2	T1	cp4 epsps (aroA:CP4)
Cotton	MON15985	MON-15985-7	T7	cry1Ac; cry2Ab2
Cotton	MON1698	MON-89383-1	T7	cp4 epsps (aroA:CP4)
Cotton	MON531	MON-00531-6	T7	cry1Ac
Cotton	MON757	MON-00757-7	T7	cry1Ac
Cotton	MON88913	MON-88913-8	T1	cp4 epsps (aroA:CP4)
Cotton	Nqwe Chi 6 Bt	-	T7	-
Cotton	SKG321	-	T7	cry1A; CpTI
Cotton	T303-3	BCS-GH003-6	T3,T7	cry1Ab; bar
Cotton	T304-40	BCS-GH004-7	T3,T7	cry1Ab; bar
Cotton	CE43-67B	-	T7	cry1Ab
Cotton	CE46-02A	-	T7	cry1Ab
Cotton	CE44-69D	-	T7	cry1Ab
Cotton	1143-14A	-	T7	cry1Ab
Cotton	1143-51B	-	T7	cry1Ab
Cotton	T342-142	-	T7	cry1Ab
Cotton	PV-GHGT07 (1445)	-	T1	cp4 epsps (aroA:CP4)
Cotton	EE-GH3	-	T1	mepsps
Cotton	EE-GH5	-	T7	cry1Ab
Cotton	MON88701	MON-88701-3	T3,T12	Modified dmo; bar
Cotton	OsCr11	-	T13	Modified Cry j
Flax	FP967	CDC-FL001-2	T11	als
Lentil	RH44	-	T16	als

Maize	3272	SYN-E3272-5	T17	amy797E
Maize	5307	SYN-05307-1	T7	ecry3.1Ab
Maize	59122	DAS-59122-7	T3,T7	cry34Ab1; cry35Ab1; pat
Maize	676	PH-000676-7	T3,T18	pat; dam
Maize	678	PH-000678-9	T3,T18	pat; dam
Maize	680	PH-000680-2	T3,T18	pat; dam
Maize	98140	DP-098140-6	T1,T11	gat4621; zm-hra
Maize	Bt10	-	T3,T7	cry1Ab; pat
Maize	Bt176 (176)	SYN-EV176-9	T3,T7	cry1Ab; bar
Maize	BVLA430101	-	T4	phyA2
Maize	CBH-351	ACS-ZM004-3	T3,T7	cry9C; bar
Maize	DAS40278-9	DAS40278-9	T19	aad-1
Maize	DBT418	DKB-89614-9	T3,T7	cry1Ac; pinII; bar
Maize	DLL25 (B16)	DKB-89790-5	T3	bar
Maize	GA21	MON-00021-9	T1	mepsps
Maize	GG25	-	T1	mepsps
Maize	GJ11	-	T1	mepsps
Maize	Fl117	-	T1	mepsps
Maize	GAT-ZM1	-	T3	pat
Maize	LY038	REN-00038-3	T20	cordapA
Maize	MIR162	SYN-IR162-4	T7	vip3Aa20
Maize	MIR604	SYN-IR604-5	T7	mcry3A
Maize	MON801 (MON80100)	MON801	T1,T7	cry1Ab; cp4 epsps (aroA:CP4); goxv247
Maize	MON802	MON-80200-7	T1,T7	cry1Ab; cp4 epsps (aroA:CP4); goxv247
Maize	MON809	PH-MON-809-2	T1,T7	cry1Ab; cp4 epsps (aroA:CP4); goxv247
Maize	MON810	MON-00810-6	T1,T7	cry1Ab; cp4 epsps (aroA:CP4); goxv247
Maize	MON832	-	T1	cp4 epsps (aroA:CP4); goxv247
Maize	MON863	MON-00863-5	T7	cry3Bb1
Maize	MON87427	MON-87427-7	T1	cp4 epsps (aroA:CP4)
Maize	MON87460	MON-87460-4	T21	cspB
Maize	MON88017	MON-88017-3	T1,T7	cry3Bb1; cp4 epsps (aroA:CP4)
Maize	MON89034	MON-89034-3	T7	cry2Ab2; cry1A.105
Maize	MS3	ACS-ZM001-9	T3,T18	bar; barnase
Maize	MS6	ACS-ZM005-4	T3,T18	bar; barnase
Maize	NK603	MON-00603-6	T1	cp4 epsps (aroA:CP4)
Maize	T14	ACS-ZM002-1	T3	pat (syn)
Maize	T25	ACS-ZM003-2	T3	pat (syn)
Maize	TC1507	DAS-01507-1	T3,T7	cry1Fa2; pat
Maize	TC6275	DAS-06275-8	T3,T7	mocry1F; bar
Maize	VIP1034	-	T3,T7	vip3A; pat

Maize	43A47	DP-043A47-3	T3,T7	cry1F; cry34Ab1; cry35Ab1; pat
Maize	40416	DP-040416-8	T3,T7	cry1F; cry34Ab1; cry35Ab1; pat
Maize	32316	DP-032316-8	T3,T7	cry1F; cry34Ab1; cry35Ab1; pat
Maize	4114	DP-004114-3	T3,T7	cry1F; cry34Ab1; cry35Ab1; pat
Melon	Melon A	-	T22	sam-k
Melon	Melon B	-	T22	sam-k
Papaya	55-1	CUH-CP551-8	T6	prsv cp
Papaya	63-1	CUH-CP631-7	T6	prsv cp
Papaya	Huanong No. 1	-	T6	prsv rep
Papaya	X17-2	UFL-X17CP-6	T6	prsv cp
Plum	C-5	ARS-PLMC5-6	T6	ppv cp
Canola**	ZSR500	-	T1	cp4 epsps (aroA:CP4); goxv247
Canola**	ZSR502	-	T1	cp4 epsps (aroA:CP4); goxv247
Canola**	ZSR503	-	T1	cp4 epsps (aroA:CP4); goxv247
Rice	7Crp#242-95-7	-	T13	7crp
Rice	7Crp#10	-	T13	7crp
Rice	GM Shanyou 63	-	T7	cry1Ab; cry1Ac
Rice	Huahui-1/TT51-1	-	T7	cry1Ab; cry1Ac
Rice	LLRICE06	ACS-OS001-4	T3	bar
Rice	LLRICE601	BCS-OS003-7	T3	bar
Rice	LLRICE62	ACS-OS002-5	T3	bar
Rice	Tarom molaii + cry1Ab	-	T7	cry1Ab (truncated)
Rice	GAT-OS2	-	T3	bar
Rice	GAT-OS3	-	T3	bar
Rice	PE-7	-	T7	Cry1Ac
Rice	7Crp#10	-	T13	7crp
Rice	KPD627-8	-	T27	OASA1D
Rice	KPD722-4	-	T27	OASA1D
Rice	KA317	-	T27	OASA1D
Rice	HW5	-	T27	OASA1D
Rice	HW1	-	T27	OASA1D
Rice	B-4-1-18	-	T28	Δ OsBRI1
Rice	G-3-3-22	-	T29	OSGA2ox1
Rice	AD77	-	T6	DEF
Rice	AD51	-	T6	DEF
Rice	AD48	-	T6	DEF
Rice	AD41	-	T6	DEF
Rice	13pNasNa800725atAprt1	-	T30	HvNAS1; HvNAAT-A; APRT
Rice	13pAprt1	-	T30	APRT
Rice	gHvNAS1-gHvNAAT-1	-	T30	HvNAS1; HvNAAT-A; HvNAAT-B

Rice	gHvIDS3-1	-	T30	HvIDS3
Rice	gHvNAAT1	-	T30	HvNAAT-A; HvNAAT-B
Rice	gHvNAS1-1	-	T30	HvNAS1
Rice	NIA-OS006-4	-	T6	WRKY45
Rice	NIA-OS005-3	-	T6	WRKY45
Rice	NIA-OS004-2	-	T6	WRKY45
Rice	NIA-OS003-1	-	T6	WRKY45
Rice	NIA-OS002-9	-	T6	WRKY45
Rice	NIA-OS001-8	-	T6	WRKY45
Rice	OsCr11	-	T13	Modified Cry j
Rice	17053	-	T1	cp4 epsps (aroA:CP4)
Rice	17314	-	T1	cp4 epsps (aroA:CP4)
Rose	WKS82 / 130-4-1	IFD-52401-4	T9	5AT; bp40 (f3'5'h)
Rose	WKS92 / 130-9-1	IFD-52901-9	T9	5AT; bp40 (f3'5'h)
Soybean	260-05 (G94-1, G94-19, G168)	-	T9	gm-fad2-1 (silencing locus)
Soybean	A2704-12	ACS-GM005-3	T3	pat
Soybean	A2704-21	ACS-GM004-2	T3	pat
Soybean	A5547-127	ACS-GM006-4	T3	pat
Soybean	A5547-35	ACS-GM008-6	T3	pat
Soybean	CV127	BPS-CV127-9	T16	csr1-2
Soybean	DAS68416-4	DAS68416-4	T3	pat
Soybean	DP305423	DP-305423-1	T11,T31	gm-fad2-1 (silencing locus); gm-hra
Soybean	DP356043	DP-356043-5	T1,T31	gm-fad2-1 (silencing locus); gat4601
Soybean	FG72	MST-FG072-3	T32,T1	2mepsps; hppdPF W336
Soybean	GTS 40-3-2 (40-3-2)	MON-04032-6	T1	cp4 epsps (aroA:CP4)
Soybean	GU262	ACS-GM003-1	T3	pat
Soybean	MON87701	MON-87701-2	T7	cry1Ac
Soybean	MON87705	MON-87705-6	T1,T31	fatb1-A (sense & antisense); fad2-1A (sense & antisense); cp4 epsps (aroA:CP4)
Soybean	MON87708	MON-87708-9	T1,T12	dmo; cp4 epsps (aroA:CP4)
Soybean	MON87769	MON-87769-7	T1,T31	Pj.D6D; Nc.Fad3; cp4 epsps (aroA:CP4)
Soybean	MON89788	MON-89788-1	T1	cp4 epsps (aroA:CP4)
Soybean	W62	ACS-GM002-9	T3	bar
Soybean	W98	ACS-GM001-8	T3	bar
Soybean	MON87754	MON-87754-1	T33	dgat2A
Soybean	DAS21606	DAS-21606	T34,T3	Modified aad-12; pat
Soybean	DAS44406	DAS-44406-6	T1,T3,T34	Modified aad-12; 2mepsps; pat

Soybean	SYHT04R	SYN-0004R-8	T35	Modified avhppd
Soybean	9582.814.19.1	-	T3,T7	cry1Ac, cry1F, PAT
Squash	CZW3	SEM-ØCZW3-2	T6	cmv cp, zymv cp, wmv cp
Squash	ZW20	SEM-0ZW20-7	T6	zymv cp, wmv cp
Sugar Beet	GTSB77 (T9100152)	SY-GTSB77-8	T1	cp4 epsps (aroA:CP4); goxv247
Sugar Beet	H7-1	KM-000H71-4	T1	cp4 epsps (aroA:CP4)
Sugar Beet	T120-7	ACS-BV001-3	T3	pat
Sugar Beet	T227-1	-	T1	cp4 epsps (aroA:CP4)
Sugarcane	NXI-1T	-	T21	EcbetA
Sunflower	X81359	-	T16	als
Pepper	PK-SP01	-	T6	cmv cp
Tobacco	C/F/93/08-02	-	T5	bxn
Tobacco	Vector 21-41	-	T36	NtQPT1 (antisense)
Sunflower	X81359	-	T16	als
Wheat	MON71800	MON-718ØØ-3	T1	cp4 epsps (aroA:CP4)

* Argentine (*Brassica napus*), ** Polish (*B. rapa*), # Eggplant

Although most typically, compounds of the invention are used to control undesired vegetation, contact of desired vegetation in the treated locus with compounds of the invention may result in super-additive or synergistic effects with genetic traits in the desired vegetation, including traits incorporated through genetic modification. For example, 5 resistance to phytophagous insect pests or plant diseases, tolerance to biotic/abiotic stresses or storage stability may be greater than expected from the genetic traits in the desired vegetation.

Compounds of this invention can also be mixed with one or more other biologically 10 active compounds or agents including herbicides, herbicide safeners, fungicides, insecticides, nematocides, bactericides, acaricides, growth regulators such as insect molting inhibitors and rooting stimulants, chemosterilants, semiochemicals, repellents, attractants, pheromones, feeding stimulants, plant nutrients, other biologically active compounds or entomopathogenic bacteria, virus or fungi to form a multi-component pesticide giving an 15 even broader spectrum of agricultural protection. Mixtures of the compounds of the invention with other herbicides can broaden the spectrum of activity against additional weed species, and suppress the proliferation of any resistant biotypes. Thus the present invention also pertains to a composition comprising a compound of Formula 1 (in a herbicidally effective amount) and at least one additional biologically active compound or agent (in a 20 biologically effective amount) and can further comprise at least one of a surfactant, a solid diluent or a liquid diluent. The other biologically active compounds or agents can be formulated in compositions comprising at least one of a surfactant, solid or liquid diluent. For mixtures of the present invention, one or more other biologically active compounds or

agents can be formulated together with a compound of Formula 1, to form a premix, or one or more other biologically active compounds or agents can be formulated separately from the compound of Formula 1, and the formulations combined together before application (e.g., in a spray tank) or, alternatively, applied in succession.

5 A mixture of one or more of the following herbicides with a compound of this invention may be particularly useful for weed control: acetochlor, acifluorfen and its sodium salt, aclonifen, acrolein (2-propenal), alachlor, alloxydim, ametryn, amicarbazone, amidosulfuron, aminocyclopyrachlor and its esters (e.g., methyl, ethyl) and salts (e.g., sodium, potassium), aminopyralid, amitrole, ammonium sulfamate, anilofos, asulam, 10 atrazine, azimsulfuron, beflubutamid, benazolin, benazolin-ethyl, bencarbazone, benfluralin, benfuresate, bensulfuron-methyl, bensulide, bentazone, benzobicyclon, benzofenap, bicyclopyrone, bifenoxy, bilanafos, bispyribac and its sodium salt, bromacil, bromobutide, bromofenoxim, bromoxynil, bromoxynil octanoate, butachlor, butafenacil, butamifos, butralin, butroxydim, butylate, cafenstrole, carbetamide, carfentrazone-ethyl, catechin, 15 chlomethoxyfen, chloramben, chlorbromuron, chlorflurenol-methyl, chloridazon, chlorimuron-ethyl, chlorotoluron, chlorpropham, chlorsulfuron, chlorthal-dimethyl, chlorthiamid, cinidon-ethyl, cinmethylin, cinosulfuron, clacyfos, clefoxydim, clethodim, clodinafop-propargyl, clomazone, clomeprop, clopyralid, clopyralid-olamine, cloransulam-methyl, cumyluron, cyanazine, cycloate, cyclopyrimorate, cyclosulfamuron, cycloxydim, 20 cyhalofop-butyl, 2,4-D and its butotyl, butyl, isooctyl and isopropyl esters and its dimethylammonium, diolamine and trolamine salts, daimuron, dalapon, dalapon-sodium, dazomet, 2,4-DB and its dimethylammonium, potassium and sodium salts, desmedipham, desmetryn, dicamba and its diglycolammonium, dimethylammonium, potassium and sodium salts, dichlobenil, dichlorprop, diclofop-methyl, diclosulam, difenzoquat metilsulfate, 25 diflufenican, diflufenzopyr, dimefuron, dimepiperate, dimethachlor, dimethametryn, dimethenamid, dimethenamid-P, dimethipin, dimethylarsinic acid and its sodium salt, dinitramine, dinoterb, diphenamid, diquat dibromide, dithiopyr, diuron, DNOC, endothal, EPTC, esprocarb, ethalfluralin, ethametsulfuron-methyl, ethiozin, ethofumesate, ethoxyfen, ethoxysulfuron, etobenzanid, fenoxaprop-ethyl, fenoxaprop-P-ethyl, fenoxasulfone, 30 fenquinotrione, fentrazamide, fenuron, fenuron-TCA, flamprop-methyl, flamprop-M-isopropyl, flamprop-M-methyl, flazasulfuron, florasulam, fluazifop-butyl, fluazifop-P-butyl, fluazolate, flucarbazone, flucetosulfuron, fluchloralin, flufenacet, flufenpyr, flufenpyr-ethyl, flumetsulam, flumiclorac-pentyl, flumioxazin, fluometuron, fluoroglycofen-ethyl, flupoxam, flupyrulfuron-methyl and its sodium salt, flurenol, 35 flurenol-butyl, fluridone, flurochloridone, fluroxypyr, flurtamone, fluthiacet-methyl, fomesafen, foramsulfuron, fosamine-ammonium, glufosinate, glufosinate-ammonium, glufosinate-P, glyphosate and its salts such as ammonium, isopropylammonium, potassium, sodium (including sesquisodium) and trimesium (alternatively named sulfosate), halauxifen,

halauxifen-methyl, halosulfuron-methyl, haloxyfop-etyl, haloxyfop-methyl, hexazinone, hydantocidin, imazamethabenz-methyl, imazamox, imazapic, imazapyr, imazaquin, imazaquin-ammonium, imazethapyr, imazethapyr-ammonium, imazosulfuron, indanofan, indaziflam, iofensulfuron, iodosulfuron-methyl, ioxynil, ioxynil octanoate, ioxynil-sodium, 5 ipfencarbazone, isoproturon, isouron, isoxaben, isoxaflutole, isoxachlortole, lactofen, lenacil, linuron, maleic hydrazide, MCPA and its salts (e.g., MCPA-dimethylammonium, MCPA-potassium and MCPA-sodium, esters (e.g., MCPA-2-ethylhexyl, MCPA-butotyl) and thioesters (e.g., MCPA-thioethyl), MCPB and its salts (e.g., MCPB-sodium) and esters (e.g., MCPB-ethyl), mecoprop, mecoprop-P, mefenacet, mefluidide, mesosulfuron-methyl, 10 mesotrione, metam-sodium, metamifop, metamitron, metazachlor, metazosulfuron, methabenzthiazuron, methylarsonic acid and its calcium, monoammonium, monosodium and disodium salts, methyldymron, metobenzuron, metobromuron, metolachlor, S-metolachlor, metosulam, metoxuron, metribuzin, metsulfuron-methyl, molinate, monolinuron, naproanilide, napropamide, napropamide-M, naptalam, neburon, nicosulfuron, norflurazon, 15 orbencarb, orthosulfamuron, oryzalin, oxadiargyl, oxadiazon, oxasulfuron, oxaziclofone, oxyfluorfen, paraquat dichloride, pebulate, pelargonic acid, pendimethalin, penoxsulam, pentanochlor, pentozacone, perfluidone, pethoxamid, pethoxyamid, phenmedipham, picloram, picloram-potassium, picolinafen, pinoxaden, piperophos, pretilachlor, primisulfuron-methyl, prodiamine, profoxydim, prometon, prometryn, propachlor, propanil, 20 propaquizafofop, propazine, propham, propisochlor, propoxycarbazone, propyrisulfuron, propyzamide, prosulfocarb, prosulfuron, pyraclonil, pyraflufen-ethyl, pyrasulfotole, pyrazogyl, pyrazolynate, pyrazoxyfen, pyrazosulfuron-ethyl, pyribenzoxim, pyributicarb, pyridate, pyriftalid, pyriminobac-methyl, pyrimisulfan, pyrithiobac, pyrithiobac-sodium, pyroxasulfone, pyroxsulam, quinclorac, quinmerac, quinoclamine, quinalofop-ethyl, 25 quinalofop-P-ethyl, quinalofop-P-tefuryl, rimsulfuron, saflufenacil, sethoxydim, siduron, simazine, simetryn, sulcotrione, sulfentrazone, sulfometuron-methyl, sulfosulfuron, 2,3,6-TBA, TCA, TCA-sodium, tebutam, tebuthiuron, tefuryltrione, tembotrione, tepraloxydim, terbacil, terbumeton, terbutylazine, terbutryn, thenylchlor, thiazopyr, thiencarbazone, thifensulfuron-methyl, thiobencarb, tiafenacil, tiocarbazil, tolpyralate, topramezone, 30 tralkoxydim, tri-allate, triafamone, triasulfuron, triaziflam, tribenuron-methyl, triclopyr, triclopyr-butotyl, triclopyr-triethylammonium, tridiphane, trietazine, trifloxysulfuron, trifludimoxazin, trifluralin, triflusulfuron-methyl, tritosulfuron, vernolate, 3-(2-chloro-3,6-difluorophenyl)-4-hydroxy-1-methyl-1,5-naphthyridin-2(1H)-one, 5-chloro-3-[(2-hydroxy-6-oxo-1-cyclohexen-1-yl)carbonyl]-1-(4-methoxyphenyl)-2(1H)-quinoxalinone, 2-chloro-N- 35 (1-methyl-1H-tetrazol-5-yl)-6-(trifluoromethyl)-3-pyridinecarboxamide, 7-(3,5-dichloro-4-pyridinyl)-5-(2,2-difluoroethyl)-8-hydroxypyrido[2,3-*b*]pyrazin-6(5H)-one, 4-(2,6-diethyl-4-methylphenyl)-5-hydroxy-2,6-dimethyl-3(2H)-pyridazinone), 5-[[2,6-difluorophenyl)methoxy]methyl]-4,5-dihydro-5-methyl-3-(3-methyl-2-thienyl)isoxazole

(previously methioxolin), 4-(4-fluorophenyl)-6-[(2-hydroxy-6-oxo-1-cyclohexen-1-yl)carbonyl]-2-methyl-1,2,4-triazine-3,5(2H,4H)-dione, methyl 4-amino-3-chloro-6-(4-chloro-2-fluoro-3-methoxyphenyl)-5-fluoro-2-pyridinecarboxylate, 2-methyl-3-(methylsulfonyl)-N-(1-methyl-1H-tetrazol-5-yl)-4-(trifluoromethyl)benzamide and 2-methyl-5-N-(4-methyl-1,2,5-oxadiazol-3-yl)-3-(methylsulfinyl)-4-(trifluoromethyl)benzamide. Other herbicides also include bioherbicides such as *Alternaria destruens* Simmons, *Colletotrichum gloeosporioides* (Penz.) Penz. & Sacc., *Drechslera monoceras* (MTB-951), *Myrothecium verrucaria* (Albertini & Schweinitz) Ditmar: Fries, *Phytophthora palmivora* (Butl.) Butl. and *Puccinia thlaspeos* Schub.

10 Compounds of this invention can also be used in combination with plant growth regulators such as aviglycine, *N*-(phenylmethyl)-1*H*-purin-6-amine, epocholeone, gibberellic acid, gibberellin A₄ and A₇, harpin protein, mepiquat chloride, prohexadione calcium, prohydrojasmon, sodium nitrophenolate and trinexapac-methyl, and plant growth modifying organisms such as *Bacillus cereus* strain BP01.

15 General references for agricultural protectants (i.e. herbicides, herbicide safeners, insecticides, fungicides, nematocides, acaricides and biological agents) include *The Pesticide Manual, 13th Edition*, C. D. S. Tomlin, Ed., British Crop Protection Council, Farnham, Surrey, U.K., 2003 and *The BioPesticide Manual, 2nd Edition*, L. G. Copping, Ed., British Crop Protection Council, Farnham, Surrey, U.K., 2001.

20 For embodiments where one or more of these various mixing partners are used, the mixing partners are typically used in the amounts similar to amounts customary when the mixture partners are used alone. More particularly in mixtures, active ingredients are often applied at an application rate between one-half and the full application rate specified on product labels for use of active ingredient alone. These amounts are listed in references such as *The Pesticide Manual* and *The BioPesticide Manual*. The weight ratio of these various mixing partners (in total) to the compound of Formula 1 is typically between about 1:3000 and about 3000:1. Of note are weight ratios between about 1:300 and about 300:1 (for example ratios between about 1:30 and about 30:1). One skilled in the art can easily determine through simple experimentation the biologically effective amounts of active ingredients necessary for the desired spectrum of biological activity. It will be evident that including these additional components may expand the spectrum of weeds controlled beyond the spectrum controlled by the compound of Formula 1 alone.

25 In certain instances, combinations of a compound of this invention with other biologically active (particularly herbicidal) compounds or agents (i.e. active ingredients) can result in a greater-than-additive (i.e. synergistic) effect on weeds and/or a less-than-additive effect (i.e. safening) on crops or other desirable plants. Reducing the quantity of active ingredients released in the environment while ensuring effective pest control is always desirable. Ability to use greater amounts of active ingredients to provide more effective

weed control without excessive crop injury is also desirable. When synergism of herbicidal active ingredients occurs on weeds at application rates giving agronomically satisfactory levels of weed control, such combinations can be advantageous for reducing crop production cost and decreasing environmental load. When safening of herbicidal active ingredients occurs on crops, such combinations can be advantageous for increasing crop protection by reducing weed competition.

Of note is a combination of a compound of the invention with at least one other herbicidal active ingredient. Of particular note is such a combination where the other herbicidal active ingredient has different site of action from the compound of the invention.

10 In certain instances, a combination with at least one other herbicidal active ingredient having a similar spectrum of control but a different site of action will be particularly advantageous for resistance management. Thus, a composition of the present invention can further comprise (in a herbicidally effective amount) at least one additional herbicidal active ingredient having a similar spectrum of control but a different site of action.

15 Compounds of this invention can also be used in combination with herbicide safeners such as allidochlor, benoxacor, cloquintocet-mexyl, cumyluron, cyometrinil, cyprosulfonamide, daimuron, dichlormid, dicyclonon, dietholate, dimepiperate, fenchlorazole-ethyl, fenclorim, flurazole, fluxofenim, furilazole, isoxadifen-ethyl, mefenpyr-diethyl, mephenate, methoxyphenone naphthalic anhydride (1,8-naphthalic anhydride), oxabetrinil, *N*-(aminocarbonyl)-2-methylbenzenesulfonamide, *N*-(aminocarbonyl)-2-fluorobenzenesulfonamide, 1-bromo-4-[(chloromethyl)sulfonyl]benzene (BCS), 4-(dichloroacetyl)-1-oxa-4-azospiro[4.5]decane (MON 4660), 2-(dichloromethyl)-2-methyl-1,3-dioxolane (MG 191), ethyl 1,6-dihydro-1-(2-methoxyphenyl)-6-oxo-2-phenyl-5-pyrimidinecarboxylate, 2-hydroxy-*N,N*-dimethyl-6-(trifluoromethyl)pyridine-3-carboxamide, and 3-oxo-1-cyclohexen-1-yl 1-(3,4-dimethylphenyl)-1,6-dihydro-6-oxo-2-phenyl-5-pyrimidinecarboxylate, 2,2-dichloro-1-(2,2,5-trimethyl-3-oxazolidinyl)-ethanone and 2-methoxy-*N*-[[4-[[methylamino]carbonyl]amino]phenyl]sulfonyl]-benzamide to increase safety to certain crops. Antidotally effective amounts of the herbicide safeners can be applied at the same time as the compounds of this invention, or applied as seed treatments. Therefore an aspect of the present invention relates to a herbicidal mixture comprising a compound of this invention and an antidotally effective amount of a herbicide safener. Seed treatment is particularly useful for selective weed control, because it physically restricts antidoting to the crop plants. Therefore a particularly useful embodiment of the present invention is a method for selectively controlling the growth of undesired vegetation in a crop comprising contacting the locus of the crop with a herbicidally effective amount of a compound of this invention wherein seed from which the crop is grown is treated with an antidotally effective amount of safener. Antidotally effective amounts of safeners can be easily determined by one skilled in the art through simple experimentation.

Compounds of the invention can also be mixed with: (1) polynucleotides including but not limited to DNA, RNA, and/or chemically modified nucleotides influencing the amount of a particular target through down regulation, interference, suppression or silencing of the genetically derived transcript that render a herbicidal effect; or (2) polynucleotides including but not limited to DNA, RNA, and/or chemically modified nucleotides influencing the amount of a particular target through down regulation, interference, suppression or silencing of the genetically derived transcript that render a safening effect.

Of note is a composition comprising a compound of the invention (in a herbicidally effective amount), at least one additional active ingredient selected from the group consisting of other herbicides and herbicide safeners (in an effective amount), and at least one component selected from the group consisting of surfactants, solid diluents and liquid diluents.

Preferred for better control of undesired vegetation (e.g., lower use rate such as from synergism, broader spectrum of weeds controlled, or enhanced crop safety) or for preventing the development of resistant weeds are mixtures of a compound of this invention with another herbicide. Table A1 lists particular combinations of Component (a) (i.e. a specific compound of the present invention) with another herbicide as Component (b) illustrative of the mixtures, compositions and methods of the present invention. Compound 20 in the Component (a) column is identified in Index Table A. The second column of Table A1 lists the specific Component (b) compound (e.g., "2,4-D" in the first line). The third, fourth and fifth columns of Table A1 lists ranges of weight ratios for rates at which the Component (a) compound is typically applied to a field-grown crop relative to Component (b) (i.e. (a):(b)). Thus, for example, the first line of Table A1 specifically discloses the combination of Component (a) (i.e. Compound 17 in Index Table A) with 2,4-D is typically applied in a weight ratio between 1:192 – 6:1. The remaining lines of Table A1 are to be construed similarly.

TABLE A1

<u>Component (a)</u> <u>(Compound #)</u>	<u>Component (b)</u>	<u>Typical</u> <u>Weight Ratio</u>	<u>More Typical</u> <u>Weight Ratio</u>	<u>Most Typical</u> <u>Weight Ratio</u>
20	2,4-D	1:192 – 6:1	1:64 – 2:1	1:24 – 1:3
20	Acetochlor	1:768 – 2:1	1:256 – 1:2	1:96 – 1:11
20	Acifluorfen	1:96 – 12:1	1:32 – 4:1	1:12 – 1:2
20	Aclonifen	1:857 – 2:1	1:285 – 1:3	1:107 – 1:12
20	Alachlor	1:768 – 2:1	1:256 – 1:2	1:96 – 1:11
20	Ametryn	1:384 – 3:1	1:128 – 1:1	1:48 – 1:6
20	Amicarbazone	1:192 – 6:1	1:64 – 2:1	1:24 – 1:3
20	Amidosulfuron	1:6 – 168:1	1:2 – 56:1	1:1 – 11:1

<u>Component (a)</u> (Compound #)	Component (b)	<u>Typical</u> Weight Ratio	<u>More Typical</u> Weight Ratio	<u>Most Typical</u> Weight Ratio
20	Aminocyclopyrachlor	1:48 – 24:1	1:16 – 8:1	1:6 – 2:1
20	Aminopyralid	1:20 – 56:1	1:6 – 19:1	1:2 – 4:1
20	Amitrole	1:768 – 2:1	1:256 – 1:2	1:96 – 1:11
20	Anilofos	1:96 – 12:1	1:32 – 4:1	1:12 – 1:2
20	Asulam	1:960 – 2:1	1:320 – 1:3	1:120 – 1:14
20	Atrazine	1:192 – 6:1	1:64 – 2:1	1:24 – 1:3
20	Azimsulfuron	1:6 – 168:1	1:2 – 56:1	1:1 – 11:1
20	Beflubutamid	1:342 – 4:1	1:114 – 2:1	1:42 – 1:5
20	Benfuresate	1:617 – 2:1	1:205 – 1:2	1:77 – 1:9
20	Bensulfuron-methyl	1:25 – 45:1	1:8 – 15:1	1:3 – 3:1
20	Bentazone	1:192 – 6:1	1:64 – 2:1	1:24 – 1:3
20	Benzobicyclon	1:85 – 14:1	1:28 – 5:1	1:10 – 1:2
20	Benzofenap	1:257 – 5:1	1:85 – 2:1	1:32 – 1:4
20	Bicyclopyrone	1:42 – 27:1	1:14 – 9:1	1:5 – 2:1
20	Bifenox	1:257 – 5:1	1:85 – 2:1	1:32 – 1:4
20	Bispyribac-sodium	1:10 – 112:1	1:3 – 38:1	1:1 – 7:1
20	Bromacil	1:384 – 3:1	1:128 – 1:1	1:48 – 1:6
20	Bromobutide	1:384 – 3:1	1:128 – 1:1	1:48 – 1:6
20	Bromoxynil	1:96 – 12:1	1:32 – 4:1	1:12 – 1:2
20	Butachlor	1:768 – 2:1	1:256 – 1:2	1:96 – 1:11
20	Butafenacil	1:42 – 27:1	1:14 – 9:1	1:5 – 2:1
20	Butylate	1:1542 – 1:2	1:514 – 1:5	1:192 – 1:22
20	Carfenstrole	1:192 – 6:1	1:64 – 2:1	1:24 – 1:3
20	Carfentrazone-ethyl	1:128 – 9:1	1:42 – 3:1	1:16 – 1:2
20	Chlorimuron-ethyl	1:8 – 135:1	1:2 – 45:1	1:1 – 9:1
20	Chlorotoluron	1:768 – 2:1	1:256 – 1:2	1:96 – 1:11
20	Chlorsulfuron	1:6 – 168:1	1:2 – 56:1	1:1 – 11:1
20	Cincosulfuron	1:17 – 68:1	1:5 – 23:1	1:2 – 5:1
20	Cinidon-ethyl	1:384 – 3:1	1:128 – 1:1	1:48 – 1:6
20	Cinmethylin	1:34 – 34:1	1:11 – 12:1	1:4 – 3:1
20	Clacyfos	1:34 – 34:1	1:11 – 12:1	1:4 – 3:1
20	Clethodim	1:48 – 24:1	1:16 – 8:1	1:6 – 2:1
20	Clodinafop-propargyl	1:20 – 56:1	1:6 – 19:1	1:2 – 4:1
20	Clomazone	1:384 – 3:1	1:128 – 1:1	1:48 – 1:6
20	Clomeprop	1:171 – 7:1	1:57 – 3:1	1:21 – 1:3

<u>Component (a)</u> (Compound #)	Component (b)	<u>Typical</u> Weight Ratio	<u>More Typical</u> Weight Ratio	<u>Most Typical</u> Weight Ratio
20	Clopyralid	1:192 – 6:1	1:64 – 2:1	1:24 – 1:3
20	Cloransulam-methyl	1:12 – 96:1	1:4 – 32:1	1:1 – 6:1
20	Cumyluron	1:384 – 3:1	1:128 – 1:1	1:48 – 1:6
20	Cyanazine	1:384 – 3:1	1:128 – 1:1	1:48 – 1:6
20	Cyclopyrimorate	1:17 – 68:1	1:5 – 23:1	1:2 – 5:1
20	Cyclosulfamuron	1:17 – 68:1	1:5 – 23:1	1:2 – 5:1
20	Cycloxydim	1:96 – 12:1	1:32 – 4:1	1:12 – 1:2
20	Cyhalofop	1:25 – 45:1	1:8 – 15:1	1:3 – 3:1
20	Daimuron	1:192 – 6:1	1:64 – 2:1	1:24 – 1:3
20	Desmedipham	1:322 – 4:1	1:107 – 2:1	1:40 – 1:5
20	Dicamba	1:192 – 6:1	1:64 – 2:1	1:24 – 1:3
20	Dichlobenil	1:1371 – 1:2	1:457 – 1:4	1:171 – 1:20
20	Dichlorprop	1:925 – 2:1	1:308 – 1:3	1:115 – 1:13
20	Diclofop-methyl	1:384 – 3:1	1:128 – 1:1	1:48 – 1:6
20	Diclosulam	1:10 – 112:1	1:3 – 38:1	1:1 – 7:1
20	Difenoquat	1:288 – 4:1	1:96 – 2:1	1:36 – 1:4
20	Diflufenican	1:857 – 2:1	1:285 – 1:3	1:107 – 1:12
20	Diflufenzopyr	1:12 – 96:1	1:4 – 32:1	1:1 – 6:1
20	Dimethachlor	1:768 – 2:1	1:256 – 1:2	1:96 – 1:11
20	Dimethametryn	1:192 – 6:1	1:64 – 2:1	1:24 – 1:3
20	Dimethenamid-P	1:384 – 3:1	1:128 – 1:1	1:48 – 1:6
20	Dithiopyr	1:192 – 6:1	1:64 – 2:1	1:24 – 1:3
20	Diuron	1:384 – 3:1	1:128 – 1:1	1:48 – 1:6
20	EPTC	1:768 – 2:1	1:256 – 1:2	1:96 – 1:11
20	Esprocarb	1:1371 – 1:2	1:457 – 1:4	1:171 – 1:20
20	Ethalfluralin	1:384 – 3:1	1:128 – 1:1	1:48 – 1:6
20	Ethametsulfuron-methyl	1:17 – 68:1	1:5 – 23:1	1:2 – 5:1
20	Ethoxyfen	1:8 – 135:1	1:2 – 45:1	1:1 – 9:1
20	Ethoxysulfuron	1:20 – 56:1	1:6 – 19:1	1:2 – 4:1
20	Etobenzanid	1:257 – 5:1	1:85 – 2:1	1:32 – 1:4
20	Fenoxaprop-ethyl	1:120 – 10:1	1:40 – 4:1	1:15 – 1:2
20	Fenoxyasulfone	1:85 – 14:1	1:28 – 5:1	1:10 – 1:2
20	Fenquinotriione	1:17 – 68:1	1:5 – 23:1	1:2 – 5:1
20	Fentrazamide	1:17 – 68:1	1:5 – 23:1	1:2 – 5:1
20	Flazasulfuron	1:17 – 68:1	1:5 – 23:1	1:2 – 5:1

<u>Component (a)</u> (Compound #)	Component (b)	<u>Typical</u> Weight Ratio	<u>More Typical</u> Weight Ratio	<u>Most Typical</u> Weight Ratio
20	Florasulam	1:2 – 420:1	1:1 – 140:1	2:1 – 27:1
20	Fluazifop-butyl	1:192 – 6:1	1:64 – 2:1	1:24 – 1:3
20	Flucarbazone	1:8 – 135:1	1:2 – 45:1	1:1 – 9:1
20	Flucetosulfuron	1:8 – 135:1	1:2 – 45:1	1:1 – 9:1
20	Flufenacet	1:257 – 5:1	1:85 – 2:1	1:32 – 1:4
20	Flumetsulam	1:24 – 48:1	1:8 – 16:1	1:3 – 3:1
20	Flumiclorac-pentyl	1:10 – 112:1	1:3 – 38:1	1:1 – 7:1
20	Flumioxazin	1:25 – 45:1	1:8 – 15:1	1:3 – 3:1
20	Fluometuron	1:384 – 3:1	1:128 – 1:1	1:48 – 1:6
20	Flupyralsulfuron-methyl	1:3 – 336:1	1:1 – 112:1	2:1 – 21:1
20	Fluridone	1:384 – 3:1	1:128 – 1:1	1:48 – 1:6
20	Fluroxypyr	1:96 – 12:1	1:32 – 4:1	1:12 – 1:2
20	Flurtamone	1:857 – 2:1	1:285 – 1:3	1:107 – 1:12
20	Fluthiacet-methyl	1:48 – 42:1	1:16 – 14:1	1:3 – 3:1
20	Fomesafen	1:96 – 12:1	1:32 – 4:1	1:12 – 1:2
20	Foramsulfuron	1:13 – 84:1	1:4 – 28:1	1:1 – 6:1
20	Glufosinate	1:288 – 4:1	1:96 – 2:1	1:36 – 1:4
20	Glyphosate	1:288 – 4:1	1:96 – 2:1	1:36 – 1:4
20	Halosulfuron-methyl	1:17 – 68:1	1:5 – 23:1	1:2 – 5:1
20	Halauxifen	1:20 – 56:1	1:6 – 19:1	1:2 – 4:1
20	Halauxifen methyl	1:20 – 56:1	1:6 – 19:1	1:2 – 4:1
20	Haloxifop-methyl	1:34 – 34:1	1:11 – 12:1	1:4 – 3:1
20	Hexazinone	1:192 – 6:1	1:64 – 2:1	1:24 – 1:3
20	Hydantocidin	1:1100 – 16:1	1:385 – 8:1	1:144 – 4:1
20	Imazamox	1:13 – 84:1	1:4 – 28:1	1:1 – 6:1
20	Imazapic	1:20 – 56:1	1:6 – 19:1	1:2 – 4:1
20	Imazapyr	1:85 – 14:1	1:28 – 5:1	1:10 – 1:2
20	Imazaquin	1:34 – 34:1	1:11 – 12:1	1:4 – 3:1
20	Imazethabenz-methyl	1:171 – 7:1	1:57 – 3:1	1:21 – 1:3
20	Imazethapyr	1:24 – 48:1	1:8 – 16:1	1:3 – 3:1
20	Imazosulfuron	1:27 – 42:1	1:9 – 14:1	1:3 – 3:1
20	Indanofan	1:342 – 4:1	1:114 – 2:1	1:42 – 1:5
20	Indaziflam	1:25 – 45:1	1:8 – 15:1	1:3 – 3:1
20	Iodosulfuron-methyl	1:3 – 336:1	1:1 – 112:1	2:1 – 21:1
20	Ioxynil	1:192 – 6:1	1:64 – 2:1	1:24 – 1:3

<u>Component (a)</u> (Compound #)	Component (b)	<u>Typical</u> Weight Ratio	<u>More Typical</u> Weight Ratio	<u>Most Typical</u> Weight Ratio
20	Ipfencarbazone	1:85 – 14:1	1:28 – 5:1	1:10 – 1:2
20	Isoproturon	1:384 – 3:1	1:128 – 1:1	1:48 – 1:6
20	Isoxaben	1:288 – 4:1	1:96 – 2:1	1:36 – 1:4
20	Isoxaflutole	1:60 – 20:1	1:20 – 7:1	1:7 – 2:1
20	Lactofen	1:42 – 27:1	1:14 – 9:1	1:5 – 2:1
20	Lenacil	1:384 – 3:1	1:128 – 1:1	1:48 – 1:6
20	Linuron	1:384 – 3:1	1:128 – 1:1	1:48 – 1:6
20	MCPA	1:192 – 6:1	1:64 – 2:1	1:24 – 1:3
20	MCPB	1:288 – 4:1	1:96 – 2:1	1:36 – 1:4
20	Mecoprop	1:768 – 2:1	1:256 – 1:2	1:96 – 1:11
20	Mefenacet	1:384 – 3:1	1:128 – 1:1	1:48 – 1:6
20	Mefluidide	1:192 – 6:1	1:64 – 2:1	1:24 – 1:3
20	Mesosulfuron-methyl	1:5 – 224:1	1:1 – 75:1	1:1 – 14:1
20	Mesotriione	1:42 – 27:1	1:14 – 9:1	1:5 – 2:1
20	Metamifop	1:42 – 27:1	1:14 – 9:1	1:5 – 2:1
20	Metazachlor	1:384 – 3:1	1:128 – 1:1	1:48 – 1:6
20	Metazosulfuron	1:25 – 45:1	1:8 – 15:1	1:3 – 3:1
20	Methabenzthiazuron	1:768 – 2:1	1:256 – 1:2	1:96 – 1:11
20	Metolachlor	1:768 – 2:1	1:256 – 1:2	1:96 – 1:11
20	Metosulam	1:8 – 135:1	1:2 – 45:1	1:1 – 9:1
20	Metribuzin	1:192 – 6:1	1:64 – 2:1	1:24 – 1:3
20	Metsulfuron-methyl	1:2 – 560:1	1:1 – 187:1	3:1 – 35:1
20	Molinate	1:1028 – 2:1	1:342 – 1:3	1:128 – 1:15
20	Napropamide	1:384 – 3:1	1:128 – 1:1	1:48 – 1:6
20	Napropamide-M	1:192 – 6:1	1:64 – 2:1	1:24 – 1:3
20	Naptalam	1:192 – 6:1	1:64 – 2:1	1:24 – 1:3
20	Nicosulfuron	1:12 – 96:1	1:4 – 32:1	1:1 – 6:1
20	Norflurazon	1:1152 – 1:1	1:384 – 1:3	1:144 – 1:16
20	Orbencarb	1:1371 – 1:2	1:457 – 1:4	1:171 – 1:20
20	Orthosulfamuron	1:20 – 56:1	1:6 – 19:1	1:2 – 4:1
20	Oryzalin	1:514 – 3:1	1:171 – 1:2	1:64 – 1:8
20	Oxadiargyl	1:384 – 3:1	1:128 – 1:1	1:48 – 1:6
20	Oxadiazon	1:548 – 3:1	1:182 – 1:2	1:68 – 1:8
20	Oxasulfuron	1:27 – 42:1	1:9 – 14:1	1:3 – 3:1
20	Oxaziclofomefone	1:42 – 27:1	1:14 – 9:1	1:5 – 2:1

<u>Component (a)</u> (Compound #)	Component (b)	<u>Typical</u> Weight Ratio	<u>More Typical</u> Weight Ratio	<u>Most Typical</u> Weight Ratio
20	Oxyfluorfen	1:384 – 3:1	1:128 – 1:1	1:48 – 1:6
20	Paraquat	1:192 – 6:1	1:64 – 2:1	1:24 – 1:3
20	Pendimethalin	1:384 – 3:1	1:128 – 1:1	1:48 – 1:6
20	Penoxsulam	1:10 – 112:1	1:3 – 38:1	1:1 – 7:1
20	Penthoxamid	1:384 – 3:1	1:128 – 1:1	1:48 – 1:6
20	Pentoxazone	1:102 – 12:1	1:34 – 4:1	1:12 – 1:2
20	Phenmedipham	1:102 – 12:1	1:34 – 4:1	1:12 – 1:2
20	Picloram	1:96 – 12:1	1:32 – 4:1	1:12 – 1:2
20	Picolinafen	1:34 – 34:1	1:11 – 12:1	1:4 – 3:1
20	Pinoxaden	1:25 – 45:1	1:8 – 15:1	1:3 – 3:1
20	Pretilachlor	1:192 – 6:1	1:64 – 2:1	1:24 – 1:3
20	Primsulfuron-methyl	1:8 – 135:1	1:2 – 45:1	1:1 – 9:1
20	Prodiamine	1:384 – 3:1	1:128 – 1:1	1:48 – 1:6
20	Profoxydim	1:42 – 27:1	1:14 – 9:1	1:5 – 2:1
20	Prometryn	1:384 – 3:1	1:128 – 1:1	1:48 – 1:6
20	Propachlor	1:1152 – 1:1	1:384 – 1:3	1:144 – 1:16
20	Propanil	1:384 – 3:1	1:128 – 1:1	1:48 – 1:6
20	Propaquizafop	1:48 – 24:1	1:16 – 8:1	1:6 – 2:1
20	Propoxycarbazone	1:17 – 68:1	1:5 – 23:1	1:2 – 5:1
20	Propyrisulfuron	1:17 – 68:1	1:5 – 23:1	1:2 – 5:1
20	Propyzamide	1:384 – 3:1	1:128 – 1:1	1:48 – 1:6
20	Prosulfocarb	1:1200 – 1:2	1:400 – 1:4	1:150 – 1:17
20	Prosulfuron	1:6 – 168:1	1:2 – 56:1	1:1 – 11:1
20	Pyraclonil	1:42 – 27:1	1:14 – 9:1	1:5 – 2:1
20	Pyraflufen-ethyl	1:5 – 224:1	1:1 – 75:1	1:1 – 14:1
20	Pyrasulfotole	1:13 – 84:1	1:4 – 28:1	1:1 – 6:1
20	Pyrazolynate	1:857 – 2:1	1:285 – 1:3	1:107 – 1:12
20	Pyrazosulfuron-ethyl	1:10 – 112:1	1:3 – 38:1	1:1 – 7:1
20	Pyrazoxyfen	1:5 – 224:1	1:1 – 75:1	1:1 – 14:1
20	Pyribenzoxim	1:10 – 112:1	1:3 – 38:1	1:1 – 7:1
20	Pyributicarb	1:384 – 3:1	1:128 – 1:1	1:48 – 1:6
20	Pyridate	1:288 – 4:1	1:96 – 2:1	1:36 – 1:4
20	Pyriflatalid	1:10 – 112:1	1:3 – 38:1	1:1 – 7:1
20	Pyriminobac-methyl	1:20 – 56:1	1:6 – 19:1	1:2 – 4:1
20	Pyrimisulfan	1:17 – 68:1	1:5 – 23:1	1:2 – 5:1

<u>Component (a)</u> (Compound #)	Component (b)	<u>Typical</u> Weight Ratio	<u>More Typical</u> Weight Ratio	<u>Most Typical</u> Weight Ratio
20	Pyrithiobac	1:24 – 48:1	1:8 – 16:1	1:3 – 3:1
20	Pyroxasulfone	1:85 – 14:1	1:28 – 5:1	1:10 – 1:2
20	Pyroxsulam	1:5 – 224:1	1:1 – 75:1	1:1 – 14:1
20	Quinclorac	1:192 – 6:1	1:64 – 2:1	1:24 – 1:3
20	Quizalofop-ethyl	1:42 – 27:1	1:14 – 9:1	1:5 – 2:1
20	Rimsulfuron	1:13 – 84:1	1:4 – 28:1	1:1 – 6:1
20	Saflufenacil	1:25 – 45:1	1:8 – 15:1	1:3 – 3:1
20	Sethoxydim	1:96 – 12:1	1:32 – 4:1	1:12 – 1:2
20	Simazine	1:384 – 3:1	1:128 – 1:1	1:48 – 1:6
20	Sulcotrione	1:120 – 10:1	1:40 – 4:1	1:15 – 1:2
20	Sulfentrazone	1:147 – 8:1	1:49 – 3:1	1:18 – 1:3
20	Sulfometuron-methyl	1:34 – 34:1	1:11 – 12:1	1:4 – 3:1
20	Sulfosulfuron	1:8 – 135:1	1:2 – 45:1	1:1 – 9:1
20	Tebuthiuron	1:384 – 3:1	1:128 – 1:1	1:48 – 1:6
20	Tefuryltrione	1:42 – 27:1	1:14 – 9:1	1:5 – 2:1
20	Tembotrione	1:31 – 37:1	1:10 – 13:1	1:3 – 3:1
20	Tepraloxymid	1:25 – 45:1	1:8 – 15:1	1:3 – 3:1
20	Terbacil	1:288 – 4:1	1:96 – 2:1	1:36 – 1:4
20	Terbutylazine	1:857 – 2:1	1:285 – 1:3	1:107 – 1:12
20	Terbutryn	1:192 – 6:1	1:64 – 2:1	1:24 – 1:3
20	Thenylchlor	1:85 – 14:1	1:28 – 5:1	1:10 – 1:2
20	Thiazopyr	1:384 – 3:1	1:128 – 1:1	1:48 – 1:6
20	Thiencarbazone	1:3 – 336:1	1:1 – 112:1	2:1 – 21:1
20	Thifensulfuron-methyl	1:5 – 224:1	1:1 – 75:1	1:1 – 14:1
20	Tiafenacil	1:17 – 68:1	1:5 – 23:1	1:2 – 5:1
20	Thiobencarb	1:768 – 2:1	1:256 – 1:2	1:96 – 1:11
20	Tolpyralate	1:31 – 37:1	1:10 – 13:1	1:3 – 3:1
20	Topramzone	1:6 – 168:1	1:2 – 56:1	1:1 – 11:1
20	Tralkoxydim	1:68 – 17:1	1:22 – 6:1	1:8 – 2:1
20	Triafamone	1:2 – 420:1	1:1 – 140:1	2:1 – 27:1
20	Triallate	1:768 – 2:1	1:256 – 1:2	1:96 – 1:11
20	Triasulfuron	1:5 – 224:1	1:1 – 75:1	1:1 – 14:1
20	Triaziflam	1:171 – 7:1	1:57 – 3:1	1:21 – 1:3
20	Tribenuron-methyl	1:3 – 336:1	1:1 – 112:1	2:1 – 21:1
20	Triclopyr	1:192 – 6:1	1:64 – 2:1	1:24 – 1:3

<u>Component (a)</u> (Compound #)	<u>Component (b)</u>	<u>Typical</u> Weight Ratio	<u>More Typical</u> Weight Ratio	<u>Most Typical</u> Weight Ratio
20	Trifloxysulfuron	1:2 – 420:1	1:1 – 140:1	2:1 – 27:1
20	Trifludimoxazin	1:25 – 45:1	1:8 – 15:1	1:3 – 3:1
20	Trifluralin	1:288 – 4:1	1:96 – 2:1	1:36 – 1:4
20	Triflusulfuron-methyl	1:17 – 68:1	1:5 – 23:1	1:2 – 5:1
20	Tritosulfuron	1:13 – 84:1	1:4 – 28:1	1:1 – 6:1

Table A2 is constructed the same as Table A1 above except that entries below the “Component (a)” column heading (i.e. “20”) are replaced with the respective Component (a) Column Entries shown below. Compound # in the Component (a) column is identified in Index Table A. Thus, for example, in Table A2 the entries below the “Component (a)” column heading all recite “Compound 1” (i.e. Compound 1 identified in Index Table A), and the first line below the column headings in Table A2 specifically discloses a mixture of Compound 1 with 2,4-D. Tables A3 through A94 are constructed similarly.

<u>Table Number</u>	<u>Component (a) Column Entries</u>	<u>Table Number</u>	<u>Component (a) Column Entries</u>
A2	Compound 1	A24	Compound 24
A3	Compound 2	A25	Compound 25
A4	Compound 3	A26	Compound 26
A5	Compound 4	A27	Compound 27
A6	Compound 5	A28	Compound 28
A7	Compound 6	A29	Compound 29
A8	Compound 7	A30	Compound 30
A9	Compound 8	A31	Compound 31
A10	Compound 9	A32	Compound 32
A11	Compound 10	A33	Compound 33
A12	Compound 11	A34	Compound 34
A13	Compound 12	A35	Compound 35
A14	Compound 13	A36	Compound 36
A15	Compound 14	A37	Compound 37
A16	Compound 15	A38	Compound 38
A17	Compound 16	A39	Compound 39
A18	Compound 17	A40	Compound 40
A19	Compound 18	A41	Compound 41
A20	Compound 19	A42	Compound 42
A21	Compound 21	A43	Compound 43
A22	Compound 22	A44	Compound 44
A23	Compound 23	A45	Compound 45


<u>Table Number</u>	<u>Component (a) Column Entries</u>	<u>Table Number</u>	<u>Component (a) Column Entries</u>
A46	Compound 46	A70	Compound 70
A47	Compound 47	A71	Compound 71
A48	Compound 48	A72	Compound 72
A49	Compound 49	A73	Compound 73
A50	Compound 50	A74	Compound 74
A51	Compound 51	A75	Compound 75
A52	Compound 52	A76	Compound 76
A53	Compound 53	A77	Compound 77
A54	Compound 54	A78	Compound 78
A55	Compound 55	A79	Compound 79
A56	Compound 56	A80	Compound 80
A57	Compound 57	A81	Compound 81
A58	Compound 58	A82	Compound 82
A59	Compound 59	A83	Compound 83
A60	Compound 60	A84	Compound 84
A61	Compound 61	A85	Compound 85
A62	Compound 62	A86	Compound 86
A63	Compound 63	A87	Compound 87
A64	Compound 64	A88	Compound 88
A65	Compound 65	A89	Compound 89
A66	Compound 66	A90	Compound 90
A67	Compound 67	A91	Compound 91
A68	Compound 68	A92	Compound 92
A69	Compound 69	A93	Compound 93
A70	Compound 70	A94	Compound 94

Preferred for better control of undesired vegetation (e.g., lower use rate such as from synergism, broader spectrum of weeds controlled, or enhanced crop safety) or for preventing the development of resistant weeds are mixtures of a compound of this invention with a herbicide selected from the group consisting of chlorimuron-ethyl, nicosulfuron, mesotrione, 5 thifensulfuron-methyl, flupyrifururon-methyl, tribenuron, pyroxasulfone, pinoxaden, tembotrione, pyroxasulfone, metolachlor and *S*-metolachlor.


The following Tests demonstrate the control efficacy of the compounds of this invention against specific weeds. The weed control afforded by the compounds is not limited, however, to these species. See Index Tables A for compound descriptions. The 10 following abbreviations are used in the Index Tables which follow: *t* is tertiary, *s* is secondary, *n* is normal, *i* is iso, *c* is cyclo, Me is methyl, Et is ethyl, Pr is propyl, *i*-Pr is isopropyl, Bu is butyl, *c*-Pr is cyclopropyl, *t*-Bu is *tert*-butyl, Ph is phenyl, OMe is methoxy,

OEt is ethoxy, SME is methylthio, SEt is ethylthio, -CN is cyano, -NO₂ is nitro, TMS is trimethylsilyl,

(-CH₂O)₂CH means




3-CH₃-3-oxetanyl means



and naphthyl means naphthalenyl. (R) or (S) denotes the absolute chirality of the asymmetric carbon center. The abbreviation "(d)" indicates that the compound appeared to decompose on melting. The abbreviation "Cmpd. No." stands for "Compound Number". The abbreviation "Ex." stands for "Example" and is followed by a number indicating in which example the compound is prepared. Mass spectra are reported with an estimated precision within ± 0.5 Da as the molecular weight of the highest isotopic abundance parent ion (M+1) formed by addition of H⁺ (molecular weight of 1) to the molecule observed by using atmospheric pressure chemical ionization (AP+).

INDEX TABLE A



Cmpd. No.	J ¹	A***	Q ²	R ¹	m.p. (°C)	M-1	M+1
1	2-furanyl	-CH ₂ O-	Ph(2-Cl)	H			411
2	2-furanyl	-CH ₂ O-	Ph(2-CF ₃)	H			445
3	c-Pr-CH ₂	-O-	Ph(2,4-di-F)	H			387
4	c-Pr-CH ₂	-O-	Ph(2-Cl)	H			385
5	(-CH ₂ O) ₂ CH	-CH ₂ O-	Ph(2-CF ₃)	H	60-64		451
6	(-CH ₂ O) ₂ CH	-CH ₂ O-	Ph(2-Cl)	H	122-126		417
7	(-CH ₂ O) ₂ CH	-CH ₂ O-	Ph(2,3-di-F)	H	140-146		419
8	(-CH ₂ O) ₂ CH	-CH ₂ O-	Ph(2-F)	H	113-116		401
9	2-furanyl	-CH ₂ O-	Ph(2,3-di-F)	H	138-142		413
10	2-furanyl	-CH ₂ O-	Ph(2-F)	H			395
11	c-Pr-CH ₂	-O-	Ph(2-F)	H			369
12	c-Pr-CH ₂	-O-	Ph(2,3-di-F)	H			387
13	3-CH ₃ -3-oxetanyl	-CH ₂ O-	Ph(2,3-di-F)	H			415
14	3-CH ₃ -3-oxetanyl	-CH ₂ O-	Ph(2-F)	H			397

Cmpd. No.	J ¹	A***	Q ²	R ¹	m.p. (°C)	M-1	M+1
15	3-CH ₃ -3-oxetanyl	-CH ₂ O-	Ph(2-CF ₃)	H			449
16	3-CH ₃ -3-oxetanyl	-CH ₂ O-	Ph(2-Cl)	H			415
17	Phenyl	-OCH ₂ -	Ph(2,3,4-tri-F)	H			441
18	Phenyl	-OCH ₂ -	Ph(2-Cl)	H			421
19	Phenyl	-OCH ₂ -	Ph(2-F)	H			405
20	Phenyl	-OCH ₂ -	Ph(2,4-di-F)	H			423
21	Phenyl	-OCH ₂ -	Ph(2,3-di-F)	H			423
22	3-CF ₃ -1 <i>H</i> -pyrazol-1-yl	-CH ₂ -	Ph(2,3,4-tri-F)	H			483
23	3-CF ₃ -1 <i>H</i> -pyrazol-1-yl	-CH ₂ -	Ph(2-F)	H			447
24	3-CF ₃ -1 <i>H</i> -pyrazol-1-yl	-CH ₂ -	Ph(2,4-di-F)	H			465
25 (Ex. 2)	3-CF ₃ -1 <i>H</i> -pyrazol-1-yl	-CH ₂ -	Ph(2,3-di-F)	H	**		465
26	1 <i>H</i> -pyrazol-1-yl	-CH ₂ -	Ph(2,3,4-tri-F)	H			415
27	1 <i>H</i> -pyrazol-1-yl	-CH ₂ -	Ph(2-F)	H			379
28	1 <i>H</i> -pyrazol-1-yl	-CH ₂ -	Ph(2,4-di-F)	H			397
29	1 <i>H</i> -pyrazol-1-yl	-CH ₂ -	Ph(2-Cl)	H			395
30	1 <i>H</i> -pyrazol-1-yl	-CH ₂ -	Ph(2,3-di-F)	H			397
31	1 <i>H</i> -1,2,4-triazol-1-yl	-CH ₂ -	Ph(2-F)	H			380
32	1 <i>H</i> -1,2,4-triazol-1-yl	-CH ₂ -	Ph(2,3-di-F)	H			398
33	TMS	-C≡C-	Ph(2,3-di-F)	H		411	
34 (Ex. 1)	pyridin-2-yl	-O-	Ph(2-F)	H	*		
35	pyridin-2-yl	-O-	Ph(2,4-di-F)	H			428
36 ^a	pyrimidin-2-yl(5-F)	-O-	Ph(2-F)	CH ₃	61-65		
37 ^a	pyrimidin-2-yl(5-F)	-O-	Ph(2,3-di-F)	H	174-178		
38 ^a	pyrimidin-2-yl(5-F)	-O-	Ph(2,3-di-F)	CH ₃	71-75		
39 ^a	pyrimidin-2-yl(5-F)	-O-	Ph(2-F)	H	76-79		
40	CF ₃ OCHF-	-CF ₂ O-	Ph(2-F)	H	129-131		
41	CF ₃ OCHF-	-CF ₂ O-	Ph(2-F)	CH ₃	110-113		
42	pyridin-2-yl	-O-	Ph(2,3,4-tri-F)	H			428
43 ^a	pyridin-2-yl(5-CF ₃)	-O-	Ph(2-F)	CH ₃	56-60		
44 ^a	pyridin-2-yl(5-CF ₃)	-O-	Ph(2,3-di-F)	CH ₃	64-68		
45 ^a	Ph(4-F)	-O-	Ph(2-F)	CH ₃			423
46 ^a	Ph(4-F)	-O-	Ph(2,3-di-F)	CH ₃			441
47 ^a	pyridin-2-yl(5-CF ₃)	-O-	Ph(2,3-di-F)	H	76-79		
48	CF ₃ OCHF-	-CF ₂ O-	Ph(2,3-di-F)	CH ₃			513

Cmpd. No.	J ¹	A***	Q ²	R ¹	m.p. (°C)	M-1	M+1
49 ^a	pyridin-2-yl(5-F)	-O-	Ph(2-F)	H	140-144		
50 ^a	Phenyl	-S-	Ph(2-F)	CH ₃		421	
51 ^a	Phenyl	-S-	Ph(2,3-di-F)	CH ₃		439	
52 ^a	pyridin-2-yl(5-F)	-O-	Ph(2,3-di-F)	H	185-190		
55	pyrimidin-2-yl(5-Cl)	-O-	Ph(2-F)	H		427	
56	pyrimidin-2-yl(5-Cl)	-O-	Ph(2,3-di-F)	H		445	
60 ^a	pyridin-2-yl(5-F)	-O-	Ph(2-F)	CH ₃		424	
61 ^a	pyridin-2-yl(5-F)	-O-	Ph(2,3-di-F)	CH ₃		442	
62 ^a	pyridin-2-yl(5-CF ₃)	-O-	Ph(2-F)	H	67-70		
63	Phenyl	-CH ₂ O-	Ph(2-F)	H		405	
64	Phenyl	-CH ₂ O-	Ph(2,4-di-F)	H		423	
65	Phenyl	-CH ₂ O-	Ph(2,3-di-F)	H		423	
66	Phenyl	-CH ₂ O-	Ph(2,3,4-tri-F)	H		441	
67	Phenyl	-CH ₂ O-	Ph(2-Cl)	H		421	
68	pyridin-2-yl	-O-	Ph(2,3-di-F)	H		408	
69	pyridin-2-yl	-O-	Ph(2-Cl)	H		408	
70 ^a	Phenyl	-CH=CH-	Ph(2,3-di-F)	H	150-153		
71 ^a	pyridin-2-yl(3,5-di-F)	-O-	Ph(2,3-di-F)	H		446	
72 ^a	pyridin-2-yl(3,5-di-F)	-O-	Ph(2-F)	CH ₃		442	
73 ^a	pyridin-2-yl(3,5-di-F)	-O-	Ph(2,3-di-F)	CH ₃		460	
74 ^a	pyridin-2-yl(3,5-di-F)	-O-	Ph(2,3,4-tri-F)	CH ₃		478	
75 ^a	Phenyl	-CH=CH-	Ph(2-F)	CH ₃		415	
76 ^a	Phenyl	-CH=CH-	Ph(2,3-di-F)	CH ₃		433	
77 ^a	Phenyl	-CH ₂ CH ₂ -	Ph(2,3-di-F)	CH ₃		435	
78 ^a	Phenyl	-CH ₂ CH ₂ -	Ph(2,3-di-F)	H		421	
79 ^a	Phenyl	-CH=CH-	Ph(2-SCH ₃)	CH ₃	171-175		
80 ^a	pyrimidin-2-yl(5-CH ₃)	-O-	Ph(2,3-di-F)	H		425	
81 ^a	pyrimidin-2-yl(5-CH ₃)	-O-	Ph(2-F)	CH ₃	71-72		
82 ^a	pyrimidin-2-yl(5-CH ₃)	-O-	Ph(2,3-di-F)	CH ₃	70-71		
83 ^a	pyrimidin-2-yl(5-CH ₃)	-O-	Ph(2,3,4-tri-F)	CH ₃		457	
87 ^a (Ex. 4)	pyridin-2-yl(5-F)	-O-	Ph(2,3,4-tri-F)	CH ₃		460	
88 ^a	pyridin-2-yl(5-F)	-O-	Ph(3-CN,2-F)	CH ₃		449	
89 ^a	pyridin-2-yl(5-F)	-O-	Ph(2-CN,3-F)	CH ₃		449	
90 ^a	N-morpholiny	-CH ₂ -	Ph(2,3-di-F)	H		416	
91 ^a	Phenyl	-NH-	Ph(2,3,4-tri-F)	CH ₃		440	
92 ^a	thiazol-2-yl	-O-	Ph(2-F)	CH ₃		412	
93 ^a	thiazol-2-yl	-O-	Ph(2,3-di-F)	CH ₃		430	

Cmpd. No.	J ¹	A***	Q ²	R ¹	m.p. (°C)	M-1	M+1
94 ^a	thiazol-2-yl	-O-	Ph(2,3,4-tri-F)	CH ₃			448


* See Synthesis Example 1 for ¹H NMR data.

** See Synthesis Example 2 for ¹H NMR data.

*** The free bond projecting to the right indicates the connecting point of A to Q¹ (i.e. phenyl) and the free bond projecting to the left indicates the connecting point of A to J¹.

⁵ a Indicates the compound is prepared enantio-enriched at the 3- and 4-positions.


INDEX TABLE B




Cmpd. No.	T	Q ²	R ¹	m.p. (°C)
53 (Ex. 3)	-CH=N-OCH ₃	Ph(2-F)	CH ₃	113-117
54	-CH=N-N(CH ₃) ₂	Ph(2-F)	CH ₃	107-110

10

INDEX TABLE C



Cmpd. No.	J ¹	A	Q ²	m.p. (°C)
57	3-CF ₃ -1 <i>H</i> -pyrazol-1-yl	-CH ₂ -	Ph(2,3-di-F)	170-174
58	3-CF ₃ -1 <i>H</i> -pyrazol-1-yl	-CH ₂ -	Ph(2,3,4-tri-F)	127-130
59	3-CF ₃ -1 <i>H</i> -pyrazol-1-yl	-CH ₂ -	Ph(2-F)	130-134

INDEX TABLE D

Cmpd. No.	J ¹	A	Q ²	m.p. (°C)
84 ^a	pyrimidin-2-yl(5-F)	-O-	Ph(2-F)	71-72
85 ^a	pyrimidin-2-yl(5-F)	-O-	Ph(2,3-di-F)	70-71
86 ^a	pyrimidin-2-yl(5-F)	-O-	Ph(3-Cl,2-F)	65-66

^a Indicates the compound is prepared enantio-enriched at the 3- and 4-positions.

5

BIOLOGICAL EXAMPLES OF THE INVENTIONTEST A

Seeds of plant species selected from barnyardgrass (*Echinochloa crus-galli*), kochia (*Kochia scoparia*), ragweed (common ragweed, *Ambrosia elatior*), ryegrass, Italian (*Lolium multiflorum*), foxtail, giant (*Setaria faberii*), and pigweed (*Amaranthus retroflexus*), were 10 planted into a blend of loam soil and sand and treated preemergence with a directed soil spray using test chemicals formulated in a non-phytotoxic solvent mixture which included a surfactant.

At the same time, plants selected from these weed species and also blackgrass (*Alopecurus myosuroides*), galium (catchweed bedstraw, *Galium aparine*), wheat (*Triticum aestivum*), and corn (*Zea mays*) were planted in pots containing the same blend of loam soil 15 and sand and treated with postemergence applications of test chemicals formulated in the same manner. Plants ranged in height from 2 to 10 cm and were in the one- to two-leaf stage for the postemergence treatment. Treated plants and untreated controls were maintained in a greenhouse for approximately 10 days, after which time all treated plants were compared to 20 untreated controls and visually evaluated for injury. Plant response ratings, summarized in Table A, are based on a 0 to 100 scale where 0 is no effect and 100 is complete control. A dash (-) response means no test result.

Table A

Compounds

500 g ai/ha	1	2	3	4	5	6	7	8	9	10	11	12	13	14
Postemergence														
Barnyardgrass	0	0	60	80	20	70	70	70	60	60	90	90	60	60

	Blackgrass	0	0	30	40	0	20	40	20	0	0	40	60	20	0
	Corn	0	0	20	0	0	20	20	20	20	0	20	60	0	0
	Foxtail, Giant	0	10	70	80	50	70	70	70	50	30	90	90	70	70
	Galium	0	0	40	0	0	0	40	0	0	0	30	50	40	0
5	Kochia	0	0	40	0	0	0	0	0	0	0	0	20	20	0
	Pigweed	0	0	0	30	0	0	0	0	0	0	20	20	0	0
	Ragweed	30	0	0	40	0	0	20	10	0	0	40	30	0	0
	Ryegrass, Italian	0	10	30	40	20	0	20	0	0	0	20	50	30	0
	Wheat	0	0	20	0	0	20	40	0	0	0	20	50	0	0

10	Table A														Compounds
	500 g ai/ha	15	16	17	18	19	20	21	22	23	24	25	26	27	28

	Postemergence														
	Barnyardgrass	0	50	40	20	50	70	20	60	30	0	60	70	70	20
	Blackgrass	0	0	0	0	0	0	0	0	0	0	0	0	0	0
15	Corn	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Foxtail, Giant	20	20	40	0	40	60	30	60	20	0	60	60	50	20
	Galium	0	0	30	0	0	0	0	0	0	0	0	0	0	0
	Kochia	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Pigweed	0	0	0	0	0	0	0	0	0	0	0	0	0	0
20	Ragweed	30	0	0	0	0	0	0	0	0	0	0	0	0	0
	Ryegrass, Italian	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Wheat	0	0	0	0	0	0	0	0	0	0	0	0	0	0

	Table A														Compounds
	500 g ai/ha	29	30	31	32	33	34	35	36	37	38	39	40	41	42

25	Postemergence														
	Barnyardgrass	20	60	0	10	50	60	60	90	100	100	100	40	50	60
	Blackgrass	0	0	0	0	0	20	0	50	70	70	40	30	30	0
	Corn	0	0	0	0	0	0	0	90	90	100	70	0	40	0
	Foxtail, Giant	20	50	0	20	50	80	70	80	90	90	80	60	70	70
30	Galium	0	0	20	40	20	50	0	70	70	70	30	40	60	30
	Kochia	0	0	0	0	40	0	0	50	50	60	0	0	60	0
	Pigweed	0	0	0	0	0	0	0	50	70	70	20	0	80	0
	Ragweed	0	0	0	0	0	0	0	40	70	80	30	0	0	0
	Ryegrass, Italian	0	0	0	0	0	30	30	50	60	80	20	0	20	0
35	Wheat	0	0	0	0	0	0	0	60	70	70	60	20	40	0

	Table A														Compounds
	500 g ai/ha	43	44	45	46	47	48	49	50	51	52	53	54	55	56

Table A

Compounds

Table A

Compounds

15	125 g ai/ha	29	30	31	32	33	34	35	36	37	38	39	40	41	42
Postemergence															
	Barnyardgrass	0	20	0	0	0	30	30	90	90	100	70	50	50	40
	Blackgrass	0	0	0	0	0	0	0	20	40	70	0	0	0	0
	Corn	0	0	0	0	0	0	0	40	70	90	30	0	0	0
20	Foxtail, Giant	0	30	0	0	0	30	30	80	70	90	70	40	50	50
	Galium	0	0	0	0	0	20	0	40	50	50	0	40	40	0
	Kochia	0	0	0	0	0	0	0	0	0	30	0	0	20	0
	Pigweed	0	0	0	0	0	0	0	30	40	50	0	0	40	0
	Ragweed	0	0	0	0	0	0	0	0	20	20	0	0	0	0
25	Ryegrass, Italian	0	0	0	0	0	0	0	0	0	70	0	0	0	0
	Wheat	0	0	0	0	0	0	0	20	50	0	0	0	0	0

Table A

Compounds

120

Ryegrass, Italian	0	0	0	0	0	0	0	0	20	30	0	0	0	0
Wheat	30	0	0	0	0	0	0	0	0	0	0	0	0	0

Table A	Compounds												
---------	-----------	--	--	--	--	--	--	--	--	--	--	--	--

125 g ai/ha	57	58	59	60	61	62	63	64	65	66	67	68	69	71
-------------	----	----	----	----	----	----	----	----	----	----	----	----	----	----

5	Postemergence														
	Barnyardgrass	0	0	0	70	70	70	0	0	0	0	0	10	0	70
	Blackgrass	0	0	0	0	40	0	0	0	0	0	0	0	0	0
	Corn	30	0	0	30	70	30	0	0	0	0	0	0	0	20
	Foxtail, Giant	40	30	0	80	90	80	0	0	0	0	0	0	0	70
10	Galium	0	0	0	30	60	30	0	0	0	0	0	0	0	50
	Kochia	0	0	0	-	-	-	0	0	0	0	0	0	0	20
	Pigweed	0	0	0	0	40	0	0	0	0	0	0	0	0	50
	Ragweed	0	0	0	0	40	0	0	0	0	0	0	0	0	30
	Ryegrass, Italian	0	0	0	30	70	0	0	0	0	0	0	0	0	0
15	Wheat	0	0	0	0	50	0	0	0	0	0	0	0	0	0

Table A	Compounds												
---------	-----------	--	--	--	--	--	--	--	--	--	--	--	--

125 g ai/ha	72	73	74	87	88	89	90							
-------------	----	----	----	----	----	----	----	--	--	--	--	--	--	--

	Postemergence													
	Barnyardgrass	90	70	90	80	80	70	0						
20	Blackgrass	60	40	20	60	0	20	0						
	Corn	20	20	20	90	20	0	0						
	Foxtail, Giant	90	90	80	80	70	70	0						
	Galium	60	60	70	60	40	40	0						
	Kochia	20	20	50	30	30	0	0						
25	Pigweed	30	60	60	70	20	50	0						
	Ragweed	30	30	20	0	0	0	0						
	Ryegrass, Italian	50	40	30	70	0	20	0						
	Wheat	20	20	20	40	60	0	0						

Table A	Compounds												
---------	-----------	--	--	--	--	--	--	--	--	--	--	--	--

30	31 g ai/ha	71	72	73	74	87	88	89	90					
----	------------	----	----	----	----	----	----	----	----	--	--	--	--	--

	Postemergence													
	Barnyardgrass	30	60	60	60	50	30	30	0					
	Blackgrass	0	20	0	0	30	0	0	0					
	Corn	0	0	20	0	60	0	0	0					
35	Foxtail, Giant	20	80	60	70	70	30	30	0					
	Galium	30	40	50	40	30	30	30	0					
	Kochia	0	0	0	20	0	0	0	0					

122

Kochia	30	0	20	20	0	20	70	30	50	80	70	0	20	0
Pigweed	80	80	70	70	50	70	20	20	0	70	0	0	0	0
Ragweed	80	60	30	30	60	0	40	30	0	80	0	0	0	0
Ryegrass, Italian	80	90	80	80	70	30	70	0	20	40	0	0	20	0

5	Table A	Compounds													
	500 g ai/ha	57	58	59	60	61	62	63	64	65	66	67	68	69	
	Preemergence														
	Barnyardgrass	90	90	40	90	90	90	0	0	0	0	0	50	0	
	Foxtail, Giant	90	90	50	90	90	90	0	0	0	0	0	90	50	
10	Kochia	0	-	0	80	80	60	0	0	0	0	0	0	0	
	Pigweed	0	0	0	50	90	50	0	0	0	0	0	0	0	
	Ragweed	0	0	0	50	60	50	0	0	0	0	0	0	0	
	Ryegrass, Italian	0	20	0	70	90	20	0	0	0	0	0	0	0	
	Table A	Compounds													
15	125 g ai/ha	1	2	3	4	5	6	7	8	9	10	11	12	13	14
	Preemergence														
	Barnyardgrass	0	0	40	60	0	20	60	50	10	0	60	90	0	10
	Foxtail, Giant	0	0	60	70	30	70	90	80	10	0	80	90	80	30
	Kochia	0	0	0	0	0	0	0	0	0	0	0	0	0	0
20	Pigweed	0	0	0	0	0	60	60	0	0	0	0	0	0	0
	Ragweed	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Ryegrass, Italian	0	0	0	0	0	0	30	0	0	0	0	0	0	0
	Table A	Compounds													
	125 g ai/ha	15	16	17	18	19	20	21	22	23	24	25	26	27	28
25	Preemergence														
	Barnyardgrass	0	0	20	0	30	20	0	0	0	0	20	40	0	0
	Foxtail, Giant	10	10	50	0	30	30	20	40	20	0	50	40	20	0
	Kochia	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Pigweed	0	0	0	0	0	0	0	0	0	0	0	0	0	0
30	Ragweed	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Ryegrass, Italian	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Table A	Compounds													
	125 g ai/ha	29	30	31	32	33	34	35	36	37	38	39	40	41	42
	Preemergence														
35	Barnyardgrass	0	0	0	0	60	20	20	90	90	90	70	50	20	40
	Foxtail, Giant	0	20	0	0	60	70	70	90	90	100	90	90	80	80

123

Kochia	0	0	0	0	0	0	0	0	0	30	30	0	30	0
Pigweed	0	0	0	0	0	0	0	0	60	80	0	0	70	0
Ragweed	0	0	0	0	0	0	0	0	40	0	0	20	0	0
Ryegrass, Italian	0	0	0	0	0	0	0	0	20	80	0	0	20	0

5 Table A Compounds

125 g ai/ha	43	44	45	46	47	48	49	50	51	52	53	54	55	56
-------------	----	----	----	----	----	----	----	----	----	----	----	----	----	----

Preemergence

Barnyardgrass	80	80	80	70	50	80	90	0	20	70	90	0	0	30
---------------	----	----	----	----	----	----	----	---	----	----	----	---	---	----

Foxtail, Giant	90	90	90	90	90	80	90	90	90	90	90	0	80	0
----------------	----	----	----	----	----	----	----	----	----	----	----	---	----	---

10 Kochia	30	0	0	0	0	0	20	0	20	70	60	0	0	0
-----------	----	---	---	---	---	---	----	---	----	----	----	---	---	---

Pigweed	40	30	40	40	0	70	0	20	0	60	0	0	0	0
---------	----	----	----	----	---	----	---	----	---	----	---	---	---	---

Ragweed	0	0	0	0	0	0	0	0	0	40	0	0	0	0
---------	---	---	---	---	---	---	---	---	---	----	---	---	---	---

Ryegrass, Italian	30	30	30	20	0	30	40	0	0	30	0	0	0	0
-------------------	----	----	----	----	---	----	----	---	---	----	---	---	---	---

Table A Compounds

15 125 g ai/ha	57	58	59	60	61	62	63	64	65	66	67	68	69	71
----------------	----	----	----	----	----	----	----	----	----	----	----	----	----	----

Preemergence														
--------------	--	--	--	--	--	--	--	--	--	--	--	--	--	--

Barnyardgrass	40	30	0	90	90	90	0	0	0	0	0	20	0	70
---------------	----	----	---	----	----	----	---	---	---	---	---	----	---	----

Foxtail, Giant	60	60	0	90	90	90	0	0	0	0	0	60	0	90
----------------	----	----	---	----	----	----	---	---	---	---	---	----	---	----

Kochia	-	0	0	70	60	30	0	0	0	0	0	0	0	30
--------	---	---	---	----	----	----	---	---	---	---	---	---	---	----

20 Pigweed	0	0	0	60	70	30	0	0	0	0	0	0	0	80
------------	---	---	---	----	----	----	---	---	---	---	---	---	---	----

Ragweed	0	0	0	40	30	0	0	0	0	0	0	0	0	0
---------	---	---	---	----	----	---	---	---	---	---	---	---	---	---

Ryegrass, Italian	0	0	0	20	80	0	0	0	0	0	0	0	0	0
-------------------	---	---	---	----	----	---	---	---	---	---	---	---	---	---

Table A Compounds

125 g ai/ha	72	73	74	87	88	89	90
-------------	----	----	----	----	----	----	----

25 Preemergence														
-----------------	--	--	--	--	--	--	--	--	--	--	--	--	--	--

Barnyardgrass	90	90	90	90	30	70	0
---------------	----	----	----	----	----	----	---

Foxtail, Giant	90	90	100	90	90	90	0
----------------	----	----	-----	----	----	----	---

Kochia	0	20	40	60	30	0	0
--------	---	----	----	----	----	---	---

Pigweed	0	0	80	70	20	60	0
---------	---	---	----	----	----	----	---

30 Ragweed	0	0	0	0	0	0	0
------------	---	---	---	---	---	---	---

Ryegrass, Italian	50	40	80	80	20	40	0
-------------------	----	----	----	----	----	----	---

Table A Compounds

31 g ai/ha	71	72	73	74	87	88	89	90
------------	----	----	----	----	----	----	----	----

Preemergence								
--------------	--	--	--	--	--	--	--	--

Barnyardgrass	0	90	50	70	60	0	30	0
---------------	---	----	----	----	----	---	----	---

Foxtail, Giant	70	90	80	90	90	30	40	0
----------------	----	----	----	----	----	----	----	---

Kochia	0	0	0	0	0	0	0	0
Pigweed	20	0	0	0	70	0	0	0
Ragweed	0	0	0	0	0	0	0	0
Ryegrass, Italian	0	0	0	30	0	0	0	0

5 TEST B

Plant species in the flooded paddy test selected from rice (*Oryza sativa*), sedge, umbrella (small-flower umbrella sedge, *Cyperus difformis*), ducksalad (*Heteranthera limosa*), and barnyardgrass (*Echinochloa crus-galli*) were grown to the 2-leaf stage for testing. At time of treatment, test pots were flooded to 3 cm above the soil surface, treated by application of test compounds directly to the paddy water, and then maintained at that water depth for the duration of the test. Treated plants and controls were maintained in a greenhouse for 13 to 15 days, after which time all species were compared to controls and visually evaluated. Plant response ratings, summarized in Table B, are based on a scale of 0 to 100 where 0 is no effect and 100 is complete control. A dash (-) response means no test result.

Table B Compounds

Table B Compounds

250 g ai/ha	1	2	4	5	6	7	8	9	10	11	12	14	15	16
Flood														
Barnyardgrass	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Ducksalad	65	0	0	65	0	75	35	30	60	0	20	70	50	30
Rice	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Sedge, Umbrella	30	0	0	0	0	0	0	30	40	0	0	20	0	30

30 Table B

		Compounds													
Table B		50	51	52	53	54	57	58	59	60	61	62	87	88	89
	250 g ai/ha														
	Flood														
	Barnyardgrass	0	0	40	30	0	0	0	0	65	40	40	60	0	0
5	Ducksalad	70	40	100	70	0	0	0	0	100	100	100	85	50	70
	Rice	0	0	0	0	0	0	0	0	0	0	20	0	0	0
	Sedge, Umbrella	0	0	0	0	0	0	0	0	0	0	0	0	0	0

Table B Compound

250 g ai/ha 90

10 Flood

Barnyardgrass 0

Ducksalad 0


Rice 0

Sedge, Umbrella 0

CLAIMS

What is claimed is:

1. A compound selected from Formula 1, *N*-oxides and salts thereof,



1

5

wherein

Q¹ is a phenyl ring or a naphthalenyl ring system, each ring or ring system optionally substituted with 1 to 4 substituents independently selected from R⁷; or a 5- to 10

6-membered heteroaromatic ring or an 8- to 10-membered heteroaromatic bicyclic ring system, each ring or ring system containing ring members selected from carbon atoms and 1 to 4 heteroatoms independently selected from up to 2 O, up to 2 S and up to 4 N atoms, wherein up to 3 carbon ring members are independently selected from C(=O) and C(=S), and the sulfur atom ring members are independently selected from S(=O)_u(=NR⁸)_v, each ring or ring system optionally substituted with up to 4 substituents independently selected from R⁷ on carbon atom ring members and selected from R⁹ on nitrogen atom ring members;

15 Q² is a phenyl ring or a naphthalenyl ring system, each ring or ring system optionally substituted with up to 5 substituents independently selected from R¹⁰; or a 5- to 20 6-membered heteroaromatic ring or an 8- to 10-membered heteroaromatic bicyclic ring system, each ring or ring system containing ring members selected from carbon atoms and 1 to 4 heteroatoms independently selected from up to 2 O, up to 2 S and up to 4 N atoms, wherein up to 3 carbon ring members are

25 independently selected from C(=O) and C(=S), and the sulfur atom ring members are independently selected from S(=O)_u(=NR⁸)_v, each ring or ring system optionally substituted with up to 5 substituents independently selected from R¹⁰ on carbon atom ring members and selected from R¹¹ on nitrogen atom ring members;

30 T is J¹-A-, wherein the free bond projecting to the right next to A indicates the connecting point of J¹-A- to Q¹; or

T is $R^{17}ON=CR^{17a}-$, $(R^{18})_2C=NO-$, $(R^{19})_2NN=CR^{17a}-$, $(R^{18})_2C=NNR^{20a}-$, $R^{20}N=CR^{17a}-$, $(R^{18})_2C=N-$, $R^{17}ON=CR^{17a}C(R^{23b})_2-$ or $(R^{18})_2C=NOC(R^{24a})_2-$, wherein the free bond projecting to the right indicates the connecting point to Q¹; A is a saturated, partially unsaturated or fully unsaturated chain containing 1 to 3 atoms selected from up to 3 carbon, up to 1 O, up to 1 S and up to 2 N atoms, the chain optionally substituted with up to 2 substituents independently selected from R¹⁵ on carbon atoms and R¹⁶ on nitrogen atoms;

5 Y¹ and Y² are each independently O, S or NR¹²;

10 J¹ is a phenyl ring or a naphthalenyl ring system, each ring or ring system optionally substituted with up to 5 substituents independently selected from R^{7'}; or a 4- to 6-membered heterocyclic ring or an 8- to 10-membered heteroaromatic bicyclic ring system, each ring or ring system containing ring members selected from carbon atoms and 1 to 4 heteroatoms independently selected from up to 2 O, up to 2 S and up to 4 N atoms, wherein up to 3 carbon ring members are independently selected from C(=O) and C(=S), and the sulfur atom ring members are independently selected from S(=O)_u(=NR⁸)_v, each ring or ring system optionally substituted with up to 5 substituents independently selected from R^{7'} on carbon atom ring members and selected from R^{9'} on nitrogen atom ring members; or C₄–C₁₀ cycloalkylalkoxy, C₄–C₁₀ cycloalkylalkyl, C₂–C₈ alkenyloxy, C₂–C₈ haloalkenyloxy, C₂–C₈ alkoxyalkoxy, C₂–C₈ alkylthioalkyl, C₂–C₈ alkylsulfinylalkyl, C₂–C₈ alkylsulfonylalkyl, C₁–C₈ alkylsulfonyloxy, C₁–C₈ haloalkylsulfonyloxy, C₁–C₈ alkylthio, C₁–C₈ haloalkylthio, C₃–C₈ cycloalkylthio, C₁–C₈ alkylsulfinyl, C₁–C₈ haloalkylsulfinyl, C₁–C₈ alkylsulfonyl, C₁–C₈ haloalkylsulfonyl, C₂–C₈ alkynyl, C₂–C₈ haloalkynyl, C₂–C₈ alkoxyalkyl, C₂–C₈ haloalkoxyalkyl, C₃–C₈ haloalkoxyalkoxy, C₂–C₈ haloalkoxyhaloalkyl, C₁–C₈ haloalkyl, C₃–C₈ halocycloalkyl, C₂–C₈ alkylcarbonyloxy or C₂–C₈ haloalkylcarbonyloxy;

20 J² is –CR²R³– or –CR²R³–CR^{2a}R^{3a}– wherein –CR²R³– moiety is connected to N;

25 R¹ is H, hydroxy, amino, cyano, formyl, C₃–C₈ alkylcarbonylalkyl, -CPh=N-O(C₁–C₄ alkyl), -C(C₁–C₄ alkyl)=N-O(C₁–C₄ alkyl), -C(O)NH₂, C₁–C₆ alkyl, C₁–C₆ haloalkyl, C₂–C₆ alkenyl, C₃–C₆ alkynyl, C₂–C₆ cyanoalkyl, C₃–C₆ cycloalkyl, C₄–C₈ cycloalkylalkyl, C₂–C₈ alkoxyalkyl, C₃–C₈ alkoxyalkoxyalkyl, C₂–C₈ haloalkoxyalkyl, C₂–C₈ alkylthioalkyl, C₂–C₈ alkylsulfinylalkyl, C₂–C₈ alkylsulfonylalkyl, C₂–C₈ alkylcarbonyl, C₂–C₈ haloalkylcarbonyl, C₄–C₁₀ cycloalkylcarbonyl, C₂–C₈ alkoxy carbonyl, C₂–C₈ haloalkoxycarbonyl, C₄–C₁₀ cycloalkoxycarbonyl, C₂–C₈ alkylaminocarbonyl, C₃–C₁₀ dialkylaminocarbonyl, C₄–C₁₀ cycloalkylaminocarbonyl, C₁–C₆ alkoxy, C₁–C₆ alkylthio, C₁–C₆ haloalkylthio, C₃–C₈ cycloalkylthio, C₁–C₆ alkylsulfinyl, C₁–

C_6 haloalkylsulfinyl, C_3 – C_8 cycloalkylsulfinyl, C_1 – C_6 alkylsulfonyl, C_1 – C_6 haloalkylsulfonyl, C_3 – C_8 cycloalkylsulfonyl, C_1 – C_6 alkylaminosulfonyl, C_2 – C_8 dialkylaminosulfonyl, C_3 – C_{10} trialkylsilyl, phenylcarbonyl or G^1 ;
 5 R^2 and R^3 are each independently H, halogen, hydroxy, C_1 – C_4 alkyl, C_1 – C_4 haloalkyl or C_1 – C_4 alkoxy; or
 R^2 and R^3 are taken together with the carbon atom to which they are bonded to form a C_3 – C_7 cycloalkyl ring;
 R^{2a} and R^{3a} are each independently H, halogen or C_1 – C_4 alkyl; or
 R^{2a} and R^{3a} are taken together with the carbon atom to which they are bonded to form
 10 a C_3 – C_7 cycloalkyl ring;
 R^4 and R^5 are each independently H, halogen, hydroxyl, C_1 – C_4 alkoxy or C_1 – C_4 alkyl;
 R^6 is H, hydroxy, amino, C_1 – C_6 alkyl, C_1 – C_6 haloalkyl, C_2 – C_6 alkenyl, C_3 – C_6 alkynyl, C_2 – C_8 alkoxyalkyl, C_2 – C_8 haloalkoxyalkyl, C_2 – C_8 alkylthioalkyl, C_2 – C_8 alkylsulfinylalkyl, C_2 – C_8 alkylsulfonylalkyl, C_2 – C_8 alkylcarbonyl, C_2 – C_8 haloalkylcarbonyl, C_4 – C_{10} cycloalkylcarbonyl, C_2 – C_8 alkoxy carbonyl, C_2 – C_8 haloalkoxycarbonyl, C_4 – C_{10} cycloalkoxycarbonyl, C_2 – C_8 alkylaminocarbonyl, C_3 – C_{10} dialkylaminocarbonyl, C_4 – C_{10} cycloalkylaminocarbonyl, C_1 – C_6 alkoxy, C_1 – C_6 alkylthio, C_1 – C_6 haloalkylthio, C_3 – C_8 cycloalkylthio, C_1 – C_6 alkylsulfinyl, C_1 – C_6 haloalkylsulfinyl, C_3 – C_8 cycloalkylsulfinyl, C_1 – C_6 alkylsulfonyl, C_1 – C_6 haloalkylsulfonyl, C_3 – C_8 cycloalkylsulfonyl, C_1 – C_6 alkylaminosulfonyl, C_2 – C_8 dialkylaminosulfonyl, C_3 – C_{10} trialkylsilyl or G^1 ;
 15 each R^7 is independently halogen, hydroxyl, cyano, nitro, C_1 – C_4 alkyl, C_1 – C_4 cyanoalkyl, C_1 – C_4 cyanoalkoxy, C_1 – C_4 haloalkyl, C_2 – C_4 alkenyl, C_2 – C_4 haloalkenyl C_2 – C_4 alkynyl, C_2 – C_4 haloalkynyl, C_1 – C_4 nitroalkyl, C_2 – C_4 nitroalkenyl, C_2 – C_4 alkoxyalkyl, C_3 – C_8 alkoxyalkoxyalkyl, C_2 – C_4 haloalkoxyalkyl, C_3 – C_4 cycloalkyl, C_3 – C_4 halocycloalkyl, cyclopropylmethyl, 1-methylcyclopropyl, 2-methylcyclopropyl, C_1 – C_4 alkoxy, C_1 – C_4 haloalkoxy, C_2 – C_4 alkenyloxy, C_2 – C_4 haloalkenyloxy, C_3 – C_4 alkynyloxy, C_3 – C_4 haloalkynyloxy, C_3 – C_4 cycloalkoxy, C_1 – C_4 alkylthio, C_1 – C_4 haloalkylthio, C_1 – C_4 alkylsulfinyl, C_1 – C_4 haloalkylsulfinyl, C_1 – C_4 alkylsulfonyl, C_1 – C_4 haloalkylsulfonyl, hydroxy, -CHO, C_2 – C_4 alkylcarbonyl, C_2 – C_4 alkylcarbonyloxy, C_1 – C_4 alkylsulfonyloxy, C_1 – C_4 haloalkylsulfonyloxy, amino, C_1 – C_4 alkylamino, C_2 – C_4 dialkylamino, formylamino, C_2 – C_4 alkylcarbonylamino, -SF₅, -SCN, C_3 – C_4 trialkylsilyl, trimethylsilylmethyl or trimethylsilylmethoxy; or
 20 two adjacent R^7 are taken together along with the carbon atoms to which they are bonded to form a C_3 – C_7 cycloalkyl ring;

each R^{10} is independently halogen, hydroxyl, cyano, nitro, C_1 – C_8 alkyl, C_1 – C_8 haloalkyl, C_1 – C_8 nitroalkyl, C_2 – C_8 alkenyl, C_2 – C_4 alkoxyalkyl, C_3 – C_8 alkoxyalkoxyalkyl, C_1 – C_4 cyanoalkyl, C_1 – C_4 cyanoalkoxy, C_2 – C_8 haloalkenyl, C_2 – C_8 nitroalkenyl, C_2 – C_8 alkynyl, C_2 – C_8 haloalkynyl, C_4 – C_{10} cycloalkylalkyl, C_4 – C_{10} halocycloalkylalkyl, C_5 – C_{12} alkylcycloalkylalkyl, C_5 – C_{12} cycloalkylalkenyl, C_5 – C_{12} cycloalkylalkynyl, C_3 – C_8 cycloalkyl, C_3 – C_8 halocycloalkyl, C_4 – C_{10} alkylcycloalkyl, C_6 – C_{12} cycloalkylcycloalkyl, C_3 – C_8 cycloalkenyl, C_3 – C_8 halocycloalkenyl, C_2 – C_8 alkoxyalkyl, C_2 – C_8 haloalkoxyalkyl, C_4 – C_{10} cycloalkoxyalkyl, C_3 – C_{10} alkoxyalkoxyalkyl, C_2 – C_8 alkylthioalkyl, C_2 – C_8 alkylsulfinylalkyl, C_2 – C_8 alkylsulfonylalkyl, C_2 – C_8 alkylaminoalkyl, C_2 – C_8 haloalkylaminoalkyl, C_4 – C_{10} cycloalkylaminoalkyl, C_3 – C_{10} dialkylaminoalkyl, $-CHO$, C_2 – C_8 alkylcarbonyl, C_2 – C_8 haloalkylcarbonyl, C_4 – C_{10} cycloalkylcarbonyl, $-C(=O)OH$, C_2 – C_8 alkoxy carbonyl, C_2 – C_8 haloalkoxycarbonyl, C_4 – C_{10} cycloalkoxycarbonyl, C_5 – C_{12} cycloalkylalkoxycarbonyl, $-C(=O)NH_2$, C_2 – C_8 alkylaminocarbonyl, C_4 – C_{10} cycloalkylaminocarbonyl, C_3 – C_{10} dialkylaminocarbonyl, hydroxy, C_1 – C_8 alkoxy, C_1 – C_8 haloalkoxy, C_2 – C_8 alkoxyalkoxy, C_2 – C_8 alkenyloxy, C_2 – C_8 haloalkenyloxy, C_3 – C_8 alkynyloxy, C_3 – C_8 haloalkynyloxy, C_3 – C_8 cycloalkoxy, C_3 – C_8 halocycloalkoxy, C_4 – C_{10} cycloalkylalkoxy, C_3 – C_{10} alkylcarbonylalkoxy, C_2 – C_8 alkylcarbonyloxy, C_2 – C_8 haloalkylcarbonyloxy, C_4 – C_{10} cycloalkylcarbonyloxy, C_1 – C_8 alkylsulfonyloxy, C_1 – C_8 haloalkylsulfonyloxy, C_1 – C_8 alkylthio, C_1 – C_8 haloalkylthio, C_3 – C_8 cycloalkylthio, C_1 – C_8 alkylsulfinyl, C_1 – C_8 haloalkylsulfinyl, C_1 – C_8 alkylsulfonyl, C_1 – C_8 haloalkylsulfonyl, C_3 – C_8 cycloalkylsulfonyl, amino, C_1 – C_8 alkylamino, C_1 – C_6 haloalkylamino, C_3 – C_8 cycloalkylamino, C_2 – C_8 dialkylamino, C_2 – C_8 halodialkylamino, formylamino, C_2 – C_8 alkylcarbonylamino, C_2 – C_8 haloalkylcarbonylamino, C_1 – C_6 alkylsulfonylamino, C_1 – C_6 haloalkylsulfonylamino, $-SF_5$, $-SCN$, C_3 – C_{12} trialkylsilyl, C_4 – C_{12} trialkylsilylalkyl, C_4 – C_{12} trialkylsilylalkoxy or G^2 ; or

two adjacent R^{10} are taken together along with the carbon atoms to which they are bonded to form a C_3 – C_7 cycloalkyl ring;

each R^7 is independently halogen, hydroxyl, cyano, nitro, C_1 – C_8 alkyl, C_2 – C_4 alkoxyalkyl, C_3 – C_8 alkoxyalkoxyalkyl, C_1 – C_4 cyanoalkyl, C_1 – C_4 cyanoalkoxy, C_1 – C_8 haloalkyl, C_1 – C_8 nitroalkyl, C_2 – C_8 alkenyl, C_2 – C_8 haloalkenyl, C_2 – C_8 nitroalkenyl, C_2 – C_8 alkynyl, C_2 – C_8 haloalkynyl, C_4 – C_{10} cycloalkylalkyl, C_4 – C_{10} halocycloalkylalkyl, C_5 – C_{12} alkylcycloalkylalkyl, C_5 – C_{12} cycloalkylalkenyl, C_5 – C_{12} cycloalkylalkynyl, C_3 – C_8 cycloalkyl, C_3 – C_8 halocycloalkyl, C_4 – C_{10} alkylcycloalkyl, C_6 – C_{12} cycloalkylcycloalkyl, C_3 – C_8

cycloalkenyl, C₃–C₈ halocycloalkenyl, C₂–C₈ alkoxyalkyl, C₂–C₈
haloalkoxyalkyl, C₄–C₁₀ cycloalkoxyalkyl, C₃–C₁₀ alkoxyalkoxyalkyl, C₂–C₈
alkylthioalkyl, C₂–C₈ alkylsulfinylalkyl, C₂–C₈ alkylsulfonylalkyl, C₂–C₈
alkylaminoalkyl, C₂–C₈ haloalkylaminoalkyl, C₄–C₁₀ cycloalkylaminoalkyl,
5 C₃–C₁₀ dialkylaminoalkyl, -CHO, C₂–C₈ alkylcarbonyl, C₂–C₈
haloalkylcarbonyl, C₄–C₁₀ cycloalkylcarbonyl, -C(=O)OH, C₂–C₈
alkoxycarbonyl, C₂–C₈ haloalkoxycarbonyl, C₄–C₁₀ cycloalkoxycarbonyl, C₅–
C₁₂ cycloalkylalkoxycarbonyl, -C(=O)NH₂, C₂–C₈ alkylaminocarbonyl, C₄–C₁₀
cycloalkylaminocarbonyl, C₃–C₁₀ dialkylaminocarbonyl, hydroxy, C₁–C₈
10 alkoxy, C₁–C₈ haloalkoxy, C₂–C₈ alkoxyalkoxy, C₂–C₈ alkenyloxy, C₂–C₈
haloalkenyloxy, C₃–C₈ alkynyloxy, C₃–C₈ haloalkynyloxy, C₃–C₈ cycloalkoxy,
C₃–C₈ halocycloalkoxy, C₄–C₁₀ cycloalkylalkoxy, C₃–C₁₀ alkylcarbonylalkoxy,
C₂–C₈ alkylcarbonyloxy, C₂–C₈ haloalkylcarbonyloxy, C₄–C₁₀
15 cycloalkylcarbonyloxy, C₁–C₈ alkylsulfonyloxy, C₁–C₈ haloalkylsulfonyloxy,
C₁–C₈ alkylthio, C₁–C₈ haloalkylthio, C₃–C₈ cycloalkylthio, C₁–C₈
alkylsulfinyl, C₁–C₈ haloalkylsulfinyl, C₁–C₈ alkylsulfonyl, C₁–C₈
haloalkylsulfonyl, C₃–C₈ cycloalkylsulfonyl, amino, C₁–C₈ alkylamino, C₁–C₆
haloalkylamino, C₃–C₈ cycloalkylamino, C₂–C₈ dialkylamino, C₂–C₈
halodialkylamino, formylamino, C₂–C₈ alkylcarbonylamino, C₂–C₈
20 haloalkylcarbonylamino, C₁–C₆ alkylsulfonylamino, C₁–C₆
haloalkylsulfonylamino, -SF₅, -SCN, C₃–C₁₂ trialkylsilyl, C₄–C₁₂
trialkylsilylalkyl, C₄–C₁₂ trialkylsilylalkoxy; or
two adjacent R⁷ are taken together along with the carbon atoms to which they are
bonded to form a C₃–C₇ cycloalkyl ring;
25 each R⁸ is independently H, cyano, C₂–C₃ alkylcarbonyl or C₂–C₃ haloalkylcarbonyl;
each R⁹, R⁹' and R¹¹ is independently cyano, C₁–C₃ alkyl, C₂–C₃ alkenyl, C₂–C₃
alkynyl, C₃–C₆ cycloalkyl, C₂–C₃ alkoxyalkyl, C₁–C₃ alkoxy, C₂–C₃
alkylcarbonyl, C₂–C₃ alkoxy carbonyl, C₂–C₃ alkylaminoalkyl or C₃–C₄
dialkylaminoalkyl;
30 each R¹² is independently H, cyano, C₁–C₄ alkyl, C₁–C₄ haloalkyl, C₁–C₄ alkoxy,
C₁–C₄ haloalkoxy, -(C=O)CH₃ or -(C=O)CF₃;
each G¹ is independently phenyl, phenylmethyl, pyridinylmethyl, phenylcarbonyl,
phenoxy, phenylethynyl, phenylsulfonyl, phenylcarbonylalkyl; or a 5- or 6-
membered heteroaromatic ring, each optionally substituted on ring members with
35 up to 5 substituents independently selected from R¹³;
each G² is independently phenyl, phenylmethyl, pyridinylmethyl, phenylcarbonyl,
phenylcarbonylalkyl, phenoxy, phenylethynyl, phenylsulfonyl; or a 5- or 6-

membered heteroaromatic ring, each optionally substituted on ring members with up to 5 substituents independently selected from R¹⁴;

each R¹³ and R¹⁴ is independently halogen, cyano, hydroxy, amino, nitro, -CHO, -C(=O)OH, -C(=O)NH₂, -SO₂NH₂, C₁-C₆ alkyl, C₁-C₆ haloalkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, C₂-C₈ alkylcarbonyl, C₂-C₈ haloalkylcarbonyl, C₂-C₈ alkoxy carbonyl, C₄-C₁₀ cycloalkoxycarbonyl, C₅-C₁₂ cycloalkylalkoxycarbonyl, C₂-C₈ alkylaminocarbonyl, C₃-C₁₀ dialkylaminocarbonyl, C₁-C₆ alkoxy, C₁-C₆ haloalkoxy, C₂-C₈ alkylcarbonyloxy, C₁-C₆ alkylthio, C₁-C₆ haloalkylthio, C₁-C₆ alkylsulfinyl, C₁-C₆ haloalkylsulfinyl, C₁-C₆ alkylsulfonyl, C₁-C₆ haloalkylsulfonyl, C₁-C₆ alkylaminosulfonyl, C₂-C₈ dialkylaminosulfonyl, C₃-C₁₀ trialkylsilyl, C₁-C₆ alkylamino, C₂-C₈ dialkylamino, C₂-C₈ alkylcarbonylamino, C₁-C₆ alkylsulfonylamino, phenyl, pyridinyl or thienyl;

each R¹⁵ is independently halogen, cyano, hydroxy, C₁-C₄ alkyl, C₁-C₄ haloalkyl, C₁-C₄ alkoxy, C₁-C₄ haloalkoxy, C₂-C₄ alkoxyalkyl, C₂-C₄ alkylcarbonyl, C₂-C₄ alkoxy carbonyl or C₃-C₆ cycloalkyl;

each R¹⁶ is independently cyano, C₁-C₄ alkyl, C₁-C₄ haloalkyl, C₁-C₄ alkoxy, C₂-C₄ alkylcarbonyl, C₂-C₄ alkoxy carbonyl or C₃-C₆ cycloalkyl;

each R¹⁷ is independently H, C₁-C₆ alkyl, C₃-C₈ cycloalkyl, C₄-C₈ cycloalkylalkyl, C₁-C₆ haloalkyl, C₂-C₆ alkenyl, C₃-C₆ alkynyl, C₂-C₈ alkoxyalkyl, C₂-C₈ haloalkoxyalkyl, C₂-C₈ alkylthioalkyl, C₂-C₈ alkylsulfinylalkyl, C₂-C₈ alkylsulfonylalkyl, C₂-C₈ alkylcarbonyl, C₂-C₈ haloalkylcarbonyl, C₄-C₁₀ cycloalkylcarbonyl, C₂-C₈ alkoxy carbonyl, C₂-C₈ haloalkoxycarbonyl, C₄-C₁₀ cycloalkoxycarbonyl, C₂-C₈ alkylaminocarbonyl, C₃-C₁₀ dialkylaminocarbonyl, C₁-C₆ alkylsulfinyl, C₁-C₆ haloalkylsulfinyl, C₃-C₈ cycloalkylsulfinyl, C₁-C₆ alkylsulfonyl, C₁-C₆ haloalkylsulfonyl, C₃-C₈ cycloalkylsulfonyl, C₁-C₆ alkylaminosulfonyl, C₂-C₈ dialkylaminosulfonyl, C₃-C₁₀ trialkylsilyl or G¹;

each R^{17a} is independently H, C₁-C₆ alkyl, C₃-C₈ cycloalkyl, C₄-C₈ cycloalkylalkyl, C₁-C₆ haloalkyl, C₂-C₆ alkenyl, C₃-C₆ alkynyl, C₂-C₈ alkoxyalkyl, C₂-C₈ haloalkoxyalkyl, C₂-C₈ alkylthioalkyl, C₂-C₈ alkylsulfinylalkyl, C₂-C₈ alkylsulfonylalkyl, C₁-C₆ alkoxy, C₁-C₆ alkylthio, C₁-C₆ haloalkylthio, C₃-C₈ cycloalkylthio, C₃-C₁₀ trialkylsilyl or G¹;

each R¹⁸ is independently H, hydroxy, C₁-C₆ alkyl, C₃-C₈ cycloalkyl, C₄-C₈ cycloalkylalkyl, C₁-C₆ haloalkyl, C₂-C₆ alkenyl, C₃-C₆ alkynyl, C₂-C₈ alkoxyalkyl, C₂-C₈ haloalkoxyalkyl, C₂-C₈ alkylthioalkyl, C₂-C₈ alkylsulfinylalkyl, C₂-C₈ alkylsulfonylalkyl, C₂-C₈ alkylcarbonyl, C₂-C₈ haloalkylcarbonyl, C₄-C₁₀ cycloalkylcarbonyl, C₂-C₈ alkoxy carbonyl, C₂-C₈ haloalkoxycarbonyl, C₂-C₈ alkoxycarbonyl, C₂-C₈

haloalkoxycarbonyl, C_4 – C_{10} cycloalkoxycarbonyl, C_2 – C_8 alkylaminocarbonyl, C_3 – C_{10} dialkylaminocarbonyl, C_4 – C_{10} cycloalkylaminocarbonyl, C_1 – C_6 alkoxy, C_1 – C_6 alkylthio, C_1 – C_6 haloalkylthio, C_3 – C_8 cycloalkylthio, C_1 – C_6 alkylsulfinyl, C_1 – C_6 haloalkylsulfinyl, C_3 – C_8 cycloalkylsulfinyl, C_1 – C_6 alkylsulfonyl, C_1 – C_6 haloalkylsulfonyl, C_3 – C_8 cycloalkylsulfonyl, C_1 – C_6 alkylaminosulfonyl, C_2 – C_8 dialkylaminosulfonyl, C_3 – C_{10} trialkylsilyl or G^1 ;
 each R^{19} is independently H, C_1 – C_6 alkyl, C_3 – C_8 cycloalkyl, C_4 – C_8 cycloalkylalkyl, C_1 – C_6 haloalkyl, C_2 – C_6 alkenyl, C_3 – C_6 alkynyl, C_2 – C_8 alkoxyalkyl, C_2 – C_8 alkylthioalkyl, C_2 – C_8 alkylsulfinylalkyl, C_2 – C_8 alkylsulfonylalkyl, C_2 – C_8 alkylcarbonyl, C_2 – C_8 haloalkylcarbonyl, C_4 – C_{10} cycloalkylcarbonyl, C_2 – C_8 alkoxy carbonyl, C_2 – C_8 haloalkoxycarbonyl, C_4 – C_{10} cycloalkoxycarbonyl, C_2 – C_8 alkylaminocarbonyl, C_3 – C_{10} dialkylaminocarbonyl, C_4 – C_{10} cycloalkylaminocarbonyl, C_1 – C_6 alkoxy, C_1 – C_6 alkylsulfinyl, C_1 – C_6 haloalkylsulfinyl, C_3 – C_8 cycloalkylsulfinyl, C_1 – C_6 alkylsulfonyl, C_1 – C_6 haloalkylsulfonyl, C_3 – C_8 cycloalkylsulfonyl, C_1 – C_6 alkylaminosulfonyl, C_2 – C_8 dialkylaminosulfonyl, C_3 – C_{10} trialkylsilyl or G^1 ;
 each R^{20} is independently H, hydroxy, amino, C_1 – C_6 alkyl, C_3 – C_8 cycloalkyl, C_4 – C_8 cycloalkylalkyl, C_1 – C_6 haloalkyl, C_2 – C_6 alkenyl, C_3 – C_6 alkynyl, C_2 – C_8 alkoxyalkyl, C_2 – C_8 haloalkoxyalkyl, C_2 – C_8 alkylthioalkyl, C_2 – C_8 alkylsulfinylalkyl, C_2 – C_8 alkylsulfonylalkyl, C_2 – C_8 alkylcarbonyl, C_2 – C_8 haloalkylcarbonyl, C_4 – C_{10} cycloalkylcarbonyl, C_2 – C_8 alkoxy carbonyl, C_2 – C_8 haloalkoxycarbonyl, C_4 – C_{10} cycloalkoxycarbonyl, C_2 – C_8 alkylaminocarbonyl, C_3 – C_{10} dialkylaminocarbonyl, C_4 – C_{10} cycloalkylaminocarbonyl, C_1 – C_6 alkoxy, C_1 – C_6 alkylsulfinyl, C_1 – C_6 haloalkylsulfinyl, C_3 – C_8 cycloalkylsulfinyl, C_1 – C_6 alkylsulfonyl, C_1 – C_6 haloalkylsulfonyl, C_3 – C_8 cycloalkylsulfonyl, C_1 – C_6 alkylaminosulfonyl, C_2 – C_8 dialkylaminosulfonyl, C_3 – C_{10} trialkylsilyl or G^1 ;
 each R^{20a} is independently H, C_1 – C_6 alkyl, C_3 – C_8 cycloalkyl, C_4 – C_8 cycloalkylalkyl, C_1 – C_6 haloalkyl, C_2 – C_6 alkenyl, C_3 – C_6 alkynyl, C_2 – C_8 alkoxyalkyl, C_2 – C_8 haloalkoxyalkyl, C_2 – C_8 alkylthioalkyl, C_2 – C_8 alkylsulfinylalkyl, C_2 – C_8 alkylsulfonylalkyl, C_1 – C_6 alkoxy C_3 – C_{10} trialkylsilyl or G^1 ;
 each R^{23b} is independently H, halogen, cyano, hydroxy, C_1 – C_4 alkyl, C_3 – C_8 cycloalkyl, C_4 – C_8 cycloalkylalkyl, C_1 – C_4 haloalkyl, C_1 – C_4 alkoxy, C_1 – C_4 haloalkoxy, C_2 – C_4 alkoxyalkyl, C_2 – C_4 alkylcarbonyl, C_2 – C_4 alkoxy carbonyl or C_3 – C_6 cycloalkyl;
 each R^{24a} is independently H, C_1 – C_4 alkyl, C_3 – C_8 cycloalkyl, C_4 – C_8 cycloalkylalkyl, C_1 – C_4 haloalkyl, C_1 – C_4 alkoxy, C_1 – C_4 haloalkoxy, C_2 – C_4 alkoxyalkyl, C_2 – C_4 alkylcarbonyl, C_2 – C_4 alkoxy carbonyl or C_3 – C_6 cycloalkyl;

each u and v are independently 0, 1 or 2 in each instance of $S(=O)_u(=NR^8)_v$, provided that the sum of u and v is 0, 1 or 2;

provided that when

- a) J^1 is an unsubstituted phenyl ring, A is other than $-CH_2-$, $-O-$, $-C\equiv C-$, $-C(=O)-$ or $-SO_2-$; or
- b) J^1 is an unsubstituted pyridinyl ring, A is other than $-CH_2-$;
- c) J^1 is C_4-C_{10} cycloalkylalkyl, A is other than alkyl; or
- d) J^1-A- is at the para position of Q^1 , A is other than O and J^1 is other than 2-furanylmethyl.

10 2. The compound of Claim 1 wherein

Q^1 is a phenyl ring optionally substituted with 1 to 4 substituents independently selected from R^7 ; or a 5- to 6-membered heteroaromatic ring containing ring members selected from carbon atoms and 1 to 4 heteroatoms independently selected from up to 2 O, up to 2 S and up to 4 N atoms, optionally substituted with up to 4 substituents independently selected from R^7 on carbon atom ring members and selected from R^9 on nitrogen atom ring members;

Q^2 is a phenyl ring optionally substituted with up to 5 substituents independently selected from R^{10} ; or a 5- to 6-membered heteroaromatic ring containing ring members selected from carbon atoms and 1 to 4 heteroatoms independently selected from up to 2 O, up to 2 S and up to 4 N atoms, optionally substituted with up to 5 substituents independently selected from R^{10} on carbon atom ring members and selected from R^{11} on nitrogen atom ring members;

J^1 is a phenyl ring optionally substituted with up to 5 substituents independently selected from $R^{7'}$; or a 4- to 6-membered heterocyclic ring containing ring members selected from carbon atoms and 1 to 4 heteroatoms independently selected from up to 2 O, up to 2 S and up to 4 N atoms, optionally substituted with up to 5 substituents independently selected from $R^{7'}$ on carbon atom ring members and selected from $R^{9'}$ on nitrogen atom ring members;

R^1 is H, hydroxy, amino, C_1-C_6 alkyl, C_1-C_6 haloalkyl, C_2-C_6 alkenyl, C_3-C_6 alkynyl, C_2-C_6 cyanoalkyl, C_3-C_6 cycloalkyl or C_4-C_8 cycloalkylalkyl; and

A is a saturated, partially unsaturated or fully unsaturated chain containing 2- to 3- atoms selected from up to 3 carbon, up to 1 O, up to 1 S and up to 1 N atom, the chain optionally substituted with up to 2 substituents independently selected from R^{15} on carbon atoms and R^{16} on nitrogen atoms.

35 3. The compound of Claim 1 wherein

Q^1 is a phenyl ring or a naphthalenyl ring system, each ring or ring system optionally substituted with 1 to 4 substituents independently selected from R^7 ;

Q² is a phenyl ring optionally substituted with 1 to 5 substituents independently selected from R¹⁰; and

J¹ is a phenyl ring or a naphthalenyl ring system, each ring or ring system optionally substituted with up to 4 substituents independently selected from R⁷.

5 4. The compound of Claim 3 wherein

A is -CH₂-, -CH₂O-, -CH₂NH-, -CH=CH-, -C≡C-, -NH-, -O-, -S-, -SO- or -SO₂-; each R⁷ is independently halogen, cyano, C₁-C₂ alkyl, C₁-C₃ haloalkyl or C₁-C₃ alkylsulfonyl;

10 each R¹⁰ is independently halogen, cyano, nitro, C₁-C₂ alkyl, C₁-C₃ haloalkyl or C₁-C₃ alkylsulfonyl;

each R⁷ is independently halogen, cyano, nitro, C₁-C₈ alkyl or C₁-C₈ haloalkyl; Y¹ and Y² are both O.

5. The compound of Claim 1 wherein

Q¹ is a phenyl ring or a naphthalenyl ring system, each ring or ring system optionally substituted with 1 to 4 substituents independently selected from R⁷;

15 Q² is a phenyl ring optionally substituted with 1 to 5 substituents independently selected from R¹⁰; and J¹ is a 4- to 6-membered heterocyclic ring containing ring members selected from carbon atoms and 1 to 3 heteroatoms independently selected from up to 2 O, up to 2 S and up to 3 N atoms, wherein up to 2 carbon ring members are independently selected from C(=O) and C(=S), and the sulfur atom ring members are independently selected from S(=O)_u(=NR⁸)_v, each ring or ring system optionally substituted with up to 3 substituents independently selected from R⁷ on carbon atom ring members and selected from R⁹ on nitrogen atom ring members.

20 25 6. The compound of Claim 5 wherein

A is -CH₂-, -CH₂O-, -CH₂NH-, -CH=CH-, -C≡C-, -NH-, -O-, -S-, -SO- or -SO₂-; each R⁷ is independently halogen, cyano, C₁-C₂ alkyl, C₁-C₃ haloalkyl or C₁-C₃ alkylsulfonyl;

30 each R¹⁰ is independently halogen, cyano, nitro, C₁-C₂ alkyl, C₁-C₃ haloalkyl or C₁-C₃ alkylsulfonyl;

each R⁷ is independently halogen, cyano, nitro, C₁-C₈ alkyl or C₁-C₈ haloalkyl; and Y¹ and Y² are both O.

7. The compound of Claim 1 wherein

Q¹ is a 5- to 6-membered heteroaromatic ring or an 8- to 10-membered heteroaromatic bicyclic ring system, each ring or ring system optionally substituted with up to 4

substituents independently selected from R⁷ on carbon atom ring members and selected from R⁹ on nitrogen atom ring members;

Q² is a phenyl ring optionally substituted with 1 to 5 substituents independently selected from R¹⁰; and

5 J¹ is a 4- to 6-membered heterocyclic ring containing ring members selected from carbon atoms and 1 to 3 heteroatoms independently selected from up to 2 O, up to 2 S and up to 3 N atoms, wherein up to 2 carbon ring members are independently selected from C(=O) and C(=S), and the sulfur atom ring members are independently selected from S(=O)_u(=NR⁸)_v, each ring or ring system optionally substituted with up to 3 substituents independently selected from R^{7'} on carbon atom ring members and selected from R^{9'} on nitrogen atom ring members.

10 8. The compound of Claim 7 wherein

A is -CH₂-, -CH₂O-, -CH₂NH-, -CH=CH-, -C≡C-, -NH-, -O-, -S-, -SO- or -SO₂-;

15 each R⁷ is independently halogen, cyano, C₁-C₂ alkyl, C₁-C₃ haloalkyl or C₁-C₃ alkylsulfonyl;

each R¹⁰ is independently halogen, cyano, nitro, C₁-C₂ alkyl, C₁-C₃ haloalkyl or C₁-C₃ alkylsulfonyl;

each R^{7'} is independently halogen, cyano, nitro, C₁-C₈ alkyl or C₁-C₈ haloalkyl; and

20 Y¹ and Y² are both O.

9. The compound of Claim 1 wherein

Q¹ is a 5- to 6-membered heteroaromatic ring or an 8- to 10-membered heteroaromatic bicyclic ring system, each ring or ring system optionally substituted with up to 4 substituents independently selected from R⁷ on carbon atom ring members and selected from R⁹ on nitrogen atom ring members;

25 Q² is a phenyl ring optionally substituted with 1 to 5 substituents independently selected from R¹⁰; and

J¹ is a phenyl ring or a naphthalenyl ring system, each ring or ring system optionally substituted with up to 4 substituents independently selected from R^{7'}.

30 10. The compound of Claim 9 wherein

A is -CH₂-, -CH₂O-, -CH₂NH-, -CH=CH-, -C≡C-, -NH-, -O-, -S-, -SO- or -SO₂-;

each R⁷ is independently halogen, cyano, C₁-C₂ alkyl, C₁-C₃ haloalkyl or C₁-C₃ alkylsulfonyl;

each R¹⁰ is independently halogen, cyano, nitro, C₁-C₂ alkyl, C₁-C₃ haloalkyl or C₁-C₃ alkylsulfonyl;

35 each R^{7'} is independently halogen, cyano, nitro, C₁-C₈ alkyl or C₁-C₈ haloalkyl; and Y¹ and Y² are both O.

11. The compound of Claim 1 selected from the group consisting of N-(2,4-difluorophenyl)-2-oxo-4-[3-(phenoxyethyl)phenyl]-3-pyrrolidinecarboxamide; and 2-oxo-4-[3-(2-pyridinyloxy)phenyl]-N-(2,3,4-trifluorophenyl)-3-pyrrolidinecarboxamide.
- 5
12. A herbicidal composition comprising a compound of Claim 1 and at least one component selected from the group consisting of surfactants, solid diluents and liquid diluents.
13. A herbicidal composition comprising a compound of Claim 1, at least one additional active ingredient selected from the group consisting of other herbicides and herbicide safeners, and at least one component selected from the group consisting of surfactants, solid diluents and liquid diluents.
- 10
14. A herbicidal mixture comprising (a) a compound of Claim 1, and (b) at least one additional active ingredient selected from (b1) photosystem II inhibitors, (b2) acetohydroxy acid synthase (AHAS) inhibitors, (b3) acetyl-CoA carboxylase (ACCase) inhibitors, (b4) auxin mimics, (b5) 5-enol-pyruvylshikimate-3-phosphate (EPSP) synthase inhibitors, (b6) photosystem I electron diverters, (b7) protoporphyrinogen oxidase (PPO) inhibitors, (b8) glutamine synthetase (GS) inhibitors, (b9) very long chain fatty acid (VLCFA) elongase inhibitors, (b10) auxin transport inhibitors, (b11) phytoene desaturase (PDS) inhibitors, (b12) 4-hydroxyphenyl-pyruvate dioxygenase (HPPD) inhibitors, (b13) homogentisate solenesyltransferase (HST) inhibitors, (b14) cellulose biosynthesis inhibitors, (b15) other herbicides including mitotic disruptors, organic arsenicals, asulam, bromobutide, cinmethylin, cumyluron, dazomet, difenzoquat, dymron, etobenzanid, flurenol, fosamine, fosamine-ammonium, hydantocidin, metam, methyldymron, oleic acid, oxaziclofone, pelargonic acid and pyributicarb, and (b16) herbicide safeners; and salts of compounds of (b1) through (b16).
- 15
- 20
- 25
- 30
15. A method for controlling the growth of undesired vegetation comprising contacting the vegetation or its environment with a herbicidally effective amount of a compound of Claim 1.

INTERNATIONAL SEARCH REPORT

International application No
PCT/US2016/024669

A. CLASSIFICATION OF SUBJECT MATTER				
INV.	C07D403/12	A01N43/36	A01N43/40	A01N43/647
	C07D401/10	C07D403/10	C07D405/10	C07D405/12
	C07D413/12	C07D417/10	C07D417/12	C07D471/04
				C07D207/277

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

C07D A01N

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

EPO-Internal, WPI Data, CHEM ABS Data

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X, P	WO 2015/084796 A1 (DU PONT [US]) 11 June 2015 (2015-06-11) pages 49-143; claim 1; compounds 68, 69, 121-130, 172-174, 222-230 compounds 256-258, 298-300, 321-325, 348-350 ----- WO 2016/003997 A1 (DU PONT [US]) 7 January 2016 (2016-01-07) pages 48-53; claim 1; compounds 37-41, 44-46, 58-61 ----- EP 0 451 168 A1 (ICI AMERICA INC [US]) 16 October 1991 (1991-10-16) the whole document -----	1,12-15 1,12-15 1-15
A		



Further documents are listed in the continuation of Box C.



See patent family annex.

* Special categories of cited documents :

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier application or patent but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"&" document member of the same patent family

Date of the actual completion of the international search	Date of mailing of the international search report
17 May 2016	30/05/2016
Name and mailing address of the ISA/ European Patent Office, P.B. 5818 Patentlaan 2 NL - 2280 HV Rijswijk Tel. (+31-70) 340-2040, Fax: (+31-70) 340-3046	Authorized officer Grassi, Damian

INTERNATIONAL SEARCH REPORT

Information on patent family members

International application No

PCT/US2016/024669

Patent document cited in search report	Publication date	Patent family member(s)		Publication date
WO 2015084796	A1 11-06-2015	UY 35863 A WO 2015084796 A1		31-07-2015 11-06-2015

WO 2016003997	A1 07-01-2016	UY 36201 A WO 2016003997 A1		29-01-2016 07-01-2016

EP 0451168	A1 16-10-1991	AT 107281 T AU 4750590 A CA 2006543 A1 DE 68916265 D1 DE 68916265 T2 EP 0451168 A1 JP 2812553 B2 JP H04503947 A US 4874422 A WO 9007500 A1		15-07-1994 01-08-1990 27-06-1990 21-07-1994 13-10-1994 16-10-1991 22-10-1998 16-07-1992 17-10-1989 12-07-1990
